Methods and compositions for cosmetic applications
Lipid vesicle compositions with encapsulated peptides and hyaluronic acid are used to deliver cosmetic agents below the skin surface, addressing the need for effective wrinkle prevention and skin enhancement.
Patent Information
- Application Number
- JP2024526772
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-15
- Filing Date
- 2022-11-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for improved methods and compositions to deliver cosmetic agents below the surface of the skin for various cosmetic and pharmaceutical purposes, including the prevention or reduction of wrinkles.
The development of lipid vesicle compositions comprising a lipid bilayer and encapsulated peptides and anionic polymeric materials, such as hyaluronic acid, which are formulated to penetrate and deliver cosmetic agents to specific layers of the skin, including the epidermis, dermis, or subcutaneous tissue.
The compositions effectively deliver cosmetic agents below the skin surface, providing benefits like wrinkle prevention or temporary improvement in skin appearance by targeting specific skin layers.
Smart Images

Figure 2024543039000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 406,873, filed September 15, 2022, and U.S. Provisional Patent Application No. 63 / 75,878, filed November 4, 2021, which are incorporated by reference in their entireties. [Background technology]
[0002] Certain cosmetic agents are desirably delivered below the surface of the skin. There is a need for improved methods and compositions for the delivery of such cosmetic agents for a variety of cosmetic and medical purposes, including the prevention, reduction, or elimination of wrinkles. Summary of the Invention
[0003] The present invention relates to a composition for delivering a cosmetic agent. In some embodiments, the composition is a lipid vesicle formulation of the cosmetic agent that allows delivery below the surface of the skin upon topical application. In some embodiments, the cosmetic agent comprises an anionic polymeric material such as hyaluronic acid or a peptide that benefits the appearance of the skin, such as the skin around the lips, face, eyes, or neck of a subject, or all of the above. In some embodiments, the cosmetic agent is delivered to a preferred or preselected layer of the skin or surrounding tissue, such as the epidermis, dermis, subcutaneous tissue, or muscle tissue.
[0004] In one aspect, provided herein is a lipid vesicle composition comprising: (a) lipid vesicles comprising lipid bilayers, each comprising a vesicle-forming lipid; and (b) an oil-in-water emulsion encapsulated within said lipid vesicles and stabilized by one or more surfactants, wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof, comprises one or more peptides and an anionic, one or more peptides comprising the amino acid sequence: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8, where Xaa1 is absent or is selected from the group consisting of Ala, Arg, Gly, Lys, Xaa2 is absent or selected from Ala, Arg, Cys, Gly, Ile, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Cys, Gly, Ile, Lys, Pro, Tyr, or Val, and Xaa3 is absent or selected from Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, or Val. is selected from a derivative of Val; Xaa4 is absent or selected from Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Val, and a derivative of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Val; Xaa5 is absent or selected from Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Val, and a derivative of Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Val; and Xaa6 is absent or selected from Ala. , Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Val, and derivatives of Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Val; Xaa7 is selected from Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Val; Xaa8 isThe peptides are selected from Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Val, and derivatives of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In some embodiments, the one or more peptides are encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides are present at a concentration of about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the one or more peptides comprise a tetrapeptide, a pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprise an amino acid sequence of at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, one or more peptides comprise an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, one or more peptides have an amino acid sequence consisting of ... an amino acid sequence of SEQ ID NO: 31, 36, or 37. In some embodiments, one or more peptides have an amino acid sequence consisting of an amino acid sequence identical to an amino acid sequence of SEQ ID NO: 21. In some embodiments, one or more peptides have an amino acid sequence consisting of an amino acid sequence identical to an amino acid sequence of SEQ ID NO: 24. In some embodiments, one or more peptides have an amino acid sequence consisting of an amino acid sequence identical to an amino acid sequence of SEQ ID NO: 30. In some embodiments, one or more peptides have an amino acid sequence consisting of an amino acid sequence identical to an amino acid sequence of SEQ ID NO: 31. In some embodiments, one or more peptides have an amino acid sequence consisting of an amino acid sequence identical to an amino acid sequence of SEQ ID NO: 36. In some embodiments, one or more peptidesThe peptide has an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 38. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the lipid bilayer, oil-in-water emulsion, or combination thereof further comprises an anionic polymeric material. In some embodiments, the anionic polymeric material is encapsulated in the lipid bilayer, oil-in-water emulsion, or combination thereof. In some embodiments, the anionic polymeric material comprises an anionic polysaccharide. In some embodiments, the anionic polymer is present in an amount of about 0.01 mg / mL to about 10 mg / mL of the composition. In some embodiments, the anionic polysaccharide comprises hyaluronic acid or a salt thereof. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the anionic polymeric material comprises a first anionic polymeric material and a second anionic polymeric material, each of which has a different molecular weight. In some embodiments, the first anionic polymeric material and the second anionic polymeric material are the same material. In some embodiments, the first anionic polymeric material has a molecular weight of up to 75 kDa, and the second anionic polymeric material has a molecular weight of greater than about 75 kDa. In some embodiments, the first anionic polymeric material has a molecular weight of about 5 kDa to about 50 kDa, and the second anionic polymeric material has a molecular weight of about 100 kDa to about 500 kDa. In some embodiments, the vesicle-forming lipid comprises a phospholipid, a glycolipid, a lecithin, a ceramide, a lysolecithin, a lysophosphatidylethanolamine, a phosphatidylserine, a phosphatidylinositol, a sphingomyelin, a cardiolipin, a phosphatidic acid, a cerebroside, or any combination thereof. In some embodiments, the vesicle-forming lipid comprises a phospholipid. In some embodiments, the composition comprises a vesicle-forming lipid in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments,The oil-in-water emulsion comprises a triglyceride in the oil component. In some embodiments, the triglyceride comprises a medium chain triglyceride. In some embodiments, the triglyceride is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the composition comprises a sterol. In some embodiments, the sterol is present in an amount of about 1% to about 5% (w / w) of the composition. In some embodiments, the composition comprises propylene glycol. In some embodiments, the propylene glycol is present in an amount of about 1% to about 25% (w / w) of the composition. In some embodiments, the composition comprises one or more viscosity enhancers. In some embodiments, the one or more viscosity enhancers are present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the composition comprises one or more penetration enhancers. In some embodiments, the one or more penetration enhancers comprise a non-ionic surfactant or a combination of non-ionic surfactants. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, sorbitan esters, and polyethylene glycol fatty acid esters, and combinations thereof. In some embodiments, the polyethylene glycol ethers of fatty alcohols are selected from C8-C, 22The sorbitan ester comprises an aliphatic alcohol and a polyethylene glycol group having about 2 to about 8 ethylene glycol subunits. In some embodiments, the polyethylene glycol ether of the aliphatic alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) plyyl ether, polyoxyethylene (3) plyyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof. In some embodiments, the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glyceride, or any combination thereof. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the nonionic surfactant or combination of nonionic surfactants has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 5% (w / w) of the composition. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, at least one non-ionic surfactant is present in the oil-in-water emulsion. In some embodiments, at least one non-ionic surfactant is present in the lipid bilayer. In some embodiments, the one or more penetration enhancers include a combination of sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters.In some embodiments, the one or more penetration enhancers include a combination of polyethylene glycol ethers of fatty alcohols, sorbitan esters, and polysorbates. In some embodiments, the one or more penetration enhancers include monolauroyl lysine or dipalmitoyl lysine, or a combination thereof. In some embodiments, the composition includes a cationic surfactant. In some embodiments, the cationic surfactant is a monocationic surfactant. In some embodiments, the cationic surfactant includes a propylene glycol diammonium phosphate ester derived from a fatty amide. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 20%. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 10%. In some embodiments, the cationic penetration enhancer includes a dicationic penetration enhancer. In some embodiments, the dicationic penetration enhancer is a gemini cationic surfactant. In some embodiments, the cationic penetration enhancer includes a cationic polymer. In some embodiments, the cationic penetration enhancer is present in an amount of about 0.01% to about 1% (w / w) of the composition. In some embodiments, the penetration enhancer is a salicylate or a nicotinate. In some embodiments, the ester is a C1-6 alkyl ester or a benzyl ester. In some embodiments, the penetration enhancer comprises methyl salicylate or benzyl nicotinate. In some embodiments, the composition further comprises one or more additional agents. In some embodiments, the additional agents comprise one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial agent, a biological extract, or any combination thereof. In some embodiments, the composition is formulated for topical application to the skin of the subject. In some embodiments, the composition is formulated to deliver the anionic polymer to a specific layer of the skin of the subject. In some embodiments, the composition is formulated to deliver one or more peptides to a specific layer of the skin of the subject. In some embodiments, the composition is formulated as a cream, a lotion, a suspension, or an emulsion.
[0005] In one aspect, provided herein is a lipid vesicle composition comprising: (a) lipid vesicles each comprising a lipid bilayer comprising vesicle-forming lipids; and (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants, wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof comprises one or more peptides, wherein the one or more peptides comprise an amino acid sequence of at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides are encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides are present at a concentration of about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the one or more peptides comprise a tetrapeptide, a pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprise an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise at least two peptides, each having an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 21-40. In some embodiments, the one or more peptides comprise at least two peptides, each having an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 21-40. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 31, 36, or 37. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 21. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 24.In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:30. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:31. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:36. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:37. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:38. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:40. In some embodiments, the lipid bilayer, oil-in-water emulsion, or combination thereof further comprises an anionic polymeric material. In some embodiments, the anionic polymeric material is encapsulated in the lipid bilayer, oil-in-water emulsion, or combination thereof. In some embodiments, the anionic polymeric material comprises an anionic polysaccharide. In some embodiments, the anionic polymer is present in an amount of about 0.1 mg / mL to about 10 mg / mL of the composition. In some embodiments, the anionic polysaccharide comprises hyaluronic acid or a salt thereof. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the anionic polymeric material comprises a first anionic polymeric material and a second anionic polymeric material, each of the anionic polymeric materials having a different molecular weight. In some embodiments, the first anionic polymeric material and the second anionic polymeric material are the same material. In some embodiments, the first anionic polymeric material has a molecular weight of up to about 75 kDa, and the second anionic polymeric material has a molecular weight greater than about 75 kDa. In some embodiments, the first anionic polymeric material has a molecular weight of about 5 kDa to about 50 kDa, and the second anionic polymeric material has a molecular weight of about 100 kDa to about 500 kDa.In some embodiments, the vesicle-forming lipid comprises a phospholipid, glycolipid, lecithin, ceramide, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof. In some embodiments, the vesicle-forming lipid comprises a phospholipid. In some embodiments, the composition comprises a vesicle-forming lipid in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, the oil-in-water emulsion comprises a triglyceride in the oil component. In some embodiments, the triglyceride comprises a medium chain triglyceride. In some embodiments, the triglyceride is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the composition comprises a sterol. In some embodiments, the sterol is present in an amount of about 1% to about 5% (w / w) of the composition. In some embodiments, the composition comprises propylene glycol. In some embodiments, propylene glycol is present in an amount of about 1% to about 25% (w / w) of the composition. In some embodiments, the composition comprises one or more viscosity enhancing agents. In some embodiments, the one or more viscosity enhancing agents are present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the composition comprises one or more penetration enhancers. In some embodiments, the one or more penetration enhancers comprise a non-ionic surfactant or a combination of non-ionic surfactants. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, sorbitan esters, and polyethylene glycol fatty acid esters, and combinations thereof. In some embodiments, the polyethylene glycol ethers of fatty alcohols are C8-C. 22The polyethylene glycol ether of the aliphatic alcohol comprises an aliphatic alcohol and a polyethylene glycol group having about 2 to about 8 ethylene glycol subunits. In some embodiments, the polyethylene glycol ether of the aliphatic alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof. In some embodiments, the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glyceride, or any combination thereof. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the nonionic surfactant or combination of nonionic surfactants has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 5% (w / w) of the composition. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, at least one non-ionic surfactant is present in the oil-in-water emulsion. In some embodiments, at least one non-ionic surfactant is present in the lipid bilayer. In some embodiments, the one or more penetration enhancers include a combination of sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters.In some embodiments, the one or more penetration enhancers include a combination of polyethylene glycol ethers of fatty alcohols, sorbitan esters, and polysorbates. In some embodiments, the one or more penetration enhancers include monolauroyl lysine or dipalmitoyl lysine, or a combination thereof. In some embodiments, the composition includes a cationic surfactant. In some embodiments, the cationic surfactant is a monocationic surfactant. In some embodiments, the cationic surfactant includes a propylene glycol diammonium phosphate ester derived from a fatty amide. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 20%. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 10%. In some embodiments, the cationic penetration enhancer includes a dicationic penetration enhancer. In some embodiments, the dicationic penetration enhancer is a gemini cationic surfactant. In some embodiments, the cationic penetration enhancer includes a cationic polymer. In some embodiments, the cationic penetration enhancer is present in an amount of about 0.01% to about 1% (w / w) of the composition. In some embodiments, the penetration enhancer includes a salicylate or a nicotinate. In some embodiments, the ester is a C1-C6 alkyl ester or a benzyl ester. In some embodiments, the penetration enhancer comprises methyl salicylate or benzyl nicotinate. In some embodiments, the composition further comprises one or more additional agents. In some embodiments, the additional agents comprise one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial agent, a biological extract, or any combination thereof. In some embodiments, the composition is formulated for topical application to the skin of the subject. In some embodiments, the composition is formulated to deliver the anionic polymer to a specific layer of the skin of the subject. In some embodiments, the composition is formulated to deliver one or more peptides to a specific layer of the skin of the subject. In some embodiments, the composition is formulated as a cream, a lotion, a suspension, or an emulsion.
[0006] In one aspect, a composition is provided herein that includes a peptide comprising the amino acid sequence of SEQ ID NO: 37. In some embodiments, the composition further includes one or more additional agents. In some embodiments, the additional agent includes one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antibacterial agent, a biological extract, or any combination thereof. In some embodiments, the additional agent includes an anionic polymeric material. In some embodiments, the anionic polymeric material includes hyaluronic acid. In some embodiments, the composition is formulated for topical application to the skin of a subject. In some embodiments, the composition is formulated to deliver one or more peptides to a specific layer of the skin of a subject. In some embodiments, the composition is formulated as a cream, lotion, suspension, or emulsion.
[0007] In one aspect, provided herein is a lipid vesicle composition comprising: (a) lipid vesicles comprising lipid bilayers, each comprising a vesicle-forming lipid; and (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants, wherein said lipid bilayer, said oil-in-water emulsion, or a combination thereof, comprises one or more peptides and an anionic polymeric material, wherein said one or more peptides comprise the amino acid sequence: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8, where Xaa1 is absent or is an Al Xaa2 is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Gly, Lys, Pro, Tyr, or Val, and Xaa3 is absent or selected from Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Xaa4 is absent or selected from Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Val, and Xaa5 is absent or selected from Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Val. Xaa6 is absent or selected from Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Val, and derivatives of Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Val; Xaa7 is selected from Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr,or a derivative of Val, and Xaa8 is selected from Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Val, and a derivative of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In some embodiments, the one or more peptides are encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides are present at a concentration of about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the one or more peptides include a tetrapeptide, a pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homologous to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise at least two peptides, each having an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 21-40. In some embodiments, the one or more peptides comprise at least two peptides, each having an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 21-40. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to the amino acid sequence of SEQ ID NOs: 31, 36, or 37. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 21. ...The anionic polymeric material has an amino acid sequence identical to the amino acid sequence of SEQ ID NO:24. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:30. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:31. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:36. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:37. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:38. In some embodiments, the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:40. In some embodiments, the anionic polymeric material is encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof. In some embodiments, the anionic polymeric material comprises an anionic polysaccharide. In some embodiments, the anionic polymer is present in an amount of about 0.1 mg / mL to about 10 mg / mL of the composition. In some embodiments, the anionic polysaccharide comprises hyaluronic acid or a salt thereof. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the anionic polymeric material includes a first anionic polymeric material and a second anionic polymeric material, each of the anionic polymeric materials having a different molecular weight. In some embodiments, the first anionic polymeric material and the second anionic polymeric material are the same material. In some embodiments, the first anionic polymeric material has a molecular weight of up to about 75 kDa, and the second anionic polymeric material has a molecular weight greater than about 75 kDa. In some embodiments, the first anionic polymeric material has a molecular weight of about 5 kDa to about 50 kDa, and the second anionic polymeric material has a molecular weight of about 100 kDa to about 500 kDa. In some embodiments, the vesicle-forming lipids are phospholipids, glycolipids, lecithin, ceramide, lysolecithin,The lipids include lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebrosides, or any combination thereof. In some embodiments, the vesicle-forming lipids include phospholipids. In some embodiments, the composition includes a vesicle-forming lipid in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, the oil-in-water emulsion includes a triglyceride in the oil component. In some embodiments, the triglyceride includes a medium chain triglyceride. In some embodiments, the triglyceride is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the composition includes a sterol. In some embodiments, the sterol is present in an amount of about 1% to about 5% (w / w) of the composition. In some embodiments, the composition includes propylene glycol. In some embodiments, the propylene glycol is present in an amount of about 1% to about 25% (w / w) of the composition. In some embodiments, the composition includes one or more viscosity enhancing agents. In some embodiments, the one or more viscosity enhancers are present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the composition comprises one or more penetration enhancers. In some embodiments, the one or more penetration enhancers comprise a non-ionic surfactant or a combination of non-ionic surfactants. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, sorbitan esters, and polyethylene glycol fatty acid esters, and combinations thereof. In some embodiments, the polyethylene glycol ethers of fatty alcohols are selected from C8-C, 22The polyethylene glycol ether of the aliphatic alcohol comprises an aliphatic alcohol and a polyethylene glycol group having about 2 to about 8 ethylene glycol subunits. In some embodiments, the polyethylene glycol ether of the aliphatic alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof. In some embodiments, the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glyceride, or any combination thereof. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the nonionic surfactant or combination of nonionic surfactants has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 5% (w / w) of the composition. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, at least one non-ionic surfactant is present in the oil-in-water emulsion. In some embodiments, at least one non-ionic surfactant is present in the lipid bilayer. In some embodiments, the one or more penetration enhancers include a combination of sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters.In some embodiments, the one or more penetration enhancers include a combination of polyethylene glycol ethers of fatty alcohols, sorbitan esters, and polysorbates. In some embodiments, the one or more penetration enhancers include monolauroyl lysine or dipalmitoyl lysine, or a combination thereof. In some embodiments, the composition includes a cationic surfactant. In some embodiments, the cationic surfactant is a monocationic surfactant. In some embodiments, the cationic surfactant includes a propylene glycol diammonium phosphate ester derived from a fatty amide. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 20%. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 10%. In some embodiments, the cationic penetration enhancer is a dicationic surfactant. In some embodiments, the dicationic penetration enhancer is a gemini cationic surfactant. In some embodiments, the cationic penetration enhancer comprises a cationic polymer. In some embodiments, the cationic penetration enhancer is present in an amount of about 0.01% to about 1% (w / w) of the composition. In some embodiments, the penetration enhancer comprises a salicylate or a nicotinate ester. In some embodiments, the ester is a C1-6 alkyl ester or a benzyl ester. In some embodiments, the penetration enhancer comprises methyl salicylate or benzyl nicotinate. In some embodiments, the composition further comprises one or more additional agents. In some embodiments, the additional agents comprise one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial agent, a biological extract, or any combination thereof. In some embodiments, the composition is formulated for topical application to the skin of the subject. In some embodiments, the composition is formulated to deliver an anionic polymer to a specific layer of the skin of the subject. In some embodiments, the composition is formulated to deliver one or more peptides to a specific layer of the skin of the subject. In some embodiments, the composition is formulated as a cream, lotion, suspension, or emulsion.
[0008] In one aspect, provided herein is a lipid vesicle composition comprising: (a) lipid vesicles each comprising a lipid bilayer comprising vesicle-forming lipids; and (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants, wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof comprises one or more peptides and an anionic polymeric material, and wherein the one or more peptides comprise an amino acid sequence of at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides are encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides are present at a concentration of about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the one or more peptides are tetrapeptides, pentapeptides, hexapeptides, or any combination thereof. In some embodiments, the one or more peptides comprise an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise at least two peptides, each having an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 21-40. In some embodiments, the one or more peptides comprise at least two peptides, each having an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 21-40. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to any one of the amino acid sequences of SEQ ID NOs: 31, 36, or 37. In some embodiments, the one or more peptides comprise an amino acid sequence consisting of an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 21.In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:24. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:30. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:31. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:36. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:37. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:38. In some embodiments, one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:40. In some embodiments, the anionic polymeric material is encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof. In some embodiments, the anionic polymeric material comprises an anionic polysaccharide. In some embodiments, the anionic polymer is present in an amount of about 0.1 mg / mL to about 10 mg / mL of the composition. In some embodiments, the anionic polysaccharide comprises hyaluronic acid or a salt thereof. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the anionic polymeric material comprises a first anionic polymeric material and a second anionic polymeric material, each of the anionic polymeric materials having a different molecular weight. In some embodiments, the first anionic polymeric material and the second anionic polymeric material are the same material. In some embodiments, the first anionic polymeric material has a molecular weight of up to about 75 kDa, and the second anionic polymeric material has a molecular weight greater than about 75 kDa. In some embodiments, the first anionic polymeric material has a molecular weight of about 5 kDa to about 50 kDa, and the second anionic polymeric material has a molecular weight of about 100 kDa to about 500 kDa.In some embodiments, the vesicle-forming lipid comprises a phospholipid, glycolipid, lecithin, ceramide, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof. In some embodiments, the vesicle-forming lipid comprises a phospholipid. In some embodiments, the composition comprises a vesicle-forming lipid in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, the oil-in-water emulsion comprises a triglyceride in the oil component. In some embodiments, the triglyceride comprises a medium chain triglyceride. In some embodiments, the triglyceride is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the composition comprises a sterol. In some embodiments, the sterol is present in an amount of about 1% to about 5% (w / w) of the composition. In some embodiments, the composition comprises propylene glycol. In some embodiments, propylene glycol is present in an amount of about 1% to about 25% (w / w) of the composition. In some embodiments, the composition comprises one or more viscosity enhancing agents. In some embodiments, the one or more viscosity enhancing agents are present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the composition comprises one or more penetration enhancers. In some embodiments, the one or more penetration enhancers comprise a non-ionic surfactant or a combination of non-ionic surfactants. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, sorbitan esters, and polyethylene glycol fatty acid esters, and combinations thereof. In some embodiments, the polyethylene glycol ethers of fatty alcohols are C8-C. 22The polyethylene glycol ether of the aliphatic alcohol comprises an aliphatic alcohol and a polyethylene glycol group having about 2 to about 8 ethylene glycol subunits. In some embodiments, the polyethylene glycol ether of the aliphatic alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof. In some embodiments, the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glyceride, or any combination thereof. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the nonionic surfactant or combination of nonionic surfactants has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 5% (w / w) of the composition. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, at least one non-ionic surfactant is present in the oil-in-water emulsion. In some embodiments, at least one non-ionic surfactant is present in the lipid bilayer. In some embodiments, the one or more penetration enhancers include a combination of sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters.In some embodiments, the one or more penetration enhancers include a combination of polyethylene glycol ethers of fatty alcohols, sorbitan esters, and polysorbates. In some embodiments, the one or more penetration enhancers include monolauroyl lysine or dipalmitoyl lysine, or a combination thereof. In some embodiments, the composition includes a cationic surfactant. In some embodiments, the cationic surfactant is a monocationic surfactant. In some embodiments, the cationic surfactant includes a propylene glycol diammonium phosphate ester derived from a fatty amide. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 20%. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 10%. In some embodiments, the cationic penetration enhancer includes a dicationic penetration enhancer. In some embodiments, the dicationic penetration enhancer is a gemini cationic surfactant. In some embodiments, the cationic penetration enhancer includes a cationic polymer. In some embodiments, the cationic penetration enhancer is present in an amount of about 0.01% to about 1% (w / w) of the composition. In some embodiments, the penetration enhancer includes a salicylate or a nicotinate ester. In some embodiments, the ester is a C1-C6 alkyl ester or a benzyl ester. In some embodiments, the penetration enhancer comprises methyl salicylate or benzyl nicotinate. In some embodiments, the composition further comprises one or more additional agents. In some embodiments, the additional agents comprise one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial agent, a biological extract, or any combination thereof. In some embodiments, the composition is formulated for topical application to the skin of the subject. In some embodiments, the composition is formulated to deliver the anionic polymer to a specific layer of the skin of the subject. In some embodiments, the composition is formulated to deliver one or more peptides to a specific layer of the skin of the subject. In some embodiments, the composition is formulated as a cream, a lotion, a suspension, or an emulsion.
[0009] In some aspects, provided herein is a method of preparing a lipid vesicle composition comprising: a) preparing an oil-in-water emulsion comprising one or more peptides by mixing an oil component of the oil-in-water emulsion with an aqueous component of the oil-in-water emulsion, wherein the oil component and / or the aqueous component of the oil-in-water emulsion comprises one or more surfactants; b) solubilizing vesicle-forming lipids in an acceptable solvent other than water; c) adding the oil-in-water emulsion to the solubilized vesicle-forming lipids; and d) mixing the oil-in-water emulsion with the solubilized vesicle-forming lipids under mixing conditions effective to form lipid vesicles comprising a lipid bilayer comprising the vesicle-forming lipids, and the oil-in-water emulsion encapsulated in the lipid vesicles. In some embodiments, a) further comprises an anionic polymeric material.
[0010] In one aspect provided herein, there is a method of delivering a cosmetic agent below the skin surface of a subject, comprising applying a lipid vesicle composition provided herein to the skin surface. In some embodiments, the topical composition is administered to the dermis of the subject. In some embodiments, the topical composition is administered to the epidermis of the subject. In some embodiments, the cosmetic agent is delivered to the subject's contacting muscle or subcutaneous tissue, including adipose tissue. The one or more cosmetic effects include the prevention or temporary improvement of the appearance of one or more skin wrinkles, or the embodiment described in. The one or more skin wrinkles include moderate to severe glabellar lines associated with the activity of the corrugator supercilii and / or procerus muscles, moderate to severe lateral canthal lines (crow's feet lines) associated with the activity of the orbicularis oculi muscle, or moderate to severe frontal lines associated with the activity of the frontalis muscle.
[0011] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]
[0012] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth embodiments, in which the principles of the invention are utilized, and the accompanying drawings, in which:
[0013] [Figure 1A] Physicochemical characterization of multisome formulations F1, F2, and F3. Figure 1A shows confocal microscopy images of multisome formulations F1 (top), F2 (middle), and F3 (bottom) containing rhodamine red-labeled HA250K and green FITC-HA10K, and the FI traces show the colocalization of the two labels in the vesicles. [Figure 1B] Physicochemical characterization of multisome formulations F1, F2, and F3. Figure 1B shows optical microscopy images of multisome formulations F1 (top), F2 (middle), and F3 (bottom). [Figure 1C] Physicochemical characterization of multisome formulations F1, F2, and F3. Figure 1C shows the particle size distribution of multisome formulations F1 (top), F2 (middle), and F3 (bottom). The figures are labeled with size distribution by intensity. The x-axis is size (dnm) from 0.1 to 10000 labeled in 10-fold increments. The y-axis of F1 (top) shows intensity (percent) labeled in 5 increments from 0 to 20. The y-axis of F2 (middle) shows intensity (percent) labeled in 10 increments from 0 to 30. The y-axis of F3 (bottom) shows intensity (percent) labeled in 2 increments from 0 to 12. [Diagram 2]Confocal microscopy images of human skin to which cationic multisome formulations were applied. The cationic multisome formulations were prepared with rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K. The FI traces show the levels of rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. For the FI traces in F1 (top), the X-axis is distance (nm) labeled from 0 to 300000 in increments of 50000, and the Y-axis is intensity labeled from 0 to 66 in increments of 10 with a maximum of 60. For the FI traces in F2 (middle), the X-axis is distance (nm) labeled from 0 to 198107 in increments of 20000 with a maximum of 180000, and the Y-axis is intensity labeled from 0 to 90 in increments of 10. For the FI trace diagrams in F3 (bottom), the X-axis is distance (nm) labeled in increments of 50000 from 0 to 375190 with a maximum of 350000, and the Y-axis is intensity labeled in increments of 10 from 0 to 65 with a maximum of 65. The plane of the trace direction is indicated in each micrograph. [Figure 3A] Confocal microscopy images of human skin with applied multisome formulations are shown. Multisome formulations were prepared with rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K. FI traces show the levels of rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The X-axis shown is distance (nm) and the Y-axis is intensity in the FI traces. Each micrograph shows the plane of trace direction. Figure 3A shows the results for E1 (F4HA250+10 1mg), E4 (F4HA250+50 1mg), E7 (F3-2HA250+50 1.5mg), and E10 (F1-F6-COSM6BN-HA250+50 1.5mg) from top to bottom. [Figure 3B]Confocal microscopy images of human skin with applied multisome formulations are shown. Multisome formulations were prepared with rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K. FI traces show the levels of rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The X-axis shown is distance (nm) and the Y-axis is intensity in the FI traces. Each micrograph shows the plane of trace direction. Figure 3B shows the results for E2 (F4HA250+10 1.5mg), E5 (F4HA250+50 1.5mg), E8 (F1-F6-COSM6-HA250+10 1.5mg), and E11 (Gel-HA250+50 1.5mg) from top to bottom. [Figure 3C] Confocal microscopy images of human skin with applied multisome formulations are shown. Multisome formulations were prepared with rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K. FI traces show the levels of rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The X-axis shown is distance (nm) and the Y-axis is intensity in the FI traces. Each micrograph shows the plane of trace direction. Figure 3C shows the results for E3 (COSMF4HA250+10 1.5mg), E6 (COSMF4HA250+50 1.5mg), E9 (F1-F6-COSM6-HA250+50 1.5mg), and E12 (Gel-HA250+10 1.5mg) from top to bottom. [Figure 4A]Confocal microscopy images of human skin with applied multisome formulations are shown. Multisome formulations were prepared with rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K. FI traces show the levels of rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The X-axis shown is distance (nm) and the Y-axis is intensity in the FI traces. Each micrograph shows the plane of trace direction. Figure 4A shows the results for G1 (F1-F5-COSM4-HA250+10), G2 (F1-F5-COSM4+HA250+10+BN), G3 (F1-F6-COSM5-HA250+10), and G4 (F1-F6-COSM5-HA250+10+BN) from top to bottom. [Figure 4B] Confocal microscopy images of human skin with applied multisome formulations are shown. Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K. The FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The X-axis shown is distance (nm) and the Y-axis is intensity in the FI traces. Each micrograph shows the plane of trace direction. Figure 4B shows the results for G5 (F1-F5-COSM4-HA250+50), G6 (F1-F5-COSM4+HA250+50+BN), G7 (F1-F6-COSM5-HA250+50), and G8 (F1-F6-COSM5-HA250+50+BN) from top to bottom. [Diagram 5] FIG. 1 shows an exemplary diagrammatic workflow for the preparation of lipid vesicles provided herein. [Figure 6] FIG. 1 shows an exemplary workflow for the preparation of hyaluronic acid (HA)-containing lipid vesicles provided herein. [Figure 7A]Figure 7A shows the physicochemical characterization of multisome formulations containing various HA + functional ingredient packs (FIPs). Figure 7A shows confocal microscopy images of the multisome formulations and fluorescence intensity (FI) traces (Panel A) and optical microscopy images of the multisome formulations (Panel B). In the FI traces, the x-axis is distance (μm) from 0 to 50 in increments of 5, and the y-axis is intensity from 0 to 250 in increments of 50. [Figure 7B] Physicochemical characterization of multisome formulations containing various HA+functional ingredient packs (FIPs). FIG. 7B shows confocal microscopy images of further multisome formulations and FI traces (panel A) and optical microscopy images of the corresponding multisomes (panel B). In the FI trace for F5P2.6-F6COSM5V2-H6+P2 (top), the axis is distance (μm) from 0 to 55 in increments of 5, and the Y axis is intensity from 0 to 250 in increments of 50. In the FI trace for F1-F6-COSM5V2-H6+P2 (bottom), the axis is distance (μm) from 0 to about 130 in increments of 20, and the Y axis is intensity from 0 to 250 in increments of 50. [Figure 7C] Figure 7C shows the physicochemical characterization of multisome formulations containing various HA + functional ingredient packs (FIPs). Figure 7C shows confocal microscopy images of selected multisome formulations and FI traces (Panel A) as well as optical microscopy images of selected formulations of various batch sizes (Panel B). In the FI traces, the x-axis is distance (nm) from 0 to approximately 35000 in increments of 5000, and the y-axis shows intensity from 0 to 57 in increments of 10. [Figure 7D]Physicochemical characterization of multisome formulations containing various HA+functional ingredient packs (FIPs). Figure 7D shows confocal microscopy images of another selected multisome formulation and FI trace diagrams (panel A) as well as optical microscopy images of selected formulations before and after mixing of additional components into the formulation (panel B). In the FI trace diagram, the x-axis is distance (nm) from 0 to about 12000 in increments of 2000, and the y-axis shows intensity from 0 to 170 in increments of 20. The confocal microscopy images in panels A of Figures 7A-7D contain rhodamine red labeled HA250K and green FITC-HA10K, and the FI trace diagram shows the colocalization of the two labels within the vesicles. [Figure 8A] Confocal microscopy images and FI traces of human skin treated with two formulations, F5P2.6-F6COSM5V2-HA5-1+P2 (Figure 8A) and F1-F6COSM5V2-H5-1+P2 (Figure 8B), with HA + FIP formulations: HA5-1 and 5-2, and at two different HA250 / 50 ratios. Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The plane of trace direction is indicated on each micrograph. In the FI traces of FIG. 8A, the x-axis is distance (nm) from 0 to 133123 in increments of 20000 and for HA5-1 (top), the y-axis is intensity from 0 to 109 in increments of 10, while for HA5-2 (bottom), the x-axis is distance (nm) from 0 to 120000 in increments of 20000 and the y-axis is intensity from 0 to 80 in increments of 10. [Figure 8B]Confocal microscopy images and FI traces of human skin treated with two formulations, F5P2.6-F6COSM5V2-HA5-1+P2 (Figure 8A) and F1-F6COSM5V2-H5-1+P2 (Figure 8B), with HA + FIP formulations: HA5-1 and 5-2, and at two different HA250 / 50 ratios. Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The plane of trace direction is indicated on each micrograph. In the FI traces of FIG. 8B, the x-axis is distance (nm) from 0 to 112730 in increments of 20000 and for HA5-1 (top), the y-axis is intensity from 0 to 99 in increments of 10, while for HA5-2 (bottom), the x-axis is distance (nm) from 0 to 100000 in increments of 10000 and the y-axis is intensity from 0 to 97 in increments of 10. [Figure 9]Confocal microscopy images and FI traces of human skin treated with formulation F5P2.6-F6COSM5V2 with three different HA+FIP formulations: HA5-1+P2 (top), HA6+P2 (middle), and HA8+P2 (bottom). Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. The FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The plane of trace direction is indicated in each micrograph. For the FI traces of HA5-1+P2 (top), the X-axis is distance (nm) from 0 to 133123 in increments of 20000, and the Y-axis is intensity from 0 to 109 in increments of 10. For the FI trace of HA6+P2 (middle), the X-axis is distance (nm) from 0 to 130138 in increments of 20000, and the Y-axis is intensity from 0 to 70 in increments of 10. For the FI trace of HA8+P2 (bottom), the X-axis is distance (nm) from 0 to 118512 in increments of 20000, and the Y-axis is intensity from 0 to 23 in increments of 2. [Figure 10]Confocal microscopy images and FI traces of human skin treated with the formulation F5P2.6-F6COSM5V2 formulated in either propylene glycol (top) or butylene glycol (bottom). Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. The FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in skin layers from the surface of the skin to the upper dermis. The plane of trace direction is indicated on each micrograph. For the FI traces of F5P2.6-F6COSM5V2 formulated in propylene glycol (top), the X-axis is distance (nm) from 0 to 133123 in increments of 20000, and the Y-axis is intensity from 0 to 109 in increments of 10. For the FI of F5P2.6-F6COSM5V2 (bottom) formulated with butylene glycol, the X-axis is distance (nm) from 0 to 120000 in increments of 20000 and the Y-axis is intensity from 0 to 17 in increments of 2. [Figure 11A]Confocal microscopy images and FI traces of human skin treated with formulation F1-F6COSM5NC-HA4-2P are shown. Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. The FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plane of the trace direction is shown in each micrograph. Measurements are shown in 12 different regions, with FIG. 11A showing regions 1, 4, 7, and 10, FIG. 11B showing regions 2, 5, 8, and 11, and FIG. 11C showing regions 3, 6, 9, and 12 (from top to bottom). For each of the FI traces, the X-axis is distance (nm) and the Y-axis is intensity. In FIG. 11A, for region 1, the X-axis is shown as 0 to over 80000 with increments of 10000 and the Y-axis is shown as 0 to 120 with increments of 20; for region 4, the X-axis is shown as 0 to over 140000 with increments of 20000 and the Y-axis is shown as 0 to 100 with increments of 10; for region 7, the X-axis is shown as 0 to over 100000 with increments of 20000 and the Y-axis is shown as 0 to 120 with increments of 20; and for region 10, the X-axis is shown as 0 to over 120000 with increments of 20000 and the Y-axis is shown as 0 to 50 with increments of 5. [Figure 11B]Confocal microscopy images and FI traces of human skin treated with formulation F1-F6COSM5NC-HA4-2P are shown. Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. The FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plane of the trace direction is shown in each micrograph. Measurements are shown in 12 different regions, with FIG. 11A showing regions 1, 4, 7, and 10, FIG. 11B showing regions 2, 5, 8, and 11, and FIG. 11C showing regions 3, 6, 9, and 12 (from top to bottom). For each of the FI traces, the X-axis is distance (nm) and the Y-axis is intensity. In FIG. 11B, for region 2, the X-axis is shown as 0 to over 120000 in increments of 20000 and the Y-axis is shown as 0 to 110 in increments of 10; for region 5, the X-axis is shown as 0 to over 120000 in increments of 20000 and the Y-axis is shown as 0 to 75 in increments of 10; for region 8, the X-axis is shown as 0 to about 100000 in increments of 20000 and the Y-axis is shown as 0 to 170 in increments of 20; and for region 11, the X-axis is shown as 0 to over 150000 in increments of 20000 and the Y-axis is shown as 0 to 60 in increments of 10. [Figure 11C]Confocal microscopy images and FI traces of human skin treated with formulation F1-F6COSM5NC-HA4-2P are shown. Multisome formulations were prepared with rhodamine red-labeled HA250K and green FITC-HA50K. The FI traces show the levels of rhodamine red-labeled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plane of the trace direction is shown in each micrograph. Measurements are shown in 12 different regions, with FIG. 11A showing regions 1, 4, 7, and 10, FIG. 11B showing regions 2, 5, 8, and 11, and FIG. 11C showing regions 3, 6, 9, and 12 (from top to bottom). For each of the FI traces, the X-axis is distance (nm) and the Y-axis is intensity. In FIG. 11C, for region 3, the X-axis is shown as 0 to over 120000 in increments of 20000 and the Y-axis is shown as 0 to over 250 in increments of 50; for region 6, the X-axis is shown as 0 to over 140000 in increments of 20000 and the Y-axis is shown as 0 to over 90 in increments of 10; for region 9, the X-axis is shown as 0 to over 100000 in increments of 10000 and the Y-axis is shown as 0 to 55 in increments of 5; and for region 12, the X-axis is shown as 0 to over 120000 in increments of 20000 and the Y-axis is shown as 0 to 80 in increments of 10. [Figure 12] Confocal microscopy images and FI traces of human skin treated with gel formulation (non-vesicle formulation) as a control formulation are shown. The gel was prepared with rhodamine red labeled HA250K and green FITC-HA50K. The FI traces show the levels of rhodamine red labeled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. A plane of trace direction is shown in each micrograph. Measurements are shown in two different regions. For the FI traces of region 1 (top), the X-axis is the distance (nm) from 0 to 140000 in increments of 20000, and the Y-axis is the intensity from 0 to 80 in increments of 10. For the FI traces of region 2 (bottom), the X-axis is the distance (nm) from 0 to 112386 in increments of 20000, and the Y-axis is the intensity from 0 to 80 in increments of 10. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] definition As used herein, the term "comprise" or variations such as "comprises" or "comprising" are intended to indicate the inclusion of any recited features, but not the exclusion of any other features. Thus, as used herein, the term "comprising" is inclusive and does not exclude additional unrecited features. In some embodiments of any of the compositions and methods provided herein, "comprising" may be replaced with "consisting essentially of" or "consisting of." The phrase "consisting essentially of" is used to require specified characteristics or characteristics that do not substantially affect the characteristics or function of the invention. As used herein, the term "consisting" is used to indicate the presence of only the recited features.
[0015] As used in this specification and the appended claims, unless otherwise specified, the following terms have the following meanings.
[0016] As used herein, the term " pharmaceutically acceptable salt " includes both acid salt and base addition salt. The pharmaceutically acceptable salt of any one of the compounds described herein is intended to include all pharmaceutically appropriate salt forms. The preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0017] As used herein, the term "unmodified peptide" refers to a peptide that is not terminally modified to include additional functional groups. In some embodiments, the peptide is not modified to include a functional group that enhances transdermal penetration, such as an octanoyl group, a decanoyl group, a lauroyl group, a myristoyl group, a palmitoyl group, a stearoyl group, a biotinoyl group, an elaidoyl group, an oleoyl group, or a lipoyl group. In some embodiments, the peptide is not modified to include oleanolic acid.
[0018] As used herein, "treatment" or "treating" or "alleviating" or "ameliorating" are used interchangeably. These terms refer to an approach to obtain a beneficial or desired outcome, including but not limited to a therapeutic benefit and / or a prophylactic benefit. A "therapeutic benefit" refers to the eradication or amelioration of the underlying disease being treated. Similarly, a therapeutic benefit is achieved by the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disease, such that an improvement is observed in the patient, even though the patient still suffers from the underlying disease. For a prophylactic benefit, the composition is administered, in some embodiments, to a patient at risk of developing a particular disease, or to a patient who reports one or more of the physiological symptoms of the disease, even if the disease has not been diagnosed.
[0019] As used herein, "conservative substitution" refers to the replacement of one amino acid with another amino acid that has similar properties, such as size, charge, and polarity. Substitutions can be naturally occurring or modified (e.g., non-natural amino acids). Non-limiting examples of what can be replaced with conservative substitutions include the following groups: large hydrophobic (valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, methionine), small non-polar (alanine, glycine), polar (serine, threonine, glutamine, asparagine, cysteine, histidine), positively charged (lysine, arginine), negatively charged (glutamic acid, aspartic acid).
[0020] Where % is used herein to refer to the amount of a component, unless otherwise specified, % is intended to be % w / w.
[0021] The terms "penetration enhancing agents" and "penetration enhancers" are used interchangeably herein. As used herein, this refers to one or more ingredients that facilitate or enhance the penetration of one or more active ingredients (e.g., anionic polymeric materials such as hyaluronic acid or one or more peptides) through one or more layers of the skin of a subject. In some embodiments, the penetration enhancer is a surfactant, e.g., a nonionic surfactant having a hydrophilic-lipophilic balance (HLB) of about 10 or less, a cationic group, or another agent such as a terpene, an alkaloid, a salicylic acid derivative, a nicotinic acid derivative, or any combination thereof.
[0022] The term "multisome" as used herein refers to a lipid vesicle (such as a biphasic lipid vesicle) that contains one or more penetration enhancers, and in preferred embodiments, contains multiple penetration enhancers that act synergistically. In some embodiments, a multisome comprises a vesicle whose central core compartment is occupied by an oil-in-water emulsion composed of an aqueous continuous phase and a dispersed hydrophobic, hydrophilic, or oil phase. In one embodiment, the space between adjacent bilayers of the lipid vesicle may also be occupied by an emulsion.
[0023] The term "lipid vesicle composition" as used herein refers to a composition that includes one or more lipid vesicles (e.g., multisome lipid vesicles, lipid bilayer vesicles, etc.). When a lipid vesicle composition is described as "comprising" one or more additional components (e.g., anionic polymeric materials or one or more peptides provided herein), it is intended that the composition includes the additional components in any manner within the composition (e.g., encapsulated within the lipid vesicle, etc.). For example, a lipid vesicle composition that includes an anionic polymeric material may include the anionic polymeric material encapsulated within the lipid bilayer of the lipid vesicle composition.
[0024] As used herein, the term "emulsion" refers to a mixture of two immiscible substances.
[0025] The term "bilayer" as used herein refers to a structure composed of amphiphilic lipid molecules arranged in two molecular layers, with the hydrophobic tails on the inner surface and the polar head groups on the outer surface.
[0026] As used herein, the term "topical administration" or "topical delivery" refers to intradermal, transdermal, and / or transmucosal delivery of a compound by administration of a compound or a composition containing multiple compounds to the skin and / or mucosa.
[0027] The term "gemini surfactant" as used herein refers to a surfactant molecule that contains multiple hydrophobic tails, each of which has a hydrophilic head, and the hydrophobic tails or hydrophilic heads are linked to each other by a spacer moiety. The hydrophobic tails may be the same or different. Similarly, the hydrophilic heads may be the same or different. The hydrophilic heads may be anionic, cationic, or neutral.
[0028] The term "HLB" or "Hydrophilic-Lipophilic Balance" value refers to the standard HLB according to Griffin, J. Soc. Cosm. Chem., vol. 5, 249 (1954), which indicates the degree of hydrophilicity and lipophilicity of a surfactant.
[0029] Lipid vesicle compositions of anionic polymeric materials such as hyaluronic acid for intradermal delivery - Patent Application 20070229933 In one aspect, a lipid vesicle composition comprising an anionic polymeric material is provided herein. In some embodiments, the lipid vesicle composition comprises lipid vesicles comprising lipid bilayers, each comprising vesicle-forming lipids. In some embodiments, the lipid vesicle composition comprises an oil-in-water emulsion encapsulated in the lipid vesicle. In some embodiments, the oil-in-water emulsion is stabilized by one or more surfactants. In some embodiments, the anionic polymeric material is encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the anionic polymeric material is hyaluronic acid.
[0030] Anionic Polymer Materials In some aspects, the lipid vesicle compositions provided herein include anionic polymeric materials. The anionic polymeric materials are desirably adapted for delivery below the skin surface of a subject. In some embodiments, the anionic polymeric materials act as volumizers or fillers after being delivered below the skin surface. In some embodiments, the anionic polymeric materials act as support for another layer of the skin (e.g., the epidermis) to correct skin depressions or restore facial volume. In some embodiments, the anionic polymeric materials are not crosslinked. In some embodiments, the anionic polymeric materials are crosslinked (e.g., crosslinked hyaluronic acid such as Hyacros™ TL100).
[0031] In some embodiments, the anionic polymeric material comprises an anionic polysaccharide. In some embodiments, the anionic polysaccharide is a non-sulfated glycosaminoglycan. In some embodiments, the anionic polymeric material is a naturally occurring substance. In some embodiments, the anionic polymeric material is naturally occurring in humans. In some embodiments, the anionic polymeric material is naturally occurring in human connective or epithelial tissue. In some embodiments, the anionic polymeric material is hyaluronic acid or a pharma- ceutically acceptable salt thereof.
[0032] In some embodiments, the hyaluronic acid is a pharma- ceutically acceptable salt of hyaluronic acid. In some embodiments, the salt is a sodium salt, a potassium salt, a magnesium salt, or any combination thereof. In some embodiments, the salt is a sodium salt.
[0033] In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the molecular weight is a weight average molecular weight. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 10 kDa, about 5 kDa to about 20 kDa, about 5 kDa to about 50 kDa, about 5 kDa to about 100 kDa, about 5 kDa to about 200 kDa, about 5 kDa to about 250 kDa, about 5 kDa to about 300 kDa, about 5 kDa to about 400 kDa, about 5 kDa to about 500 kDa, about 10 kDa to about 20 kDa, about 10 kDa to about 50 kDa, about 10 kDa to about 100 kDa, about 10 kDa to about 200 kDa, about 10 kDa to about 250 kDa, about 10 kDa to about 300 kDa, about 10 kDa to about 400 kDa, about 10 kDa to about 500 kDa, about 20 kDa to about 50 kDa, about 20 kDa to about 100 kDa, about 20 kDa to about 200 kDa, about 20 kDa to about 250 kDa, about 20 kDa to about 300 kDa, about 20 kDa to about 400 kDa, About 20 kDa to about 500 kDa, about 50 kDa to about 100 kDa, about 50 kDa to about 200 kDa, about 50 kDa to about 250 kDa, about 50 kDa to about 300 kDa, about 50 kDa to about 400 kDa, about 50 kDa to about 500 kDa, about 100 kDa to about 200 kDa, about 100 kDa to about 250 kDa, about 100 kDa to about 300 kDa, about 100 kDa to about 400 kDa, about 100 kDa to about The polypeptide has a molecular weight of 500 kDa, about 200 kDa to about 250 kDa, about 200 kDa to about 300 kDa, about 200 kDa to about 400 kDa, about 200 kDa to about 500 kDa, about 250 kDa to about 300 kDa, about 250 kDa to about 400 kDa, about 250 kDa to about 500 kDa, about 300 kDa to about 400 kDa, about 300 kDa to about 500 kDa, or about 400 kDa to about 500 kDa. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa, about 10 kDa, about 20 kDa, about 50 kDa, about 100 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 400 kDa, or about 500 kDa.In some embodiments, the anionic polymeric material has a molecular weight of at least about 5 kDa, about 10 kDa, about 20 kDa, about 50 kDa, about 100 kDa, about 200 kDa, about 250 kDa, about 300 kDa, or about 400 kDa. In some embodiments, the anionic polymeric material has a molecular weight of at most about 10 kDa, about 20 kDa, about 50 kDa, about 100 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 400 kDa, or about 500 kDa.
[0034] In some embodiments, the anionic polymeric material is present in an amount of about 0.01 wt % to about 1 wt %. In some embodiments, the anionic polymeric material is from about 0.01 wt % to about 0.02 wt %, from about 0.01 wt % to about 0.05 wt %, from about 0.01 wt % to about 0.08 wt %, from about 0.01 wt % to about 0.1 wt %, from about 0.01 wt % to about 0.15 wt %, from about 0.01 wt % to about 0.2 wt %, from about 0.01 wt % to about 0.25 wt %, from about 0.01 wt % to about 0.3 wt %, from about 0.01 wt % to about 0.4 wt %, from about 0.01 wt % to about 0.5 wt %, from about 0.01 wt % to about 1 wt %, from about 0.02 wt % to about 0.05 wt %, from about 0.0 2wt% ~ approx. 0.08wt%, approx. 0.02wt% ~ approx. 0.1wt%, approx. 0.02wt% ~ approx. 0.15wt%, approx. 0.02wt% ~ approx. 0.2wt%, about 0.02wt% to about 0.25wt%, about 0.02wt% to about 0.3wt%, about 0.02wt% to about 0.4wt%, about 0.02wt%~about 0.5wt%, about 0.02wt%~about 1wt%, about 0.05wt%~about 0.08wt%, about 0.05wt%~about 0.1wt%, about 0.05wt% to about 0.15wt%, about 0.05wt% to about 0.2wt%, about 0.05wt% to about 0.25wt%, Approx. 0.05wt%~Approx. 0.3wt%, Approx. 0.05wt%~Approx. 0.4wt%, Approx. 0.05wt%~Approx. 0.5wt%, Approx. 0.05wt% ~approx. 1wt%, approx. 0.08wt% ~ approx. 0.1wt%, approx. 0.08wt% ~ approx. 0.15wt%, approx. 0.08wt% ~ approx. 0.2wt%, Approx. 0.08wt%~Approx. 0.25wt%, Approx. 0.08wt%~Approx. 0.3wt%, Approx. 0.08wt%~Approx. 0.4wt%, Approx. 0.08wt %~about 0.5wt%, about 0.08wt%~about 1wt%, about 0.1wt%~about 0.15wt%, about 0.1wt%~about 0.2wt%, about 0 .1wt% ~ approx. 0.25wt%, approx. 0.1wt% ~ approx. 0.3wt%, approx. 0.1wt% ~ approx. 0.4wt%, approx. 0.1wt% ~ approx. 0.5 wt%, about 0.1wt% to about 1wt%, about 0.15wt% to about 0.2wt%, about 0.15wt% to about 0.25wt%, about 0.15wt %~about 0.3wt%, about 0.15wt%~about 0.4wt%, about 0.15wt%~about 0.5wt%, about 0.15wt%~about 1wt%, About 0.2wt%~about 0.25wt%, about 0.2wt%~about 0.3wt%, about 0.2wt%~about 0.4wt%, about 0.2wt%~about 0.5 wt%, about 0.2 wt% to about 1 wt%, about 0.25 wt% to about 0.3 wt%, about 0.25 wt% to about 0.4 wt%, about 0.25 wt% to about 0.5 wt%, about 0.25 wt% to about 1 wt%, about 0.3 wt% to about 0.4 wt%, about 0.3 wt% to about 0.5 wt%, about 0.3 wt% to about 1 wt%, about 0.4 wt% to about 0.5 wt%, about 0.4 wt% to about 1 wt%, or about 0.5 wt% to about 1 wt%. In some embodiments, the anionic polymeric material is present in an amount of about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or 1 wt%. In some embodiments, the anionic polymeric material is present in an amount of at least about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, or about 0.5 wt%. In some embodiments, the anionic polymeric material is present in an amount of up to about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or 1 wt%.
[0035] In some embodiments, the lipid vesicle composition comprises a first anionic polymeric material and a second anionic polymeric material. In some embodiments, the first anionic polymeric material and the second anionic polymer are different types. In some embodiments, each of the first anionic polymeric material and the second anionic polymeric material is a different type of anionic polysaccharide. In some embodiments, the first anionic polymeric material and the second anionic polymeric material are the same type. In some embodiments, each of the first anionic polymeric material and the second anionic polymeric material is an anionic polysaccharide. In some embodiments, each of the first anionic polymeric material and the second anionic polymer is hyaluronic acid.
[0036] When the first anionic polymeric material and the second anionic polymeric material are the same type, each of the anionic polymeric materials has a different molecular weight.In some embodiments, the first anionic polymeric material has a molecular weight of up to about 75 kDa, and the second anionic polymeric material has a molecular weight of more than about 75 kDa.In some embodiments, the first anionic polymeric material has a molecular weight of up to about 75 kDa, and the second anionic polymeric material has a molecular weight of more than about 75 kDa.In some embodiments, the first anionic polymer comprises sodium hyaluronate having a molecular weight of 50 kDa, and the second anionic polymer comprises sodium hyaluronate having a molecular weight of 250 kDa.
[0037] When the lipid vesicle comprises a first anionic polymeric material and a second anionic polymeric material, each component may be present in different amounts. In some embodiments, the first anionic polymeric material and the second anionic polymeric material are present in approximately the same amount. In some embodiments, the ratios provided herein include weight ratios. In some embodiments, the ratio of the first anionic material to the second anionic material is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 3:2, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some embodiments, the weight ratio of the first anionic material and the second anionic material is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 3:2, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some embodiments, the first anionic polymeric material and the second anionic polymer, which include sodium hyaluronate having molecular weights of 50 kDa and 250 kDa, respectively, are present in a ratio of about 1:2. In some cases, the sodium hyaluronate having molecular weights of 250 kDa is present at 0.1 wt%, and the sodium hyaluronate having molecular weights of 50 kDa is present at 0.05 wt%. In some embodiments, the first anionic polymeric material and the second anionic polymer, comprising sodium hyaluronate having molecular weights of 50 kDa and 250 kDa, respectively, are present in a ratio of about 1:1. In some cases, the sodium hyaluronate having a molecular weight of 250 kDa is present at 0.1 wt% and the sodium hyaluronate having a molecular weight of 50 kDa is present at 0.1 wt%.
[0038] In some embodiments, the combination of the first anionic polymer and the second anionic polymer is present in an amount of about 0.01 wt % to about 1 wt %. In some embodiments, the combination is from about 0.01 wt% to about 0.02 wt%, from about 0.01 wt% to about 0.05 wt%, from about 0.01 wt% to about 0.08 wt%, from about 0.01 wt% to about 0.1 wt%, from about 0.01 wt% to about 0.15 wt%, from about 0.01 wt% to about 0.2 wt%, from about 0.01 wt% to about 0.25 wt%, from about 0.01 wt% to about 0.3 wt%, from about 0.01 wt% to about 0.4 wt%, from about 0.01 wt% to about 0.5 wt%, from about 0.01 wt% to about 1 wt%, from about 0.02 wt% to about 0.05 wt%, from about 0.02 wt%~about 0.08wt%, about 0.02wt%~about 0.1wt%, about 0.02wt%~about 0.15wt%, about 0.02wt%~about 0.2wt%, about 0.02wt%~about 0.25wt%, about 0.02wt%~about 0.3wt%, about 0.02wt%~about 0.4wt% , about 0.02wt% to about 0.5wt%, about 0.02wt% to about 1wt%, about 0.05wt% to about 0.08wt%, about 0.05wt % ~ approx. 0.1wt%, approx. 0.05wt% ~ approx. 0.15wt%, approx. 0.05wt% ~ approx. 0.2wt%, approx. 0.05wt% ~ approx. 0.2 5wt%, about 0.05wt% to about 0.3wt%, about 0.05wt% to about 0.4wt%, about 0.05wt% to about 0.5wt%, about 0 .05wt% ~ approx. 1wt%, approx. 0.08wt% ~ approx. 0.1wt%, approx. 0.08wt% ~ approx. 0.15wt%, approx. 0.08wt% ~ approx. 0.2wt%, about 0.08wt% to about 0.25wt%, about 0.08wt% to about 0.3wt%, about 0.08wt% to about 0.4wt% , about 0.08wt%~about 0.5wt%, about 0.08wt%~about 1wt%, about 0.1wt%~about 0.15wt%, about 0.1wt%~ Approx. 0.2wt%, Approx. 0.1wt%~Approx. 0.25wt%, Approx. 0.1wt%~Approx. 0.3wt%, Approx. 0.1wt%~Approx. 0.4wt%, Approx. 0.1wt%~about 0.5wt%, about 0.1wt%~about 1wt%, about 0.15wt%~about 0.2wt%, about 0.15wt%~about 0. 25wt%, about 0.15wt% to about 0.3wt%, about 0.15wt% to about 0.4wt%, about 0.15wt% to about 0.5wt%, about 0.15wt%~about 1wt%, about 0.2wt%~about 0.25wt%, about 0.2wt%~about 0.3wt%, about 0.2wt%~about 0.4 wt%, about 0.2 wt% to about 0.5 wt%, about 0.2 wt% to about 1 wt%, about 0.25 wt% to about 0.3 wt%, about 0.25 wt% to about 0.4 wt%, about 0.25 wt% to about 0.5 wt%, about 0.25 wt% to about 1 wt%, about 0.3 wt% to about 0.4 wt%, about 0.3 wt% to about 0.5 wt%, about 0.3 wt% to about 1 wt%, about 0.4 wt% to about 0.5 wt%, about 0.4 wt% to about 1 wt%, or about 0.5 wt% to about 1 wt%. In some embodiments, the combination is present in an amount of about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or 1 wt%. In some embodiments, the combination is present in an amount of at least about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, or about 0.5 wt%. In some embodiments, the combination is present in an amount of up to about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or 1 wt%. For example, the first anionic polymer may be present in an amount of about 0.1 wt%, and the second anionic polymer may be present in an amount of about 0.05 wt%. As a further example, the second anionic polymer may be present in an amount of about 0.1 wt%, and the first anionic polymer may be present in an amount of about 0.05 wt%.
[0039] In some embodiments, the composition comprises a first, a second, and a third anionic polymeric material. In some embodiments, the anionic polymeric materials can be of the same type (e.g., three different molecular weights of hyaluronic acid). In some embodiments, two of the three anionic polymeric materials are of the same type. In some embodiments, each of the anionic polymeric materials is of a different type. In some embodiments, the first anionic polymeric material, the second anionic polymeric material, the third anionic polymeric material, or any combination thereof, is not crosslinked. In some embodiments, the first anionic polymeric material, the second anionic polymeric material, or both are not crosslinked. In some embodiments, the third anionic polymeric material is crosslinked. In some embodiments, the third anionic polymeric material comprises a sodium hyaluronate crosspolymer. The sodium hyaluronate crosspolymer may be in a composition that includes one or more solvents, such as water and / or pentylene glycol. In some embodiments, the crosslinked polymer is in a gel form. In some embodiments, the first anionic polymeric material has a molecular weight of about 5 kDa to about 20 kDa, the second anionic polymeric material has a molecular weight of about 20 kDa to about 75 kDa, and the third anionic polymeric material has a molecular weight greater than about 75 kDa.
[0040] In some embodiments, each of the three anionic polymeric materials is present in approximately the same amount. In some embodiments, each of the three anionic polymeric materials is present in approximately different amounts. In some embodiments, the first anionic polymeric material, the second anionic polymeric material, the third anionic polymeric material, or any combination thereof, is present in an amount of about 0.1 mg / g to about 10 mg / g each. In some embodiments, the first anionic polymeric material, the second anionic polymeric material, the third anionic polymeric material, or any combination thereof, is present in an amount of about 0.01% to about 1% each.
[0041] In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / mL to about 10 mg / mL. In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / mL to about 0.05 mg / mL, 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 1.25 mg / mL, about 0.01 mg / mL to about 1.5 mg / mL, about 0.01 mg / mL to about 1.75 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0. 05mg / mL~about 0.1mg / mL, about 0.05mg / mL~about 0.5mg / mL, about 0.05mg / mL~about 1mg / mL, about 0.05mg / mL~about 1.25mg / mL, about 0.05mg / mL~about 1.5mg / mL, about 0.05mg / mL~1.75 mg / mL, approximately 0.05 mg / mL to approximately 2 mg / mL, approximately 0.05 mg / mL to approximately 5 mg / mL, approximately 0.05 mg / mL to approximately 10 mg / mL, approximately 0.1 mg / mL to approximately 0.5 mg / mL, approximately 0.1 mg / mL to approximately 1 mg / mL, approximately 0.1 mg / mL to approximately 1.25 mg / mL, approximately 0.1 mg / mL to approximately 1.5 mg / mL, approximately 0.1 mg / mL to approximately 1.75 mg / mL, approximately 0.1 mg / mL to approximately 2 mg / mL, approximately 0.1 mg / mL to approximately 5 mg / mL, approximately 0.1 mg / mL to approximately 10 mg / mL, approximately 0.5 mg / mL to approximately 1 mg / mL, about 0.5mg / mL to about 1.25mg / mL, about 0.5mg / mL to about 1.5mg / mL, about 0.5mg / mL to about 1.75mg / mL, about 0.5mg / mL to about 2mg / mL, about 0.5mg / mL to about 5mg / mL, about 0.5mg / mL to about 10mg / mL, about 1mg / mL to 1.25mg / mL, about 1mg / mL to about 1.5mg / mL, about 1mg / mL to about 1.75mg / mL, about 1mg / ml to about 2mg / ml, about 1mg / ml to about 5mg / ml, about 1mg / ml to about 10mg / ml, about 1.25mg / mL ml~about 1.5mg / ml, about 1.25mg / ml~about 1.75mg / ml, about 1.25mg / ml~about 2mg / ml, about 1.25mg / ml~about 5mg / ml, about 1.25mg / ml~about 10mg / ml, about 1.5mg / ml~about 1.75mg / ml, about 1.The anionic polymeric material is present in an amount of about 5 mg / mL to about 2 mg / mL, about 1.5 mg / mL to about 5 mg / mL, about 1.5 mg / mL to about 10 mg / mL, about 1.75 mg / mL to about 2 mg / mL, about 1.75 mg / mL to about 5 mg / mL, about 1.75 mg / mL to about 10 mg / mL, about 2 mg / mL to 5 mg / mL, about 2 mg / mL to about 10 mg / mL, or about 5 mg / mL to about 10 mg / mL. In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL. In some embodiments, the anionic polymeric material is present in an amount of at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, or about 5 mg / mL. In some embodiments, the anionic polymeric material is present in an amount of at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL.
[0042] In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / g to about 10 mg / g. In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / g to about 0.05 mg / g, 0.01 mg / g to about 0.1 mg / g, about 0.01 mg / g to about 0.5 mg / g, about 0.01 mg / g to about 1 mg / g, about 0.01 mg / g to about 2.5 mg / g, about 0.01 mg / g to about 5 mg / g, about 0.01 mg / g to about 7.5 mg / g, about 0.01 mg / g to about 10 ... About 10mg / g, about 0.05mg / g to about 0.1mg / g, about 0.05mg / g to about 0.5mg / g, about 0.05mg / g to about 1mg / g, about 0.05mg / g to about 2.5mg / g, Approximately 0.05mg / g to approximately 5mg / g, approximately 0.05mg / g to approximately 7.5mg / g, approximately 0.05mg / g to approximately 10mg / g, approximately 0.1mg / g to approximately 0.5mg / g, approximately 0.1mg / g to approximately 1mg / g, about 0.1mg / g to about 2.5mg / g, about 0.1mg / g to about 5mg / g, about 0.1mg / g to about 7.5mg / g, about 0.1mg / g to about 10mg / g, about 0.5mg / g g~about 1mg / g, about 0.5mg / g~about 2.5mg / g, about 0.5mg / g~about 5mg / g, about 0.5mg / g~about 7.5mg / g, about 0.5mg / g~about 10mg / g, about 1mg In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / g, about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, about 7.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, about 7.5 mg / g, about 10 mg / g, or about 7.5 mg / g to about 10 mg / g. In some embodiments, the anionic polymeric material is present in an amount of about 0.01 mg / g, about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, about 7.5 mg / g, or about 10 mg / g. In some embodiments, the anionic polymeric material is present in an amount of at least about 0.01 mg / g, about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, or about 7.5 mg / g.In some embodiments, the anionic polymeric material is present in an amount of at most about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, about 7.5 mg / g, or about 10 mg / g. As an example, the anionic polymeric material is present in an amount of about 1 mg to about 1000 mg per 100 g of product.
[0043] In some embodiments, the combination of the first anionic polymeric material and the second anionic polymeric material is present in an amount of about 0.01 mg / g to about 10 mg / g. In some embodiments, the combination of the first anionic polymeric material and the second anionic polymeric material is present in an amount of about 0.01 mg / mL to about 10 mg / mL. In some embodiments, the combination of the first anionic polymeric material and the second anionic polymeric material is present in an amount of about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2.5 mg / mL, Approx. 0.01 mg / mL to approx. 5 mg / mL, approx. 0.01 mg / mL to approx. 7.5 mg / mL, approx. 0.01 mg / mL to approx. 10 mg / mL, approx. 0.05 mg / mL to approx. 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about 1 mg / mL, about 0.05 mg / mL to about 2.5 mg / mL, about 0.05 mg / mL mL ~ approx. 5 mg / mL, approx. 0.05 mg / mL ~ approx. 7.5 mg / mL, approx. 0.05 mg / mL ~ 10 mg / mL, approx. 0.1 mg / mL ~ approx. 0.5 mg / mL, approx. 0.1 mg / mL ~ approx. 1 mg / mL, approx. 0.1 mg / mL ~ approx. 2.5 mg / mL, approx. 0.1 mg / mL ~ approx. 5 mg / mL, approx. 0.1 mg / mL ~ approx. 7.5 mg / mL, approx. 0. It is present in an amount of from 1 mg / mL to about 10 mg / mL, from about 0.5 mg / mL to about 1 mg / mL, from about 0.5 mg / mL to about 2.5 mg / mL, from about 0.5 mg / mL to about 5 mg / mL, from about 0.5 mg / mL to about 7.5 mg / mL, from about 0.5 mg / mL to about 10 mg / mL, from about 1 mg / mL to about 2.5 mg / mL, from about 1 mg / mL to about 5 mg / mL, from about 1 mg / mL to about 7.5 mg / mL, from about 1 mg / mL to about 10 mg / mL, from about 2.5 mg / mL to about 5 mg / mL, from about 2.5 mg / mL to about 7.5 mg / mL, from about 2.5 mg / mL to about 10 mg / mL, from about 5 mg / mL to about 7.5 mg / mL, from about 5 mg / mL to about 10 mg / mL, or from about 7.5 mg / mL to about 10 mg / mL.In some embodiments, the combination of the first and second anionic polymeric materials is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the combination of the first and second anionic polymeric materials is present in an amount of at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL. In some embodiments, the combination of the first and second anionic polymeric materials is present in an amount of at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. As an example, the combination of the first and second anionic polymeric materials is present in an amount of about 1 mg to about 1000 mg per 100 g of product.
[0044] In some embodiments, the first anionic polymeric material is present in an amount of about 0.01 mg / g to about 10 mg / g. In some embodiments, the first anionic polymeric material is present in an amount of about 0.01 mg / mL to about 0.05 mg / mL, 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2.5 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 7.5 mg / mL, about 0.01 mg / mL to about 10mg / mL, approximately 0.05mg / mL to approximately 0.1mg / mL, approximately 0.05mg / mL to approximately 0.5mg / mL, approximately 0.05mg / mL to approximately 1mg / mL, approximately 0.05mg / mL to approximately 2.5mg / mL, approximately 0.05mg / mL to approx. 5mg / mL, approx. 0.05mg / mL to approx. 7.5mg / mL, approx. 0.05mg / mL to approx. 10mg / mL, approx. 0.1mg / mL to approx. 0.5mg / mL, approx. 0.1mg / mL to approx. 1m g / mL, approximately 0.1 mg / mL to approximately 2.5 mg / mL, approximately 0.1 mg / mL to approximately 5 mg / mL, approximately 0.1 mg / mL to approximately 7.5 mg / mL, approximately 0.1 mg / mL to approximately 10 mg / mL, approximately 0.5 mg / mL ~1mg / mL, approximately 0.5mg / mL~2.5mg / mL, approximately 0.5mg / mL~5mg / mL, approximately 0.5mg / mL~7.5mg / mL, approximately 0.5mg / mL~10mg / mL, approximately 1mg / m In some embodiments, the first anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, or about 7.5 mg / mL. In some embodiments, the first anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL.In some embodiments, the first anionic polymeric material is present in an amount of at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL. In some embodiments, the first anionic polymeric material is present in an amount of up to about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the second anionic polymeric material is present in an amount of about 0.01 mg / g to about 10 mg / g.In some embodiments, the second anionic polymeric material is from about 0.01 mg / mL to about 0.05 mg / mL, 0.01 mg / mL to about 0.1 mg / mL, from about 0.01 mg / mL to about 0.5 mg / mL, from about 0.01 mg / mL to about 1 mg / mL, from about 0.01 mg / mL to about 2.5 mg / mL, from about 0.01 mg / mL to about 5 mg / mL, from about 0.01 mg / mL to about 7.5 mg / mL, from about 0.01 mg / mL to about 10mg / mL, approximately 0.05mg / mL to approximately 0.1mg / mL, approximately 0.05mg / mL to approximately 0.5mg / mL, approximately 0.05mg / mL to approximately 1mg / mL, approximately 0.05mg / mL to approximately 2.5mg / mL, approximately 0.05mg / mL to approx. 5mg / mL, approx. 0.05mg / mL to approx. 7.5mg / mL, approx. 0.05mg / mL to approx. 10mg / mL, approx. 0.1mg / mL to approx. 0.5mg / mL, approx. 0.1mg / mL to approx. 1m g / mL, approximately 0.1 mg / mL to approximately 2.5 mg / mL, approximately 0.1 mg / mL to approximately 5 mg / mL, approximately 0.1 mg / mL to approximately 7.5 mg / mL, approximately 0.1 mg / mL to approximately 10 mg / mL, approximately 0.5 mg / mL ~1mg / mL, approximately 0.5mg / mL~2.5mg / mL, approximately 0.5mg / mL~5mg / mL, approximately 0.5mg / mL~7.5mg / mL, approximately 0.5mg / mL~10mg / mL, approximately 1mg / m In some embodiments, the second anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, or about 7.5 mg / mL. In some embodiments, the second anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the second anionic polymeric material is present in an amount of at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL.In some embodiments, the second anionic polymeric material is present in an amount of at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some examples, the first anionic polymer is present in an amount of 0.25 mg / g and the second anionic polymer is present in an amount of about 0.5 mg / g. In some examples, the first anionic polymer is present in an amount of 0.5 mg / g and the second anionic polymer is present in an amount of about 1 mg / g. In some examples, the first anionic polymer is present in an amount of 0.5 mg / g and the second anionic polymer is present in an amount of about 0.5 mg / g. In some examples, the first anionic polymer is present in an amount of 1 mg / g and the second anionic polymer is present in an amount of about 1 mg / g. In some examples, the first anionic polymer is present in an amount of 1 mg / g and the second anionic polymer is present in an amount of about 2 mg / g. In some examples, the first anionic polymeric material is present in an amount of about 1 mg to about 500 mg per 100 g of product. In some examples, the second anionic polymeric material is present in an amount of about 5 mg to about 1000 mg per 100 g of product. In some embodiments, the composition further comprises a third anionic polymeric material present in an amount of about 0.01 mg / g to about 10 mg / g.In some embodiments, the third anionic polymeric material is from about 0.01 mg / mL to about 0.05 mg / mL, 0.01 mg / mL to about 0.1 mg / mL, from about 0.01 mg / mL to about 0.5 mg / mL, from about 0.01 mg / mL to about 1 mg / mL, from about 0.01 mg / mL to about 2.5 mg / mL, from about 0.01 mg / mL to about 5 mg / mL, from about 0.01 mg / mL to about 7.5 mg / mL, from about 0.01 mg / mL to about 10mg / mL, approximately 0.05mg / mL to approximately 0.1mg / mL, approximately 0.05mg / mL to approximately 0.5mg / mL, approximately 0.05mg / mL to approximately 1mg / mL, approximately 0.05mg / mL to approximately 2.5mg / mL, approximately 0.05mg / mL to approx. 5mg / mL, approx. 0.05mg / mL to approx. 7.5mg / mL, approx. 0.05mg / mL to approx. 10mg / mL, approx. 0.1mg / mL to approx. 0.5mg / mL, approx. 0.1mg / mL to approx. 1m g / mL, approximately 0.1 mg / mL to approximately 2.5 mg / mL, approximately 0.1 mg / mL to approximately 5 mg / mL, approximately 0.1 mg / mL to approximately 7.5 mg / mL, approximately 0.1 mg / mL to approximately 10 mg / mL, approximately 0.5 mg / mL ~1mg / mL, approximately 0.5mg / mL~2.5mg / mL, approximately 0.5mg / mL~5mg / mL, approximately 0.5mg / mL~7.5mg / mL, approximately 0.5mg / mL~10mg / mL, approximately 1mg / m In some embodiments, the third anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, or about 7.5 mg / mL. In some embodiments, the third anionic polymeric material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the third anionic polymeric material is present in an amount of at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL.In some embodiments, the third anionic polymeric material is present in an amount of at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some examples, the third anionic polymer is present in an amount of about 0.1 mg / g. In some examples, the third anionic polymer is present in an amount of about 0.2 mg / g. In some examples, the third anionic polymer is present in an amount of about 0.5 mg / g. In some examples, the third anionic polymer is present in an amount of about 1 mg / g. In some examples, the third anionic polymer is present in an amount of about 2 mg / g. In some examples, the third anionic polymer is present in an amount of about 5 mg / g. In some examples, the third anionic polymeric material is present in an amount of about 1 mg to 500 mg per 100 g of product.
[0045] vesicle-forming lipids In some embodiments, the vesicle composition comprises one or more vesicle-forming lipids. The vesicle-forming lipids act to encapsulate a portion of the oil-in-water emulsion. In some embodiments, this allows the oil-in-water emulsion to remain stable for a period of time.
[0046] The vesicle-forming lipid can be any lipid suitable for such purpose.In some embodiments, the vesicle-forming lipid comprises phospholipid, glycolipid, lecithin, ceramide, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof.In some embodiments, the vesicle-forming lipid comprises a combination of lipids.
[0047] In some embodiments, the vesicle-forming lipid comprises a phospholipid. In some embodiments, the phospholipid is naturally occurring, semi-synthetic, or synthetically prepared, or a mixture thereof. In one embodiment, the phospholipid is one or more esters of glycerol with one or two (equal or different) residues of fatty acid and phosphoric acid, where the phosphoric acid residue is in turn bound to a hydrophilic group, such as, for example, choline (phosphatidylcholine (PC)), serine (phosphatidylserine (PS)), glycerol (phosphatidylglycerol (PG)), ethanolamine (phosphatidylethanolamine (PE)), or inositol (phosphatidylinositol). Phospholipid esters with only one fatty acid residue are commonly referred to in the art as the "lyso" form of phospholipid, or "lysophospholipid". Usually, the fatty acid residues present in phospholipids are long chain aliphatic acids, typically containing 12-24 carbon atoms, or 14-22 carbon atoms, and the aliphatic chain may contain one or more unsaturations, or may be fully saturated. Examples of suitable fatty acids contained in phospholipids are, for example, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, and linolenic acid. Saturated fatty acids such as myristic acid, palmitic acid, stearic acid, and arachidic acid may be used.
[0048] In some embodiments, the phospholipid comprises one or more natural phospholipids. In some embodiments, the phospholipid comprises one or more semi-synthetic phospholipids. In some embodiments, the semi-synthetic phospholipid is a partially or fully hydrogenated derivative of naturally occurring lecithin. In some embodiments, the phospholipid comprises a fatty acid diester of phosphatidylcholine, ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, or sphingomyelin. In some embodiments, the phospholipid comprises hydrogenated phosphatidylcholine (e.g., Sunlipon 90H). In some embodiments, the phospholipid may be, for example, dilauroyl-phosphatidylcholine (DLPC), dimyristoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidylcholine (DPPC), diarachidoyl-phosphatidylcholine (DAPC), distearoyl-phosphatidylcholine (DSPC), dioleoyl-phosphatidylcholine (DOPC), 1,2 distearoyl-sn-glycero-3-ethylphosphocholine (ethyl-DSPC), dipentadecanoyl-phosphatidylcholine (DPDPC), 1-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC), 1-palmitoyl-2-myristoyl-phosphatidylcholine (PMPC), 1-palmitoyl-2-stearoyl-phosphatidylcholine (P SPC), 1-stearoyl-2-palmitoyl-phosphatidylcholine (SPPC), 1-palmitoyl-2-oleylphosphatidylcholine (POPC), 1-oleyl-2-palmitoyl-phosphatidylcholine (OPPC), dilauroylphosphatidylglycerol (DLPG) and its alkali metal salts, diarachidoylphosphatidylglycerol (DAPG) and its alkali metal salts, dimyristoylphosphatidylglycerol (DMPG) and its alkali metal salts, dipalmitoylphosphatidylglycerol (DPPG) and its alkali metal salts, distearoylphosphatidylglycerol (DSPG) and its alkali metal salts, dioleoyl-phosphatidylglycerol (DOPG) and its alkali metal salts,Dimyristoyl phosphatidic acid (DMPA) and its alkali metal salts, dipalmitoyl phosphatidic acid (DPPA) and its alkali metal salts, distearoyl phosphatidic acid (DSPA), diarachidoyl phosphatidic acid (DAPA) and its alkali metal salts, dimyristoyl phosphatidylethanolamine (DMPE), dipalmitoyl phosphatidylethanolamine (DPPE), distearoyl phosphatidylethanolamine (DSPE), dioleoyl phosphatidylethanolamine (DOPE), diarachidoyl phosphatidylethanolamine (DAPE), dilinoleyl phosphatidylethanolamine (DLPE), dimyristoyl phosphatidylserine (D MPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoyl phosphatidylserine (DSPS), dioleoyl phosphatidylserine (DOPS), dipalmitoyl sphingomyelin (DPSP), as well as distearoyl sphingomyelin (DSSP), dilauroyl-phosphatidylinositol (DLPI), diarachidoyl phosphatidylinositol (DAPI), dimyristoyl phosphatidylinositol (DMPI), dipalmitoyl phosphatidylinositol (DPPI), distearoyl phosphatidylinositol (DSPI), and dioleoyl-phosphatidylinositol (DOPI).
[0049] In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5% to about 2%, about 0.5% to about 5%, about 0.5% to about 8%, about 0.5% to about 10%, about 0.5% to about 12%, about 0.5% to about 15%, about 0.5% to about 20%, about 0.5% to about 25%, about 2% to about 5%, about 2% to about 8%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 5% to about 8%, about 5% to about 10%, about 5% to about 10%, about 5% to about 20%, about 2% to about 25%, about 5% to about 8 ...0%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 2 In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, about 25%, about 8% to about 10%, about 8% to about 12%, about 8% to about 15%, about 8% to about 20%, about 8% to about 25%, about 10% to about 12%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 12% to about 15%, about 12% to about 20%, about 12% to about 25%, about 15% to about 20%, about 15% to about 25%, or about 20% to about 25% (w / w). In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, the vesicle-forming lipids are present in an amount of at least about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, or about 20% (w / w) of the composition. In some embodiments, the vesicle-forming lipids are present in an amount of up to 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25% (w / w) of the composition.
[0050] In some embodiments, the vesicle-forming lipid is present in an amount of about 5% to about 15% (w / w) of the composition. In some embodiments, the vesicle-forming lipid is present in an amount of about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 11%, about 5% to about 12%, about 5% to about 13%, about 5% to about 14%, about 5% to about 15%, about 8% to about 9%, about 8% to about 10%, about 8% to about 11%, about 8% to about 12%, about 8% to about 13%, about 8% to about 14%, about 8% to about 15%, about 9% to about 10%, about 9% to about 11%, about 9% to about 12%, about 9% to about 13%, about 9% to about 14%, about 9% to about 15%, about 9% to about 10%, about 9% to about 11%, about 9% to about 12%, about 9% to about 15%, about 9% to about 16%, about 9% to about 17%, about 9% to about 18%, about 9% to about 19%, about 10% to about 20%, about 10% to about 21%, about 10% to about 22%, about 10% to about 23%, about 10% to about 24%, about 10% to about 25%, about 10% to about 26%, about 10% to about 27%, about 10% to about 28%, about 10% to about 29%, about 10% to about 30%, about 10% to about 31%, about 10% to about 32%, about 10% to about 33%, about 10% to about 34%, about 10 In some embodiments, the vesicle-forming lipid is present in an amount of about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% (w / w) of the composition. In some embodiments, the vesicle-forming lipids are present in an amount of at least about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, or about 14% (w / w) of the composition. In some embodiments, the vesicle-forming lipids are present in an amount of up to 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% (w / w) of the composition.
[0051] In some embodiments, the composition comprises a short-chain polyol. In some embodiments, the short-chain polyol acts to enhance the stability of the resulting lipid vesicles. In some embodiments, the short-chain polyol is a C2-C4 polyol containing two or three alcohol groups. In some embodiments, the short-chain polyol is propylene glycol. In some embodiments, the composition comprises propylene glycol. In some embodiments, the composition comprises butanediol (e.g., 2,3 butanediol). In some embodiments, the composition comprises propylene glycol, butanediol, or both.
[0052] In some embodiments, propylene glycol is present in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, propylene glycol is present in an amount of about 0.5% to about 2%, about 0.5% to about 5%, about 0.5% to about 8%, about 0.5% to about 10%, about 0.5% to about 12%, about 0.5% to about 15%, about 0.5% to about 20%, about 0.5% to about 25%, about 2% to about 5%, about 2% to about 8%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 5% to about 8%, about 5% to about 10%, about It is present in an amount of about 5% to about 12%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 8% to about 10%, about 8% to about 12%, about 8% to about 15%, about 8% to about 20%, about 8% to about 25%, about 10% to about 12%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 12% to about 15%, about 12% to about 20%, about 12% to about 25%, about 15% to about 20%, about 15% to about 25%, or about 20% to about 25%. In some embodiments, propylene glycol is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 10.5%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, propylene glycol is present in an amount of at least about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, or about 20%. In some embodiments, propylene glycol is present in an amount of up to 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, propylene glycol is present in an amount of about 1% to about 10%. In some embodiments, propylene glycol is present in an amount of about 1% to about 2%, about 1% to about 4%, about 1% to about 6%, about 1% to about 8%, about 1% to about 10%, about 2% to about 4%, about 2% to about 6%, about 2% to about 8%, about 2% to about 10%, about 4% to about 6%, about 4% to about 8%, about 4% to about 10%, about 6% to about 8%, about 6% to about 10%, or about 8% to about 10%. In some embodiments, propylene glycol is present in an amount of about 1%, about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, propylene glycol is present in an amount of at least about 1%, about 2%, about 4%, about 6%, or about 8%.In some embodiments, propylene glycol is present in an amount of up to 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, propylene glycol is present in about the same amount as the vesicle-forming lipid. In some embodiments, the ratio of propylene glycol to vesicle-forming lipid in the composition is about 2:1 to 1:2 (w / w).
[0053] In some embodiments, butanediol (e.g., 2,3-butanediol) is present in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, butanediol is present in an amount of about 0.5% to about 2%, about 0.5% to about 5%, about 0.5% to about 8%, about 0.5% to about 10%, about 0.5% to about 12%, about 0.5% to about 15%, about 0.5% to about 20%, about 0.5% to about 25%, about 2% to about 5%, about 2% to about 8%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 5% to about 8%, about 5% to about 10%, about 5% In some embodiments, butanediol is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 10.5%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, butanediol is present in an amount of at least about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, or about 20%. In some embodiments, butanediol is present in an amount of up to about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, butanediol is present in an amount of about 1% to about 10%. In some embodiments, butanediol is present in an amount of about 1% to about 2%, about 1% to about 4%, about 1% to about 6%, about 1% to about 8%, about 1% to about 10%, about 2% to about 4%, about 2% to about 6%, about 2% to about 8%, about 2% to about 10%, about 4% to about 6%, about 4% to about 8%, about 4% to about 10%, about 6% to about 8%, about 6% to about 10%, or about 8% to about 10%. In some embodiments, butanediol is present in an amount of about 1%, about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, butanediol is present in an amount of at least about 1%, about 2%, about 4%, about 6%, or about 8%.In some embodiments, butanediol is present in an amount of up to about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, butanediol is present in about the same amount as the vesicle-forming lipid. In some embodiments, the ratio of butanediol to vesicle-forming lipid in the composition is about 2:1 to 1:2 (w / w). In some embodiments, in the composition containing butanediol, the ratio of butanediol to propylene glycol is about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, or 12:1.
[0054] Oil Phase The lipid vesicle compositions provided herein include oil-in-water emulsions. The oil component is selected so that the material is liquid at the operating temperature (e.g., room temperature) and is immiscible with water.
[0055] Any suitable oil can be used as oil phase.In some embodiments, oil comprises naturally occurring oil.In some embodiments, naturally occurring oil is derived from one or more plants or plant parts (e.g., seeds or nuts).In some embodiments, oil is naturally occurring oil such as olive oil, vegetable oil, sunflower oil, or other similar plant-derived oil.
[0056] In some embodiments, the oil phase is selected from the group consisting of vegetable oils, mono-, di-, and triglycerides, silicone fluids, mineral oils, and combinations thereof.
[0057] In some embodiments, the oil comprises a silicone oil or derivative, such as dimethicone. In some embodiments, the silicone oil comprises a siloxane polymer. In some embodiments, the siloxane polymer comprises a C1-C3 substituent. In some embodiments, the siloxane is polydimethylsiloxane (PDMS). In some embodiments, the silicone oil is polymethylsilsesquioxane (e.g., Botanisil™ SP-360). In some embodiments, the oil is a mixture that includes a silicone oil (e.g., dimethicone) as a smaller component. In some embodiments, the oil is a mixture that includes a naturally occurring emollient as a replacement for dimethicone (e.g., LexFeel™ N350 MB). In some embodiments, the silicone oil is incorporated to improve the feel of the resulting composition or as a moisturizer. In some embodiments, the oil comprises a silicone oil in an amount of up to about 5%, up to about 4%, up to about 3%, up to about 2%, or up to about 1% (w / w) of the composition. In some embodiments, the silicone oil is present in an amount of about 0.1% to about 2%. In some embodiments, the silicone oil is present in an amount of about 0.1% to about 0.5%, 0.1% to about 0.7%, 0.1% to about 1%, 0.1% to about 1.5%, 0.15% to about 2%, 0.5% to about 0.7%, 0.5% to about 1%, 0.5% to about 1.5%, 0.5% to about 2%, 0.7% to about 1%, 0.7% to about 1.5%, 0.7% to about 2%, 1% to about 1.5%, or 1% to about 2% (w / w). In some embodiments, the silicone oil is present in an amount of about 0.1%, 0.5%, 0.6%, 0.7%, 1%, 1.5%, or 2% of the composition.
[0058] In some embodiments, the oil is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the oil is present in an amount of about 1% to about 5%, about 1% to about 10%, about 1% to about 15%, about 1% to about 20%, about 1% to about 25%, about 1% to about 30%, about 1% to about 35%, about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 10% to about 15%, about 10% to about ... The oil is present in an amount of about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 15% to about 35%, about 20% to about, 25%, about 20% to about 30%, about 20% to about 35%, about 25% to about 30%, about 25% to about 35%, or about 30% to about 35%. In some embodiments, the oil is present in an amount of about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%. In some embodiments, the oil is present in an amount of at least about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the oil is present in an amount of up to about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%. In some embodiments, the oil is present in an amount of about 5% to about 15%. In some embodiments, the oil is present in an amount of about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 11%, about 5% to about 12%, about 5% to about 13%, about 5% to about 14%, about 5% to about 15%, about 8% to about 9%, about 8% to about 10%, about 8% to about 11%, about 8% to about 12%, about 8% to about 13%, about 8% to about 14%, about 8% to about 15%, about 9% to about 10%, about 9% to about 11%, about 9% to about 12%, about 9% to about 1 In some embodiments, the oil is present in an amount of about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.In some embodiments, the oil is present in an amount of at least about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, or about 14%. In some embodiments, the oil is present in an amount of up to about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.
[0059] In some embodiments, the oil comprises one or more triglycerides. In some embodiments, the triglycerides are medium chain triglycerides. In some embodiments, the medium chain triglycerides are C6-C 12 The fatty acid esters include those having a chain length of
[0060] In some embodiments, the triglyceride is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the triglyceride is present in an amount of about 1% to about 5%, about 1% to about 10%, about 1% to about 15%, about 1% to about 20%, about 1% to about 25%, about 1% to about 30%, about 1% to about 35%, about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 10% to about 15%, about In some embodiments, the triglyceride is present in an amount of about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 15% to about 35%, about 20% to about 25%, about 20% to about 30%, about 20% to about 35%, about 25% to about 30%, about 25% to about 35%, or about 30% to about 35%. In some embodiments, the triglyceride is present in an amount of about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%. In some embodiments, triglycerides are present in an amount of at least about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, triglycerides are present in an amount of up to about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%.
[0061] In some embodiments, the lipid vesicles and / or the oil phase of the lipid vesicle portion of the composition comprises a sterol. In some embodiments, the sterol is a naturally occurring sterol. In some embodiments, the sterol is a synthetic sterol. In some embodiments, the sterol is cholesterol. In some embodiments, the cholesterol may be plant-derived cholesterol. In some embodiments, the cholesterol may be synthetic cholesterol. In some embodiments, the plant-derived cholesterol may be cholest-5-en-3-ol (e.g., PhytoChol®, SyntheChol®, Avanti#700100), or any other plant-derived cholesterol, or any combination thereof. In some embodiments, the sterol may be a phytosterol or a derivative thereof. In some embodiments, the phytosterol or a derivative thereof may be phytosterol MM, Advasterol™ 90 IP or 95 IP F, NET sterol-ISO, canola sterol, sitosterol 700095, lanosterol-95, brassicasterol, or any combination thereof.
[0062] In some embodiments, the sterol is present in an amount of about 0.1% to about 5% (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 0.1% to about 5%. In some embodiments, the sterol is present in an amount of about 0.1% to about 0.2%, about 0.1% to about 0.5%, about 0.1% to about 0.8%, about 0.1% to about 1%, about 0.1% to about 2%, about 0.1% to about 3%, about 0.1% to about 4%, about 0.1% to about 5%, about 0.2% to about 0.5%, about 0.2% to about 0.8%, about 0.2% to about 1%, about 0.2% to about 2%, about 0.2% to about 3%, about 0.2% to about 4%, about 0.2% to about 5%, about 0.5% to about 0.8% , about 0.5% to about 1%, about 0.5% to about 2%, about 0.5% to about 3%, about 0.5% to about 4%, about 0.5% to about 5%, about 0.8% to about 1%, about 0.8% to about 2%, about 0.8% to about 3%, about 0.8% to about 4%, about 0.8% to about 5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5%. In some embodiments, the sterol is present in an amount of about 0.1%, about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the sterol is present in an amount of at least about 0.1%, about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, or about 4%. In some embodiments, the sterol is present in an amount of up to about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the sterol is present in an amount of about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1.5% to about 2%, about 1.5% to about 2.5%, about 1.5% to about 3%, about 1.5% to about 4%, about 1.5% to about 5%, about 2% to about 2.5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2.5% to about 3%, about 2.5% to about 4%, about 2.5% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5% (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 4%, or about 5% (w / w) of the composition.In some embodiments, the sterol is present in an amount of at least about 1%, about 1.5%, about 2%, about 2.5%, about 3%, or about 4% (w / w) of the composition, in some embodiments, the sterol is present in an amount of up to 1.5%, about 2%, about 2.5%, about 3%, about 4%, or about 5% (w / w) of the composition.
[0063] In some embodiments, the lipid vesicle composition comprises one or more penetration enhancers.In some embodiments, the penetration enhancer acts to increase the amount of anionic polymeric material permeation through one or more layers of skin when applied to the skin of an individual.In some embodiments, the penetration enhancer acts to increase the amount of one or more peptides permeation through one or more layers of skin when applied to the skin of an individual.
[0064] In some embodiments, a composition comprising one or more penetration enhancers, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising the one or more other penetration enhancers is applied to one or more layers of the skin of a similar or same skin sample or individual. In some embodiments, a composition comprising one or more penetration enhancers, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by more than 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising the one or more other penetration enhancers is applied to one or more layers of the skin of a similar or same skin sample or individual. In some embodiments, a composition comprising one or more penetration enhancers, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising the one or more other penetration enhancers is applied to one or more layers of the skin of a similar or same skin sample or individual.
[0065] In some embodiments, a composition comprising one or more nonionic surfactants having an HLB value of about 10 or less, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising one or more other nonionic surfactants having an HLB value of about 10 or less is applied to one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more nonionic surfactants having an HLB value of about 10 or less, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by more than 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising one or more other nonionic surfactants having an HLB value of about 10 or less is applied to one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more nonionic surfactants having an HLB value of about 10 or less, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising one or more other nonionic surfactants having an HLB value of about 10 is applied to one or more layers of the skin of a similar or same skin sample or individual.
[0066] In some embodiments, the penetration enhancer is included in an oil-in-water emulsion of the composition, hi some embodiments, the penetration enhancer is included in the lipid bilayer of the composition.
[0067] There are various types of penetration enhancers that can be used. In some embodiments, the penetration enhancer comprises an ionic surfactant, a non-ionic surfactant, or a combination thereof. In some embodiments, the ionic surfactant, the non-ionic surfactant, or a combination thereof is not a penetration enhancer.
[0068] In some embodiments, the penetration enhancer comprises a nonionic surfactant or a combination of nonionic surfactants. In some embodiments, the penetration enhancer is a single nonionic surfactant. In some embodiments, the penetration enhancer is a combination of at least two, three, or four or more nonionic surfactants. In some embodiments, the penetration enhancer is a combination of two nonionic surfactants. In some embodiments, the penetration enhancer is a combination of three nonionic surfactants.
[0069] In some embodiments, the nonionic surfactant or combination of nonionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters, and combinations thereof.
[0070] In some embodiments, the nonionic surfactant comprises a polyethylene glycol (PEG) ether of an aliphatic alcohol. In some embodiments, the PEG ether of an aliphatic alcohol has from about 2 to about 8 PEG groups and C 12 -C 22In some embodiments, the polyethylene glycol ether of the aliphatic alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the polyethylene glycol ether of the aliphatic alcohol comprises 2-(2-octadecaoxyethoxy)ethanol. In some embodiments, the PEG ether of the aliphatic alcohol is super refined Brij® O2 or a derivative thereof.
[0071] In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5% to about 10%, about 0.5% to about 5%, about 0.5% to about 4%, or about 0.05% to about 3% (w / w) of the composition. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5% to about 2.5%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.5% to about 2.5%, about 1.2% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of up to 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0072] In some embodiments, the nonionic surfactant comprises a sorbitan ester. In some embodiments, the sorbitan ester is a fatty acid ester. In some embodiments, the sorbitan ester is a C 12 -C 22A fatty acid ester. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate. In some embodiments, the sorbitan ester comprises sorbitan monopalmitate. In some embodiments, the sorbitan ester comprises sorbitan monostearate. In some embodiments, the sorbitan ester comprises sorbitan monooleate. In some embodiments, the sorbitan ester comprises sorbitan trioleate. In some embodiments, the sorbitan ester comprises sorbitan sesquioleate. In some embodiments, the sorbitan ester comprises sorbitan isostearate.
[0073] In some embodiments, the sorbitan ester is present in an amount of up to about 5% (w / w) of the composition. In some embodiments, the sorbitan ester is present in an amount of about 0.5% to about 5%, about 0.5% to about 4%, or about 0.5% to about 3%. In some embodiments, the sorbitan ester is present in an amount of about 0.5% to about 2.5%. In some embodiments, the sorbitan ester is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.5% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the sorbitan esters are present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the sorbitan esters are present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the sorbitan esters are present in an amount of up to 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0074] In some embodiments, the non-ionic surfactant comprises a polysorbate. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the polysorbate is polysorbate 20. In some embodiments, the polysorbate is added to the aqueous phase of the composition.
[0075] In some embodiments, the polysorbate is present in an amount up to about 5%. In some embodiments, the polysorbate is present in an amount of about 0.5% to about 5%, about 0.5% to about 4%, or about 0.5% to about 3% (w / w) of the composition. In some embodiments, the polysorbate is present in an amount of about 0.5% to about 2.5%. In some embodiments, the polysorbate is present in an amount of about 0.2% to about 0.5%, about 0.2% to about 0.8%, about 0.2% to about 1%, about 0.2% to about 1.2%, about 0.2% to about 1.5%, about 0.2% to about 2%, about 0.2% to about 2.5%, about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, In some embodiments, the polysorbate is present in an amount of about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.5% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the polysorbate is present in an amount of about 0.2%, 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, polysorbate is present in an amount of at least about 0.2%, 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, polysorbate is present in an amount of up to about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0076] In some embodiments, the nonionic surfactant comprises a polyethylene glycol (PEG) fatty acid ester. In some embodiments, the PEG fatty acid ester comprises a C8-C hydroxyl group attached to each terminal hydroxyl group to form a fatty acid ester. 22The PEG chain is about 2-8 subunits containing fatty acids. In some embodiments, the PEG fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glyceride, or any combination thereof. In some embodiments, the PEG fatty acid ester is PEG-4 dilaurate.
[0077] In some embodiments, the PEG fatty acid ester is present in an amount of up to about 5% (w / w) of the composition. In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5% to about 5%, about 0.5% to about 4%, or about 0.5% to about 3%. In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5% to about 2.5%. In some embodiments, the PEG fatty ester is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.5% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the PEG fatty ester is present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the PEG fatty ester is present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the PEG fatty ester is present in an amount of up to 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0078] In some embodiments, the nonionic surfactant has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the nonionic surfactant comprises glyceryl monostearate (e.g., Cithrol GMS40). In some embodiments, the nonionic surfactant comprises oleyl alcohol (e.g., Lipocol O-95). In some embodiments, the nonionic surfactant comprises polyoxyethylene oleyl ether (e.g., Oleth-2). In some embodiments, the nonionic surfactant comprises propylene glycol monocaprylate (e.g., Capryol® 90). In some embodiments, the composition comprises multiple nonionic surfactants, each having an HLB of about 10 or less. In some embodiments, the nonionic surfactants having an HLB of 10 or less are selected from Table 1 below, or any combination thereof.
[0079] [Table 1]
[0080] In some embodiments, the nonionic surfactant has a hydrophobic-lipophilic balance (HLB) of about 10 or greater. In some embodiments, the composition comprises multiple nonionic surfactants, each having an HLB of about 10 or greater.
[0081] In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is from about 0.5% to about 1%, from about 0.5% to about 1.5%, from about 0.5% to about 2%, from about 0.5% to about 3%, from about 0.5% to about 4%, from about 0.5% to about 5%, from about 0.5% to about 6%, from about 0.5% to about 7%, from about 0.5% to about 8%, from about 0.5% to about 10%, from about 1% to about 1.5%, from about 1% to about 2%, from about 1% to about 3%, from about 1% to about 4%, from about 1% to about 5%, from about 1% to about 6%, from about 1% to about 7%, from about 1% to about 8%, from about 1% to about 10%, from about 1.5% to about 2%, from about 1.5% to about 3%, from about 1.5% to about 4%, from about 1.5% to about 5%, from about 1.5% to about 6%, from about 1. .5% to about 7%, about 1.5% to about 8%, about 1.5% to about 10%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2% to about 6%, about 2% to about 7%, about 2% to about 8%, about 2% to about 10%, about 3% to about 4%, about 3% to about 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 10%, In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5%, about 0.6%, about 0.7%, about 1%, about 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 8% to about 10%, about 10% to about 10%. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.6% (e.g., 0.54% to about 0.66%). In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.7% (e.g., 0.63% to about 0.77%). In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of at least about 0.5%, about 0.7%, about 1%, about 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, or about 8%.In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount up to 0.7%, about 1%, about 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 10%.
[0082] In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion, the lipid bilayer, or both. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion. In some embodiments, the composition comprises a non-ionic surfactant in the lipid bilayer. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion and the lipid bilayer, and comprises two or more different non-ionic surfactants.
[0083] In some embodiments, the penetration enhancer comprises a salicylate or a nicotinate. In some embodiments, the ester is a C1-C6 alkyl ester or a benzyl ester. In some embodiments, the penetration enhancer comprises methyl salicylate or benzyl nicotinate. In some embodiments, the penetration enhancer is a nicotinate ester present in an amount up to about 0.1%, 0.5%, 1%, 2%, or 3% (w / w) of the composition. In some embodiments, the nicotinate ester is present in an amount of about 0.1% to about 3%, about 0.1% to about 2%, about 0.1% to about 1%. In some embodiments, the benzyl nicotinate is present in an amount of about 0.5%.
[0084] Cationic Surfactants In some embodiments, the composition comprises an ionic surfactant. In some embodiments, the ionic surfactant is a cationic surfactant. In some embodiments, the cationic surfactant is a monocationic surfactant, a dicationic surfactant, or a polycationic surfactant.
[0085] In some embodiments, the monocationic surfactant is used in the composition to form a submicron emulsion prior to the formation of the final lipid vesicle composition provided herein (e.g., prior to the addition of lipid forming vesicles). In some embodiments, the monocationic surfactant is net monocationic (e.g., a phosphate containing two side chains, each with a single cationic functionality, partially neutralized by the phosphate anion).
[0086] In some embodiments, the monocationic surfactant is a propylene glycol diammonium phosphate derived from a fatty amide. A propylene glycol diammonium phosphate derived from a fatty amide is a phospholipid that contains at least one propylene glycol phosphoester linked to a quaternary ammonium group, which in turn is linked to a fatty acid amide. One non-limiting example of a propylene glycol diammonium phosphate derived from a fatty amide is linoleamidopropyl PG-dimonium chloride phosphate. Similar compounds with different fatty acid amide groups attached are also known. In some embodiments, a propylene glycol diammonium phosphate derived from a fatty amide has the following structure:
[0087] [ka] (wherein n is an integer from 1 to 3, m is an integer from 0 to 2, the sum of m and n is 3, X is a cation selected from a proton, sodium, potassium, magnesium, and calcium, and R is a C8-C 30 (the acyl group of a fatty acid).
[0088] In some embodiments, the fatty acid is 12 -C 24It is a fatty acid ester. In some embodiments, the fatty acid is an unsaturated fatty acid. In some embodiments, the fatty acid is linoleic acid. In some embodiments, the monocationic penetration enhancer is linoleamidopropyl PG-dimonium chloride phosphate (e.g., Arlasilk™ PTM, Arlasilk™ EFA).
[0089] In some embodiments, the propylene glycol diammonium phosphate ester derived from a fatty amide is present in an amount of about 1% to about 20% (w / w) of the composition. In some embodiments, the propylene glycol diammonium phosphate ester derived from a fatty amide is present in an amount of about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1% to about 6%, about 1% to about 7%, about 1% to about 8%, about 1% to about 9%, about 1% to about 10%, about 1% to about 12%, about 1% to about 15%, about 1% to about 20%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2% to about 6%, about 2% ~ about 7%, about 2% to about 8%, about 2% to about 9%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 3% to about 4%, about 3% to about 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 9%, about 3% to about 10%, about 3% to about 12%, about 3% to about 15%, about 3% to about 20%, about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 9%, about 4% to about 10%, about 4% to about 12%, about 4% to about 15%, about 4% to about 20%, about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 12%, about 5% to about 15%, about 5% to about 20%, about 6% to about 7%, about 6% to about 8%, about 6% to about 9%, about 6% to about 10%, about 6% to about 12%, about 6% to about 15%, about 6% to about 20%, about 7% to about 8%, about 7% to about 9%, about 7% to about The compound is present in an amount of about 10%, about 7% to about 12%, about 7% to about 15%, about 7% to about 20%, about 8% to about 9%, about 8% to about 10%, about 8% to about 12%, about 8% to about 15%, about 8% to about 20%, about 9% to about 10%, about 9% to about 12%, about 9% to about 15%, about 9% to about 20%, about 10% to about 12%, about 10% to about 15%, about 10% to about 20%, about 12% to about 15%, about 12% to about 20%, or about 15% to about 20%. In some embodiments, the propylene glycol-diammonium phosphate ester derived from a fatty amide is present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 9%, about 10%, about 12%, about 15%, or about 20%.In some embodiments, the propylene glycol-diammonium phosphate ester derived from a fatty amide is present in an amount of at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 9%, about 10%, about 12%, about 15%, or about 20%. In some embodiments, the propylene glycol-diammonium phosphate ester derived from a fatty amide is present in an amount of up to about 2%, about 3%, about 4%, about 5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 9%, about 10%, about 12%, about 15%, or about 20%.
[0090] In some embodiments, the cationic surfactant is a dicationic penetration enhancer. In some embodiments, the dicationic surfactant is a gemini surfactant. In some embodiments, the gemini surfactant is a surfactant comprising two quaternary amines represented by the formula AN(R)2-BN(R)2-C, where each of A and C is independently an optionally substituted C6-C 24 alkyl group, each R is independently an optionally substituted C1-C6 alkyl, and B is an optionally substituted C2-C 10 In some embodiments, each of A and C is a C-C alkylene chain. 24 In some embodiments, each of A and C is a C6-C 24 In some embodiments, B is a saturated C-C hydrocarbon. In some embodiments, each R is methyl. In some embodiments, B is a saturated C-C 10 is an alkylene chain. In some cases, gemini surfactants follow the nomenclature XYZ, where X, Y, and Z are each integers representing the number of carbon atoms in each substituent, and Y is a spacer between two quaternary amines. Thus, for example, a 12-3-12 gemini surfactant has the formula CH3(CH2) 11 -[N + (CH3)2]-(CH2)3-[N + (CH3)2]-(CH2) 11In some embodiments, the gemini surfactant is a 10-2-10, 12-2-12, 14-2-14, 10-3-10, 12-3-12, 14-3-14, 10-4-10, 12-4-12, or 14-4-14 gemini surfactant. In some embodiments, the gemini surfactant is a 12-3-12 gemini surfactant.
[0091] In some embodiments, the gemini surfactant is present in an amount of about 0.1% to about 1.5% (w / w) of the composition. In some embodiments, the gemini surfactant is present in an amount of about 0.1% to about 0.2%, about 0.1% to about 0.3%, about 0.1% to about 0.5%, about 0.1% to about 0.7%, about 0.1% to about 0.9%, about 0.1% to about 1%, about 0.1% to about 1.2%, about 0.1% to about 1.5%, about 0.2% to about 0.3%, about 0.2% to about 0.5%, about 0.2% to about 0.7%, about 0.2% to about 0.9%, about 0.2% to about 1%, about 0.2% to about 1.2%, about 0.2% to about 1.5%, about 0.3% to about 0.5%, about 0.3% to about 0.7%, about The compound is present in an amount of from about 0.3% to about 0.9%, from about 0.3% to about 1%, from about 0.3% to about 1.2%, from about 0.3% to about 1.5%, from about 0.5% to about 0.7%, from about 0.5% to about 0.9%, from about 0.5% to about 1%, from about 0.5% to about 1.2%, from about 0.5% to about 1.5%, from about 0.7% to about 0.9%, from about 0.7% to about 1%, from about 0.7% to about 1.2%, from about 0.7% to about 1.5%, from about 0.9% to about 1%, from about 0.9% to about 1.2%, from about 0.9% to about 1.5%, from about 1% to about 1.2%, from about 1% to about 1.5%, or from about 1.2% to about 1.5%. In some embodiments, the gemini surfactant is present in an amount of about 0.1%, about 0.2%, about 0.3%, about 0.5%, about 0.7%, about 0.9%, about 1%, about 1.2%, or about 1.5%. In some embodiments, the gemini surfactant is present in an amount of at least about 0.1%, about 0.2%, about 0.3%, about 0.5%, about 0.7%, about 0.9%, about 1%, or about 1.2%. In some embodiments, the gemini surfactant is present in an amount of up to about 0.2%, about 0.3%, about 0.5%, about 0.7%, about 0.9%, about 1%, about 1.2%, or about 1.5%.
[0092] In some embodiments, the cationic surfactant is a polycationic group. In some embodiments, the polycationic group is a polymer in which each monomer of the polymer contains a charged group (e.g., an amino group). In some embodiments, the polycationic group is polylysine. In some embodiments, the polycationic group is polyarginine.
[0093] In some embodiments, the polylysine has a molecular weight of about 1 kDa to about 10 kDa, about 1 kDa to about 5 kDa, or about 3 kDa to about 5 kDa. In some embodiments, the polylysine is present in an amount of about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.01% to about 0.2%, about 0.05% to about 1%, about 0.05% to about 0.5%, or about 0.05% to about 0.2% (w / w) of the composition.
[0094] Additional Components In some embodiments, the vesicle composition comprises additional components that, in some embodiments, improve one or more properties of the vesicle without dramatically altering the delivery of the anionic polymeric material.
[0095] In some embodiments, the vesicle composition comprises one or more viscosity enhancing agents. In some embodiments, the viscosity enhancing agent increases the viscosity of the composition for improved stability of the vesicle composition and / or user feel. In some embodiments, the viscosity enhancing agent further acts as a surfactant. In some embodiments, the viscosity enhancing agent comprises one or more of a fatty alcohol, a wax, a fatty acid ester of glycerol, or any combination thereof. In some embodiments, the fatty alcohol is a C8-C 20In some embodiments, the fatty alcohol is cetyl alcohol. In some embodiments, the wax is a natural or synthetic wax. In some embodiments, the wax is beeswax. In some embodiments, the wax is synthetic beeswax. In some embodiments, the synthetic beeswax is Syncrowax™ BB4. In some embodiments, the synthetic beeswax is a non-animal derived beeswax. In some embodiments, the non-animal derived beeswax is Syncrowax™ SB1. In some embodiments, the fatty acid ester of glycerol is a monoester. In some embodiments, the monoester is a C8-C 24 An ester of a fatty acid. In some embodiments, the fatty acid ester of glycerol is glycerol monostearate.
[0096] In some embodiments, the viscosity enhancing agent is present in an amount of about 0.1% to about 10% (w / w) of the composition. In some embodiments, the viscosity enhancing agent is present in an amount of about 0.1% to about 5%. In some embodiments, the viscosity enhancing agent is present in an amount of about 0.1% to about 0.3%, about 0.1% to about 0.5%, about 0.1% to about 1%, about 0.1% to about 1%, about 0.1% to about 2%, about 0.1% to about 3%, about 0.1% to about 4%, about 0.1% to about 5%, about 0.3% to about 0.5%, about 0.3% to about 1%, about 0.3% to about 1%, about 0.3% to about 2%, about 0.3% to about 3%, about 0.3% to about 4%, about 0.3% to about 5%, about 0.5% to about In some embodiments, the viscosity enhancing agent is present in an amount of about 0.1%, about 0.5% to about 1%, about 0.5% to about 2%, about 0.5% to about 3%, about 0.5% to about 4%, about 0.5% to about 5%, about 1% to about 1%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5%. In some embodiments, the viscosity enhancing agent is present in an amount of about 0.1%, about 0.3%, about 0.5%, about 1%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the viscosity enhancing agent is present in an amount of at least about 0.1%, about 0.3%, about 0.5%, about 1%, about 1%, about 2%, about 3%, or about 4%. In some embodiments, the viscosity enhancing agent is present in an amount of up to about 0.3%, about 0.5%, about 1%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the viscosity enhancing agent comprises a fatty alcohol in an amount of up to about 2%, a wax in an amount of up to about 2%, and a fatty acid ester of glycerol in an amount of up to about 5%. In some embodiments, the fatty alcohol is present in an amount of about 0.1 to about 1.5%. In some embodiments, the fatty alcohol is present in an amount of about 0.4% (e.g., 0.36% to about 0.44%). In some embodiments, the fatty alcohol is present in an amount of about 0.6%. In some embodiments, the wax is present in an amount of about 0.1% to about 1%. In some embodiments, the wax is present in an amount of about 0.2% (eg, about 0.18% to about 0.22%).In some embodiments, the wax is present in an amount of about 0.3% (e.g., about 0.27% to about 0.33%). In some embodiments, the fatty ester of glycerol is present in an amount of about 0.5% to about 2%. In some embodiments, the fatty ester of glycerol is present in an amount of about 0.8% (e.g., 0.72% to about 0.88%). In some embodiments, the fatty ester of glycerol is present in an amount of about 0.9%. In some embodiments, the fatty ester of glycerol is present in an amount of about 1%. In some embodiments, the fatty ester of glycerol is present in an amount of about 1.2%.
[0097] In some embodiments, the vesicle composition further comprises one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, or any combination thereof. In some embodiments, the vesicle composition further comprises a thickening agent. In some embodiments, the vesicle composition further comprises a preservative. In some embodiments, the vesicle composition further comprises a moisturizer. In some embodiments, the vesicle composition further comprises an emollient. In some embodiments, the vesicle composition further comprises a humectant. In some embodiments, the vesicle composition further comprises a fragrance (e.g., Mentha piperita). In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.01% to about 0.1%. In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.05%.
[0098] In some embodiments, the vesicle composition further comprises an antimicrobial agent. In some embodiments, the antimicrobial agent is a paraben ester. In some embodiments, the antimicrobial agent is methylparaben or propylparaben, or a combination thereof. In some embodiments, the antimicrobial agent is present in an amount of up to about 1%, up to about 0.9%, up to about 0.8%, up to about 0.7%, up to about 0.6%, up to about 0.5%, up to about 0.4%, up to about 0.3%, up to about 0.2% (w / w) of the composition.
[0099] In some embodiments, the vesicle composition further comprises a thickening agent. In some embodiments, the thickening agent is an inert polymeric material. In some embodiments, the thickening agent is a siloxane polymer. In some embodiments, the thickening agent is polydimethylsiloxane (PDMS). In some embodiments, the PDMS is present in an amount of at most about 5%, at most about 4%, at most about 3%, at most about 2%, or at most about 1%. In some embodiments, the PDMS is present in an amount of about 0.1% to about 2% (w / w) of the composition.
[0100] In some embodiments, the composition further comprises a humectant. In some embodiments, the composition comprises glycerol. In some embodiments, the glycerol is present in an amount of about 0.5% to about 25%, about 0.5% to about 20%, about 0.5% to about 15%, or about 0.5% to about 10%. In some embodiments, the glycerol is present in an amount of about 1% to about 10%. In some embodiments, the glycerol is present in an amount of about 1% to about 2%, about 1% to about 4%, about 1% to about 6%, about 1% to about 8%, about 1% to about 10%, about 2% to about 4%, about 2% to about 6%, about 2% to about 8%, about 2% to about 10%, about 4% to about 6%, about 4% to about 8%, about 4% to about 10%, about 6% to about 8%, about 6% to about 10%, or about 8% to about 10%. In some embodiments, glycerol is present in an amount of about 1%, about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, glycerol is present in an amount of at least about 1%, about 2%, about 4%, about 6%, or about 8%. In some embodiments, glycerol is present in an amount of up to about 2%, about 4%, about 6%, about 8%, or about 10% (w / w) of the composition.
[0101] In some embodiments, the vesicle composition includes a preservative. In some embodiments, the preservative is a cosmetic preservative such as Euxyl® PE9010 or Spectrastat®. In some embodiments, the preservative includes a phenoxyethanol / ethylhexylglycerin mixture. In some embodiments, the preservative includes a combination of caprylhydroxamic acid, caprylyl glycol, and glycerin. In some embodiments, the preservative is present in an amount of up to about 2%, up to about 1.5%, or up to about 1% (w / w) of the composition. In some embodiments, the preservative is present in an amount of about 0.1% to about 2%, about 0.1% to about 1.5%, or about 0.1% to about 1%. In some embodiments, the preservative is present in an amount of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, or 2%.
[0102] In some embodiments, the composition further comprises a material for promoting a desired change in the skin, such as smoothing out wrinkles. In some embodiments, the composition comprises a carbohydrate or an acceptable salt thereof. In some embodiments, the carbohydrate is a monosaccharide, a disaccharide, or a polysaccharide. In some embodiments, the carbohydrate or an acceptable salt thereof comprises N-acetyl-α-D-glucosamine 6-phosphate disodium salt (NovHyal™). In some embodiments, the carbohydrate comprises a saccharide isomerate (e.g., Hyanify™). In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of about 0.1% to about 0.5%. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of about 0.1% to about 0.2%, about 0.1% to about 0.3%, about 0.1% to about 0.4%, about 0.1% to about 0.5%, about 0.2% to about 0.3%, about 0.2% to about 0.4%, about 0.2% to about 0.5%, about 0.3% to about 0.4%, about 0.3% to about 0.5%, or about 0.4% to about 0.5%. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of about 0.1%, about 0.2%, 0.3%, 0.4%, or 0.5%. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of at least about 0.1%, about 0.2%, 0.3%, 0.4%, or 0.5%. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount up to about 0.1%, about 0.2%, 0.3%, 0.4%, or 0.5%.
[0103] In some embodiments, the composition comprises a polymer of amino acids. In some embodiments, the polymer of amino acids comprises a high molecular weight (MW) polymer of amino acids, a low MW polymer of amino acids, or both. In some embodiments, the polymer of amino acids comprises polyglutamic acid. In some cases, the polyglutamic acid comprises a low MW polyglutamic acid (e.g., Hyafactor™ PGA LM), a high MW polyglutamic acid (e.g., Hyafactor™ PGA HM), or both.
[0104] In some embodiments, the ratio of high MW polymers of amino acids to low MW polymers of amino acids is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 3:2, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.
[0105] In some embodiments, the amino acid polymer is present in an amount of about 0.01% to about 0.2%. In some embodiments, the amino acid polymer is present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, the amino acid polymer is present in an amount of about 0.01%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the polymer of amino acids is present in an amount of at least about 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, the polymer of amino acids is present in an amount of up to about 0.05%, about 0.1%, about 0.15%, or about 0.2%.
[0106] In some embodiments, the combination of high MW polymer and low MW polymer is present in an amount of about 0.01% to about 0.2%. In some embodiments, the combination is present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, the combination is present in an amount of about 0.01%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the combination is present in an amount of at least about 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, the combination is present in an amount of up to about 0.05%, about 0.1%, about 0.15%, or about 0.2%.
[0107] In some embodiments, the high MW polymer of amino acids is present in an amount of about 0.01% to about 0.2%. In some embodiments, the high MW polymer is present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, the high MW polymer is present in an amount of about 0.01%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the high MW polymer is present in an amount of at least about 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, the high MW polymer is present in an amount of up to about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the low MW polymer of amino acids is present in an amount of about 0.01% to about 0.2%. In some embodiments, the low MW polymer of amino acids is present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, the low MW polymer of amino acids is present in an amount of about 0.01%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the low MW polymer of amino acids is present in an amount of at least about 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, the low MW polymer of amino acids is present in an amount of up to about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some examples, the high MW polymer is present in an amount of about 0.01% and the low MW polymer is present in an amount of about 0.01%. In some examples, the high MW polymer is present in an amount of about 0.02% and the low MW polymer is present in an amount of about 0.01%. In some examples, the high MW polymer is present in an amount of about 0.05% and the low MW polymer is present in an amount of about 0.025%.In some embodiments, the high MW polymer is present in an amount of about 0.05%. In some embodiments, the low MW polymer is present in an amount of about 0.05%. In some examples, the high MW polymer is present in an amount of about 0.05% and the low MW polymer is present in an amount of about 0.05%. In some examples, the high MW polymer is present in an amount of about 0.1% and the low MW polymer is present in an amount of about 0.1%. In some examples, the high MW polymer is present in an amount of about 0.2% and the low MW polymer is present in an amount of about 0.1%. In some examples, the high MW polymer is present in an amount of about 0.2% and the low MW polymer is present in an amount of about 0.2%.
[0108] In some embodiments, the composition further comprises collagen. In some embodiments, the collagen is human collagen or vegan human collagen (e.g., HumaColl21®). In some embodiments, the molecular weight is about 15 kDa, 18 kDa, 20 kDa, 25 kDa, or 30 kDa. In some embodiments, the collagen is present in an amount of about 0.01% to about 0.2%. In some embodiments, the collagen is present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, collagen is present in an amount of about 0.01%, about 0.02%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, collagen is present in an amount of at least about 0.01%, about 0.02%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, collagen is present in an amount of up to about 0.2%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%.
[0109] In some embodiments, the composition further comprises a material for promoting a desired change in the skin, such as reducing dullness in one or more areas of the skin. In some embodiments, the material comprises one or more biological extracts. The one or more biological extracts may be present in an amount of about 0.01% to about 0.2%, individually or collectively. In some instances, the one or more biological extracts may be from about 0.01% to about 0.02%, from about 0.01% to about 0.04%, from about 0.01% to about 0.06%, from about 0.01% to about 0.08%, from about 0.01% to about 0.1%, from about 0.01% to about 0.12%, from about 0.01% to about 0.14%, from about 0.01% to about 0.16%, from about 0.01% to about 0.18%, from about 0.01% to about 0.2%, from about 0.02% to about 0.04%, from about 0.02% to about 0.06%, from about 0.02 ...8%, from about 0.01% to about 0.2%, from about 0.02% to about 0.04%, from about 0.02% to about 0.06%, from about 0.02% to about 0.08%, from about 0.02% to about 0.08%, from about 0.02% to about 0.08%, from about 0.02% to about 0.08%, from about 0.02% to about 0.08%, from about 0.02 About 0.08%, about 0.02% to about 0.1%, about 0.02% to about 0.12%, about 0.02% to about 0.14%, about 0.02% to about 0.16%, about 0.02% to about 0.18%, about 0.02% to about 0.2%, about 0.04% to about 0.06%, about 0.04% to about 0.08%, about 0.04% to about 0.1%, about 0.04% to about 0.12%, about 0.04% to about 0.14%, about 0.04% to about 0.16%, about 0.04% to about 0.18%, about 0.04% to about 0.2 %, about 0.06% to about 0.08%, about 0.06% to about 0.1%, about 0.06% to about 0.12%, about 0.06% to about 0.14%, about 0.06% to about 0.16%, about 0.06% to about 0.18%, about 0.06% to about 0.2%, about 0.08% to about 0.1%, about 0.08% to about 0.12%, about 0.08% to about 0.14%, about 0.08% to about 0.16%, about 0.08% to about 0.18%, about 0.08% to about 0.2%, about 0.1% to about 0.12%, about 0.1 % to about 0.14%, about 0.1% to about 0.16%, about 0.1% to about 0.18%, about 0.1% to about 0.2%, about 0.12% to about 0.14%, about 0.12% to about 0.16%, about 0.12% to about 0.18%, about 0.12% to about 0.2%, about 0.14% to about 0.16%, about 0.14% to about 0.18%, about 0.14% to about 0.2%, about 0.16% to about 0.18%, about 0.16% to about 0.2%, or about 0.18% to about 0.2%.In some instances, the one or more biological extracts may be present in an amount of about 0.01%, about 0.02%, about 0.04%, about 0.06%, about 0.08%, about 0.1%, about 0.12%, about 0.14%, about 0.16%, about 0.18%, or about 0.2%, respectively or in total. In some instances, the one or more biological extracts may be present in an amount of at least about 0.01%, about 0.02%, about 0.04%, about 0.06%, about 0.08%, about 0.1%, about 0.12%, about 0.14%, about 0.16%, or about 0.18%, respectively or in total. In some instances, one or more biological extracts may be present, individually or collectively, in an amount of up to about 0.02%, about 0.04%, about 0.06%, about 0.08%, about 0.1%, about 0.12%, about 0.14%, about 0.16%, about 0.18%, or about 0.2%.
[0110] In some embodiments, the one or more biological extracts are natural or synthetic extracts. In some embodiments, the one or more biological extracts include carbohydrates. In some embodiments, the carbohydrates include fucoidan. Examples of biological extracts include, but are not limited to, algae extracts, marine extracts, biotechnological extracts, root extracts, or flower extracts (e.g., Seanactiv, Shadowyl Clear, Eyedeline, Eye'fective, Meiview, Rootness Awake, etc.). In some examples, the flower extract includes Jasminum Sambac flower extract (e.g., Jasmine flower extract). In some examples, the flower extract includes Crataegus Monogyna flower extract (e.g., Crataegus flower extract). In some examples, the extract is obtained by bacterial fermentation. In one example, Bacillus fermentation may be obtained by fermentation of Bacillus subtilis. In some examples, the root extract is derived from a plant belonging to the Convolvulaceae family. As an example, the root extract may be obtained from the root of sweet potato (Ipomoea batatas). Each of the algae extract, marine extract, biotechnological extract, root extract, or flower extract may be present in the biological extract composition added to the formulation in an amount of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, or 0.08%. The biological extract composition added to the formulation provided herein may further include water, propanediol, xanthan gum, sodium sulfate, glycerin, glyceryl caprylate, or other suitable solvent, or any combination thereof.
[0111] In some embodiments, the additional component may include one or more vitamins or derivatives thereof. In some cases, when applied to the skin or epidermis, the one or more vitamins or derivatives thereof may provide one or more desired effects (e.g., smoothing, toning, moisturizing, brightening, reducing acne, eczema, wrinkles, etc.). In some instances, the additional component may include vitamin B, vitamin C (ascorbic acid), vitamin A (retinol), vitamin E, vitamin D, vitamin F, vitamin K, or any derivatives thereof. In some instances, the additional component may include vitamin B3 (niacin). In some instances, the vitamin B3 derivative may include niacinamide. In some instances, the additional component may include provitamin B5 (panthenol). In some embodiments, the one or more vitamins or derivatives thereof are present in the composition in an amount of about 0.1% to about 4% (w / w).In some embodiments, the one or more vitamins or derivatives thereof are from about 0.1% to about 0.2%, from about 0.1% to about 0.3%, from about 0.1% to about 0.5%, from about 0.1% to about 0.8%, from about 0.1% to about 1%, from about 0.1% to about 1.2%, from about 0.1% to about 1.5%, from about 0.1% to about 2%, from about 0.1% to about 2.5%, from about 0.1% to about 3%, from about 0.1% to about 3.5%, from about 0.1% to about 4%, from about 0.2% to about 0.3%, from about 0.2% to about 0.5%, from about 0.2% to about 0.8%, from about 0.2% to about 1%, from about 0.2% to about 0.8%, About 1.2%, about 0.2% to about 1.5%, about 0.2% to about 2%, about 0.2% to about 2.5%, about 0.2% to about 3%, about 0.2% to about 3.5%, about 0.2% to about 4%, about 0.3% to about 0.5%, about 0.3% to about 0.8%, about 0.3% to about 1%, about 0.3% to about 1.2%, about 0.3% to about 1.5%, about 0.3% to about 2%, about 0.3% to about 2.5%, about 0.3% to about 3%, about 0.3% to about 3.5%, about 0.3% to about 4%, about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0. 5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.5% to about 3%, about 0.5% to about 3.5%, about 0.5% to about 4%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 0.8% to about 3%, about 0.8% to about 3.5%, about 0.8% to about 4%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1% to about 3%, about 1% to about 3.5%, about 1% to about 4%, about 1.2% about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.2% to about 3%, about 1.2% to about 3.5%, about 1.2% to about 4%, about 1.5% to about 2%, about 1.5% to about 2.5%, about 1.5% to about 3%, about 1.5% to about 3.5%, about 1.5% to about 4%, about 2% to about 2.5%, about 2% to about 3%, about 2% to about 3.5%, about 2% to about 4%, about 2.5% to about 3%, about 2.5% to about 3.5%, about 2.5% to about 4%, about 3% to about 3.5%, about 3% to about 4%, or about 3.5% to about 4%. In some embodiments, the one or more vitamins or derivatives thereof are present in an amount of about 0.1%, about 0.2%, about 0.3%, about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, about 2.05%, about 2.5%, about 3%, about 3.5%, or about 4%.In some embodiments, the one or more vitamins or derivatives thereof are present in an amount of at least about 0.1%, about 0.2%, about 0.3%, about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, or about 4%. In some embodiments, the one or more vitamins or derivatives thereof are present in an amount of up to about 0.2%, about 0.3%, about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, or about 4%.
[0112] In some embodiments, additional components in the lipid vesicle composition may include an antioxidant. In some instances, the antioxidant may be vitamin C or a derivative thereof. In some instances, the antioxidant may include ascorbic acid, ascorbyl palmitate, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, retinyl ascorbate, aminopropyl ascorbyl phosphate (K3 Vita-C), tetrahexyldecyl ascorbate, ascorbyl methylsilanol pectinate (ascorbosilane SP), or combinations thereof. In some embodiments, an antioxidant such as vitamin C or a derivative thereof may further aid in collagen synthesis. In some embodiments, the additional component may include resorcinol (e.g., 4-butylresorcinol). In some embodiments, the antioxidant is present in the composition in an amount of about 0.005% to about 1%.In some embodiments, the antioxidant is from about 0.005% to about 0.01%, from about 0.005% to about 0.02%, from about 0.005% to about 0.05%, from about 0.005% to about 0.07%, from about 0.005% to about 0.1%, from about 0.005% to about 0.3%, from about 0.005% to about 0.5%, from about 0.005% to about 0.8%, from about 0.005% to about 1%, or from about 0.0 1% to about 0.02%, about 0.01% to about 0.05%, about 0.01% to about 0.07%, about 0.01% to about 0.1%, about 0.01% to about 0.3%, about 0.01% to about 0.5%, about 0.01% to about 0.8%, about 0.01% to about 1%, about 0.02% to about 0.05%, about 0.02% to about 0.07%, about 0.02% to about 0.1%, about 0.02% to about 0 0.3%, about 0.02% to about 0.5%, about 0.02% to about 0.8%, about 0.02% to about 1%, about 0.05% to about 0.07%, about 0.05% to about 0.1%, about 0.05% to about 0.3%, about 0.05% to about 0.5%, about 0.05% to about 0.8%, about 0.05% to about 1%, about 0.07% to about 0.1%, about 0.07% to about 0.3%, about 0.07% to In some embodiments, the antioxidant is present in an amount of about 0.005%, about 0.01%, about 0.02%, about 0.05%, about 0.07%, about 0.1%, about 0.3%, about 0.1%, about 0.5%, about 0.1%, about 0.8%, about 0.1%, about 1%, about 0.3%, about 0.5%, about 0.3%, about 0.8%, about 0.3%, about 1%, about 0.5%, about 0.8%, about 0.5% to about 1%, or about 0.8% to about 1%. In some embodiments, the antioxidant is present in an amount of about 0.005%, about 0.01%, about 0.02%, about 0.05%, about 0.07%, about 0.1%, about 0.3%, about 0.5%, about 0.51%, about 0.8%, or about 1%. In some embodiments, the antioxidant is present in an amount of at least about 0.005%, about 0.01%, about 0.02%, about 0.05%, about 0.07%, about 0.1%, about 0.3%, about 0.5%, about %, 0.8%, or about 1%. In some embodiments, the antioxidant is present in an amount of up to about 0.01%, about 0.02%, about 0.05%, about 0.07%, about 0.1%, about 0.3%, about 0.5%, about %, 0.8%, or about 1%.
[0113] In some embodiments, the composition includes a silicone oil or derivative, such as dimethicone. In some embodiments, the silicone oil includes a siloxane polymer. In some embodiments, the siloxane polymer includes C1-C3 substituents. In some embodiments, the siloxane is polydimethylsiloxane (PDMS). In some embodiments, the silicone oil is polymethylsilsesquioxane (e.g., Botanisil™ SP-360). In some embodiments, the oil is a mixture that includes a silicone oil (e.g., dimethicone) as a smaller component. In some embodiments, the silicone oil is incorporated to improve the feel of the resulting composition or as a moisturizer. In some embodiments, the oil includes an amount of silicone oil up to about 5%, up to about 4%, up to about 3%, up to about 2%, or up to about 1%. In some embodiments, the silicone oil is present in an amount of about 0.1% to about 2% (w / w) of the composition. In some embodiments, the silicone oil is present in an amount of about 0.1% to about 0.5%, 0.1% to about 0.7%, 0.1% to about 1%, 0.1% to about 1.5%, 0.15% to about 2%, 0.5% to about 0.7%, 0.5% to about 1%, 0.5% to about 1.5%, 0.5% to about 2%, 0.7% to about 1%, 0.7% to about 1.5%, 0.7% to about 2%, 1% to about 1.5%, or 1% to about 2% (w / w). In some embodiments, the silicone oil is present in an amount of about 0.1%, 0.5%, 0.6%, 0.7%, 1%, 1.5%, or 2% of the composition.
[0114] In some embodiments, the composition comprises an emollient. In some embodiments, the emollient comprises caprylic and / or capric triglyceride (e.g., Labrafac CC). In some embodiments, the caprylic and / or capric triglyceride is present in an amount of about 1% to about 10%. In some embodiments, the caprylic and / or capric triglycerides are from about 1% to about 2%, from about 1% to about 3%, from about 1% to about 4%, from about 1% to about 5%, from about 1% to about 6%, from about 1% to about 7%, from about 1% to about 8%, from about 1% to about 9%, from about 1% to about 10%, from about 2% to about 3%, from about 2% to about 4%, from about 2% to about 5%, from about 2% to about 6%, from about 2% to about 7%, from about 2% to about 8%, from about 2% to about 9%, from about 2% to about 10%, from about 3% to about 4%, from about 3% to about 5%, from about 3% to about 6%, from about 3% to about 7%, It is present in an amount of about 3% to about 8%, about 3% to about 9%, about 3% to about 10%, about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 9%, about 4% to about 10%, about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 6% to about 7%, about 6% to about 8%, about 6% to about 9%, about 6% to about 10%, about 7% to about 8%, about 7% to about 9%, about 7% to about 10%, about 8% to about 9%, about 8% to about 10%, or about 9% to about 10%. In some embodiments, caprylic and / or capric triglycerides are present in an amount of about 1%, about 2%, about 3%, about 3.5%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In some embodiments, caprylic and / or capric triglycerides are present in an amount of at least about 1%, about 2%, about 3%, about 3.5%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 9%. In some embodiments, caprylic and / or capric triglycerides are present in an amount of up to about 2%, about 3%, about 3.5%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%.
[0115] In some embodiments, the additional component comprises purified water, hi some embodiments, the purified water is present in an amount of about 50%-80% (w / w). In some embodiments, purified water is present in an amount of about 50% to about 55%, about 50% to about 60%, about 50% to about 65%, about 50% to about 70%, about 50% to about 75%, about 50% to about 80%, about 55% to about 60%, about 55% to about 65%, about 55% to about 70%, about 55% to about 75%, about 55% to about 80%, about 60% to about 65%, about 60% to about 70%, about 60% to about 75%, about 60% to about 80%, about 65% to about 70%, about 65% to about 75%, about 65% to about 80%, about 70% to about 75%, about 70% to about 80%, or about 75% to about 80%. In some embodiments, purified water is present in an amount of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80%. In some embodiments, purified water is present in an amount of at least about 50%, about 55%, about 60%, about 65%, about 70%, or about 75%. In some embodiments, purified water is present in an amount of up to 55%, about 60%, about 65%, about 70%, about 75%, or about 80%.
[0116] Exemplary Compositions for Delivery of Anionic Polymeric Materials Exemplary compositions for the delivery of anionic polymeric materials are provided below. The embodiments below may further include any of the other ingredients or components provided herein. In some embodiments, the other ingredients or components may be one or more peptides provided herein. In some embodiments, the one or more peptides may be dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides, or combinations thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides are encapsulated in a lipid bilayer, an oil-in-water emulsion, or combinations thereof.
[0117] Hyaluronic Acid Composition 1: In one embodiment, (a) lipid vesicles, each of which comprises a lipid bilayer comprising a vesicle-forming lipid, the vesicle-forming lipid being present in an amount of about 5% to about 20%; (b) an oil-in-water emulsion encapsulated in lipid vesicles and stabilized by one or more surfactants, the one or more surfactants comprising a cationic surfactant; and (c) hyaluronic acid in an amount of about 0.01 mg / mL to about 10 mg / mL, encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof; (d) one or more peptides in an amount of about 0.1 mg / mL to about 50 mg / mL encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof; Provided herein is a lipid vesicle composition comprising:
[0118] In some embodiments, the oil component is present in an amount of about 2.5% to about 20%.
[0119] In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of from about 0.01 mg / mL to about 0.05 mg / mL, from about 0.01 mg / mL to about 0.1 mg / mL, from about 0.01 mg / mL to about 0.5 mg / mL, from about 0.01 mg / mL to about 1 mg / mL, from about 0.01 mg / mL to about 1.25 mg / mL, from about 0.01 mg / mL to about 1.5 mg / mL, from about 0.01 mg / mL to about 1.75 mg / mL, from about 0.01 mg / mL to about 2 mg / mL, from about 0.01 mg / mL to about 5 mg / mL, from about 0.1 mg / mL to about 10 mg / mL, from about 0.1 mg / mL to about 0.5 mg / mL / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 1.25 mg / mL, about 0.1 mg / mL to about 1.5 mg / mL, about 0.1 mg / mL to about 1.75 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 1 mg / mL to about 1.5 mg / mL, about 1 mg / mL to about 1.75 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 5 mg / mL, and about 1 mg / mL to about 10 mg / mL. In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL.
[0120] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0121] In some embodiments, the lipid vesicle composition further comprises a viscosity enhancing agent in an amount of about 0.5% to about 5%. In some embodiments, the viscosity enhancing agent comprises one or more of a fatty alcohol, a wax, a fatty acid ester of glycerol, or any combination thereof.
[0122] In some embodiments, the lipid vesicle composition further comprises a non-ionic surfactant in an amount of about 0.1% to about 3%. In some embodiments, the non-ionic surfactant is a PEG ether of an aliphatic alcohol.
[0123] In some embodiments, the one or more peptides of (d) comprise a tetrapeptide, a pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identical to the amino acid sequence of any one of SEQ ID NOs: 31, 36, or 37. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identical to the amino acid sequence of any one of SEQ ID NOs: 37. In some embodiments, one or more peptides comprise an amino acid sequence identical to that of SEQ ID NO:37.
[0124] In some embodiments, the cationic surfactant is a propylene glycol diammonium phosphate ester derived from a fatty amide. In some embodiments, the cationic surfactant is present in an amount of about 1% to about 10%.
[0125] Hyaluronic Acid Composition 2: In one embodiment, (a) lipid vesicles, each of which comprises a lipid bilayer comprising a vesicle-forming lipid, the vesicle-forming lipid being present in an amount of about 2% to about 20%; (b) an oil-in-water emulsion encapsulated in lipid vesicles and stabilized by one or more surfactants; (c) hyaluronic acid in an amount of about 0.01 mg / mL to about 10 mg / mL encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof; The composition comprises: A gemini surfactant in an amount of about 0.01% to about 0.5%, and Hyaluronic acid, further comprising polysorbate in an amount of about 0.1% to about 2%; (d) one or more peptides encapsulated in a lipid bilayer, an oil-in-water emulsion, or a combination thereof, in an amount of about 0.1 mg / mL to about 50 mg / mL.
[0126] In some embodiments, the oil component is present in an amount of about 2.5% to about 20%.
[0127] In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of from about 0.01 mg / mL to about 0.05 mg / mL, from about 0.01 mg / mL to about 0.1 mg / mL, from about 0.01 mg / mL to about 0.5 mg / mL, from about 0.01 mg / mL to about 1 mg / mL, from about 0.01 mg / mL to about 1.25 mg / mL, from about 0.01 mg / mL to about 1.5 mg / mL, from about 0.01 mg / mL to about 1.75 mg / mL, from about 0.01 mg / mL to about 2 mg / mL, from about 0.01 mg / mL to about 5 mg / mL, from about 0.1 mg / mL to about 10 mg / mL, from about 0.1 mg / mL to about 0.5 mg / mL / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 1.25 mg / mL, about 0.1 mg / mL to about 1.5 mg / mL, about 0.1 mg / mL to about 1.75 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 1 mg / mL to about 1.5 mg / mL, about 1 mg / mL to about 1.75 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 5 mg / mL, and about 1 mg / mL to about 10 mg / mL. In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL.
[0128] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0129] In some embodiments, the lipid vesicle composition further comprises a viscosity enhancing agent in an amount of about 0.5% to about 5%. In some embodiments, the viscosity enhancing agent comprises one or more of a fatty alcohol, a wax, a fatty acid ester of glycerol, or any combination thereof.
[0130] In some embodiments, the one or more peptides of (d) comprise a tetrapeptide, a pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identical to the amino acid sequence of any one of SEQ ID NOs: 31, 36, or 37. In some embodiments, the one or more peptides comprise an amino acid sequence that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identical to the amino acid sequence of any one of SEQ ID NOs: 37. In some embodiments, one or more peptides comprise an amino acid sequence identical to that of SEQ ID NO:37.
[0131] In some embodiments, the polysorbate is polysorbate 80.
[0132] Lipid Vesicle Compositions of One or More Peptides for Intradermal Delivery - Patent application In one aspect, provided herein is a lipid vesicle composition comprising one or more peptides. In some embodiments, the one or more peptides may be a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, or combinations thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the lipid vesicle composition comprises lipid vesicles comprising lipid bilayers, each comprising a vesicle-forming lipid. In some embodiments, the lipid vesicle composition comprises an oil-in-water emulsion encapsulated in the lipid vesicle. In some embodiments, the oil-in-water emulsion is stabilized by one or more surfactants. In some embodiments, the one or more peptides are encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the lipid vesicle may further comprise other components or components. In some embodiments, the other components or components may be anionic polymeric materials. In some embodiments, the anionic polymeric materials may be encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the anionic polymeric materials are hyaluronic acid.
[0133] In one aspect, the present disclosure relates to lipid vesicle compositions comprising one or more peptides that can provide biological activity. Peptides that can provide biological activity can be referred to as bioactive peptides. In some embodiments, bioactive peptides may play a role in biological processes related to skin care, including but not limited to regulating cell proliferation, inflammation, angiogenesis, melanogenesis, extracellular matrix synthesis, and the like. See Falla, et.al., 2009, "Cosmeceuticals and peptides," Clinics in Dermatology 27:485-494, which is incorporated herein by reference in its entirety.
[0134] Peptides in lipid vesicle compositions The present disclosure provides lipid vesicle compositions comprising one or more peptides. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides comprise dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides, or combinations thereof. In some embodiments, the one or more peptides are tetrapeptides, pentapeptides, hexapeptides, or combinations thereof. In some embodiments, the one or more tetrapeptides, pentapeptides, hexapeptides, or combinations thereof may be in a lipid vesicle composition comprising an anionic polymeric material (e.g., hyaluronic acid). In some embodiments, the one or more peptides may exhibit high affinity for and form complexes with metals. In some embodiments, the metal may be copper.
[0135] In some embodiments, one or more peptides in the lipid vesicle compositions provided herein have desirable properties or improved properties compared to peptides known in the art, such as, for example, pharmacokinetic properties (including, but not limited to, absorption, bioavailability, distribution, metabolism, and excretion), pharmacodynamic properties (including, but not limited to, receptor binding characteristics, e.g., binding half-life, post-receptor effects, and chemical interactions), enhanced activity (e.g., IC 50 These may include the ability to permeate the skin by a formulation containing one or more peptides, stability (e.g., as represented by half-life), solubility (e.g., in a formulation), or permeability (e.g., permeability of the skin by a formulation containing one or more peptides). In some embodiments, a lipid vesicle formulation containing one or more peptides of the present disclosure has a desired property or an improved property compared to a formulation known in the art. In some embodiments, the desired property or improved property of a formulation of the present disclosure is a property related to the use of the formulation for an application as described elsewhere herein, for example, for use in reducing or improving the appearance of wrinkles on the skin.
[0136] peptide In some embodiments, one or more peptides of the lipid vesicle composition include a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, a hexapeptide, a heptapeptide, an octapeptide, or a combination thereof. In some embodiments, one or more peptides include a tetrapeptide. In some embodiments, one or more peptides include a pentapeptide. In some embodiments, one or more peptides include a hexapeptide. In some embodiments, one or more peptides include a pentapeptide and a hexapeptide. In some embodiments, one or more peptides are unmodified. In some embodiments, one or more peptides include an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, one or more peptides include one or more amino acid substitutions to any one of SEQ ID NOs: 1-51. In some embodiments, one or more peptides include one, two, or three, four amino acid substitutions to any one of SEQ ID NOs: 1-51. In some embodiments, at least one of the one, two, or three amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides comprise an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides have an amino acid sequence consisting of a sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51.
[0137] In some embodiments, one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 13. In some embodiments, one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 13. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaa1-Xaa3. In some embodiments, one or more peptides comprise one or two amino acid substitutions relative to SEQ ID NO: 13. In some embodiments, at least one of the one or two amino acid substitutions is a conservative substitution. In some embodiments, one or more peptides have an amino acid sequence consisting of the same sequence of SEQ ID NO: 13.
[0138] In some embodiments, one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO:21. In some embodiments, one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO:21. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaa1-Xaa5. In some embodiments, one or more peptides comprise one or two amino acid substitutions relative to SEQ ID NO:21. In some embodiments, at least one of the one or two amino acid substitutions is a conservative substitution. In some embodiments, one or more peptides have an amino acid sequence consisting of the identical sequence of SEQ ID NO:21.
[0139] In some embodiments, one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO:31. In some embodiments, one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO:31. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaa1-Xaa5. In some embodiments, one or more peptides comprise one or two amino acid substitutions relative to SEQ ID NO:31. In some embodiments, at least one of the one or two amino acid substitutions is a conservative substitution. In some embodiments, one or more peptides have an amino acid sequence consisting of the identical sequence of SEQ ID NO:31.
[0140] In some embodiments, one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 36. In some embodiments, one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 36. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaa1-Xaa6. In some embodiments, one or more peptides comprise one, two, or three amino acid substitutions relative to SEQ ID NO: 36. In some embodiments, at least one of the one, two, or three amino acid substitutions is a conservative substitution. In some embodiments, one or more peptides have an amino acid sequence consisting of the same sequence of SEQ ID NO: 36.
[0141] In some embodiments, one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 37. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaa1-Xaa6. In some embodiments, one or more peptides comprise one, two, or three amino acid substitutions relative to SEQ ID NO: 37. In some embodiments, at least one of the one, two, or three amino acid substitutions is a conservative substitution. In some embodiments, one or more peptides have an amino acid sequence consisting of the identical sequence of SEQ ID NO: 37.
[0142] In some embodiments, one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO:40. In some embodiments, one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO:37. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaa1-Xaa6. In some embodiments, one or more peptides comprise one, two, or three amino acid substitutions relative to SEQ ID NO:40. In some embodiments, at least one of the one, two, or three amino acid substitutions is a conservative substitution. In some embodiments, one or more peptides have an amino acid sequence consisting of the identical sequence of SEQ ID NO:40.
[0143] In some embodiments, the one or more peptides comprise at most about 8 amino acids, at most about 7 amino acids, at most 6 amino acids, at most 5 amino acids, at most 4 amino acids, at most 3 amino acids, or at most 2 amino acids. In some embodiments, the one or more peptides have a molecular weight of at most about 1500 Da, at most about 1100 Da, at most about 950 Da, at most about 800 Da, at most about 650 Da, at most about 500 Da, at most about 350 Da, or at most about 250 Da.
[0144] In some embodiments, one or more peptides of the lipid vesicle composition have between 2 and 8 residues. In some embodiments, one or more peptides of the lipid vesicle have the following amino acid sequence:
[0145] Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8,
[0146] Xaa1 is absent or selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0147] Xaa2 is selected from absent, Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0148] Xaa3 is absent or selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0149] Xaa4 is absent or selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0150] Xaa5 is absent or selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile; Xaa6 is absent or selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0151] Xaa7 is selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0152] Xaa8 is selected from Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, Ile, and derivatives of Ala, Gly, Gln, Glu, Val, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or Ile;
[0153] The N-terminus is unmodified, and
[0154] The C-terminus is unmodified.
[0155] In some embodiments, one or more peptides of the lipid vesicle composition have between 2 and 8 residues. In some embodiments, one or more peptides of the lipid vesicle have the amino acid sequence:
[0156] Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8,
[0157] Xaa1 is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Gly, Lys, Pro, Tyr, or Val;
[0158] Xaa2 is absent or selected from Ala, Arg, Cys, Gly, Ile, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Cys, Gly, Ile, Lys, Pro, Tyr, or Val;
[0159] Xaa3 is absent or selected from Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, or Val;
[0160] Xaa4 is absent or selected from Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Val;
[0161] Xaa5 is absent or selected from Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Val;
[0162] Xaa6 is absent or selected from Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Val, and derivatives of Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Val;
[0163] Xaa7 is selected from Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Val;
[0164] Xaa8 is selected from Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Val, and derivatives of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Val;
[0165] The N-terminus is unmodified, and
[0166] The C-terminus is unmodified.
[0167] Non-limiting examples of one or more peptides of the present disclosure are shown in Table 2.
[0168] [Table 2-1]
[0169] [Table 2-2]
[0170] Unless otherwise indicated in the table, the peptides listed in Table 2 may contain all L-amino acids or all D-amino acids. In some embodiments, the peptides listed in Table 2 are unmodified. In some embodiments, the peptides listed in Table 2 are synthetic human peptides (e.g., sh-polypeptides). In some embodiments, the peptides listed in Table 2 are recombinant human peptides (e.g., rh-polypeptides). In some embodiments, the peptides listed in Table 2 include a counterion (e.g., acetate). In some embodiments, the peptides listed in Table 2 are modified with an acetyl group (e.g., Ac).
[0171] Amino Acid Derivatives The present disclosure contemplates the use of any amino acid derivative or analog of any amino acid of one or more peptides of the present disclosure, such as those listed in Table 2. In some embodiments, the amino acid modification can be made chemically using any known method. Selective protein modification is described, for example, in Spicer and Davis, 2014, "Selective chemical protein modification," Nature Communications 5: 4740, which is incorporated herein by reference.
[0172] In some embodiments, the amino acid derivative is a non-standard amino acid. In some embodiments, the non-standard amino acid has an (S) configuration at the alpha position. In some embodiments, the non-standard amino acid has an (R) configuration at the alpha position. In some embodiments, the non-standard amino acid is an alpha amino acid. In some embodiments, the non-standard amino acid is a beta amino acid or a gamma amino acid (e.g., beta-alanine). In some embodiments, the non-standard amino acid is selected from the group consisting of aromatic side chain amino acids, non-aromatic side chain amino acids, aliphatic side chain amino acids, side chain amide amino acids, side chain ester amino acids, heteroaromatic side chain amino acids, side chain thiol amino acids, beta amino acids, and backbone modified amino acids. In some embodiments, the non-standard amino acid is a derivative of tyrosine, histidine, tryptophan, or phenylalanine. In some embodiments, the derivative of an amino acid includes an ester, amide, disulfide, carbamate, urea, phosphate, or ether of an amino acid. In some embodiments, the non-aromatic side chain amino acid is a derivative of serine, threonine, cysteine, methionine, arginine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, proline, glycine, alanine, valine, isoleucine, or leucine. In some embodiments, the non-standard amino acid is selected from the group consisting of 2-aminoadipic acid, 3-aminoadipic acid, β-alanine, β-aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, piperidinic acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylglycine, sarcosine, n-methylisoleucine, 6-N-methyllysine, N-methylvaline, norvaline, norleucine, and ornithine. In some embodiments, the non-standard amino acid is a proline derivative.In some embodiments, the proline derivative is 3-fluoroproline, 4-fluoroproline, 3-hydroxyproline, 4-hydroxyproline, 3-aminoproline, 4-aminoproline, 3,4-dehydroproline, aziridine-2-carboxylic acid, azetidine-2-carboxylic acid, pipecolic acid, 4-oxa-proline, 3-thiaproline, or 4-thiaproline. In some embodiments, the non-ionic amino acid comprises a lipid.
[0173] In some embodiments, one or more peptides of the disclosure include one or more amino acid derivatives or analogs, e.g., known to those of skill in the art and described in the literature or herein. In some embodiments, one or more peptides of the disclosure include 2, 3, 4, 5, 6, 7, 8, 2-3, 2-4, 2-5, 2-6, 2-7, or 2-8 amino acid derivatives. In some embodiments, one or more peptides are unmodified.
[0174] In some embodiments, each amino acid derivative present in one or more peptides of the disclosure is a non-standard amino acid independently selected from the group consisting of aromatic side chain amino acids, non-aromatic side chain amino acids, aliphatic side chain amino acids, side chain amide amino acids, side chain ester amino acids, heteroaromatic side chain amino acids, side chain thiol amino acids, beta amino acids, and backbone modified amino acids, e.g., selected from non-standard amino acids described herein or known in the art and described in the published literature.
[0175] In some embodiments, one or more peptides comprise one or more amino acids having a D-amino acid configuration, with the remaining amino acids in the peptide having the L-amino acid configuration.
[0176] In some embodiments, the non-standard amino acid is a proline derivative. In some embodiments, the proline derivative comprises one or more substitutions on the pyrrolidine ring. In some embodiments, the proline derivative comprises one or more substitutions on the pyrrolidine ring, the substitutions include halogen, alkoxy, amino, hydroxyl, alkyl (methyl, ethyl), thiol, or alkylthio. In some embodiments, the proline derivative comprises one or more substitutions on the pyrrolidine ring, the substitutions include halogen, or alkyl (methyl, ethyl). In some embodiments, the proline derivative comprises one or more substitutions on the pyrrolidine ring, the substitutions include halogen. In some embodiments, the proline derivative comprises one or more substitutions on the pyrrolidine ring, the substitutions include alkoxy, hydroxyl, amino. In some embodiments, the proline derivative comprises one or more substitutions on the pyrrolidine ring, the substitutions include halogen, alkoxy, alkyl (methyl, ethyl), thiol, or alkylthio.
[0177] Concentration of peptide in the composition The composition may include one or more peptides. In some embodiments, the one or more peptides include one or more peptides provided in Table 2. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of about 0.01 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of about 0.005 mg / mL to about 0.05 mg / mL, 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 3 mg / mL, about 0.01 mg / mL to about 4 mg / mL, about 0.01 mg / mL to about 5 ... .01mg / mL~about 10mg / mL, about 0.01mg / mL~about 20mg / mL, about 0.01mg / mL~about 50mg / mL, about 0.05mg / mL~about 0.1mg / mL, about 0.05mg / mL~about 0 .5mg / mL, about 0.05mg / mL to about 1mg / mL, about 0.05mg / mL to about 2mg / mL, about 0.05mg / mL to about 3mg / mL, about 0.05mg / mL to about 4mg / mL, about 0.05mg / mL mL ~ approx. 5 mg / mL, approx. 0.05 mg / mL ~ approx. 10 mg / mL, approx. 0.01 mg / mL ~ approx. 20 mg / mL, 0.05 mg / mL ~ approx. 50 mg / mL, approx. 0.1 mg / mL ~ approx. 0.5 mg / mL, approx. 0 .1mg / mL~about 1mg / mL, about 0.1mg / mL~about 2mg / mL, about 0.1mg / mL~about 3mg / mL, about 0.1mg / mL~about 4mg / mL, about 0.1mg / mL~about 5mg / mL, about 0.1 mg / mL~about 10mg / mL, about 0.1mg / mL~about 20mg / mL, about 0.1mg / mL~about 50mg / mL, about 0.5mg / mL~about 1mg / mL, about 0.5mg / mL~about 2mg / mL, about 0. 5mg / mL to about 3mg / mL, about 0.5mg / mL to about 4mg / mL, about 0.5mg / mL to about 5mg / mL, about 0.5mg / mL to about 10mg / mL, about 0.5mg / mL to about 20mg / mL, about 0.5 mg / mL to about 50 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 3 mg / mL, about 1 mg / mL to about 4 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 1 mg / mL to about 20 mg / mL, about 1 mg / mL to about 50 mg / mL, about 2 mg / mL to about 3 mg / mL, about 2 mg / mL to about 4 mg / mL, about 2 mg / mL to about 5 mg / mL, about 2 mg / mL to about 10 mg / mL, about 2 mg / mL to about 20 mg / mL, about 2 mg / mL to about 50 mg / mL, about 3 mg / mL to about 4 mg / mL, about 3 mg / mL In some embodiments, the vesicle composition is present in an amount of about 3 mg / mL to about 5 mg / mL, about 3 mg / mL to about 10 mg / mL, about 3 mg / mL to about 20 mg / mL, about 3 mg / mL to about 50 mg / mL, about 4 mg / mL to about 5 mg / mL, about 4 mg / mL to about 10 mg / mL, about 4 mg / mL to about 20 mg / mL, about 4 mg / mL to about 50 mg / mL, about 5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 20 mg / mL, about 5 mg / mL to about 50 mg / mL, about 10 mg / mL to about 20 mg / mL, about 10 mg / mL to about 50 mg / mL, or about 20 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of about 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of at least about 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, or about 20 mg / mL. In some embodiments, the one or more peptides are at a concentration of up to about 0.01 mg / mL, 0.02 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.The one or more peptides are present in the vesicle composition in an amount of about 5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the one or more peptides are present in the composition in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0178] In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 3 mg / mL, about 0.01 mg / mL to about 4 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 6 mg / mL, about 0.01 mg / mL to about 7 mg / mL, about 0.01 mg / mL to about 8 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.01 mg / mL to about 12 mg / mL, about 0.01 mg / mL to about 14 mg / mL, about 0.01 mg / mL to about 16 mg / mL, about 0.01 mg / mL to about 18 mg / mL, about 0.01 mg / mL to about 19 mg / mL, about 0.01 mg / mL to about 20 mg / mL, about 0.01 mg / mL to about 22 mg / mL, about 0.01 mg / mL to about 26 mg / mL, about 0.01 mg / mL to about 28 mg / mL, about 0.01 mg / mL to about 29 mg / mL, about 0.01 mg / mL to about 30 mg / mL, about 0.01 mg / mL to about 31 mg / mL, about 0.01 mg / mL to about 32 mg / .01mg / mL~about 10mg / mL, about 0.01mg / mL~about 20mg / mL, about 0.01mg / mL~about 50mg / mL, about 0.05mg / mL~about 0.1mg / mL, about 0.05mg / mL~about 0 .5mg / mL, about 0.05mg / mL to about 1mg / mL, about 0.05mg / mL to about 2mg / mL, about 0.05mg / mL to about 3mg / mL, about 0.05mg / mL to about 4mg / mL, about 0.05mg / mL mL ~ approx. 5 mg / mL, approx. 0.05 mg / mL ~ approx. 10 mg / mL, approx. 0.01 mg / mL ~ approx. 20 mg / mL, approx. 0.05 mg / mL ~ approx. 50 mg / mL, approx. 0.1 mg / mL ~ approx. 0.5 mg / mL, approx. 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0. 1mg / mL to about 10mg / mL, about 0.1mg / mL to about 20mg / mL, about 0.1mg / mL to about 50mg / mL, about 0.5mg / mL to about 1mg / mL, about 0.5mg / mL to about 2mg / mL, about 0 .5mg / mL to about 3mg / mL, about 0.5mg / mL to about 4mg / mL, about 0.5mg / mL to about 5mg / mL, about 0.5mg / mL to about 10mg / mL, about 0.5mg / mL to about 20mg / mL, about 0.5 mg / mL to about 50 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 3 mg / mL, about 1 mg / mL to about 4 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 1 mg / mL to about 20 mg / mL, about 1 mg / mL to about 50 mg / mL, about 2 mg / mL to about 3 mg / mL, about 2 mg / mL to about 4 mg / mL, about 2 mg / mL to about 5 mg / mL, about 2 mg / mL to about 10 mg / mL, about 2 mg / mL to about 20 mg / mL, about 2 mg / mL to about 50 mg / mL, about 3 mg / mL to about 4 mg / mL, about 3 mg / mL In some embodiments, the vesicle composition is present in an amount of about 3 mg / mL to about 5 mg / mL, about 3 mg / mL to about 10 mg / mL, about 3 mg / mL to about 20 mg / mL, about 3 mg / mL to about 50 mg / mL, about 4 mg / mL to about 5 mg / mL, about 4 mg / mL to about 10 mg / mL, about 4 mg / mL to about 20 mg / mL, about 4 mg / mL to about 50 mg / mL, about 5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 20 mg / mL, about 5 mg / mL to about 50 mg / mL, about 10 mg / mL to about 20 mg / mL, about 10 mg / mL to about 50 mg / mL, or about 20 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of about 0.001 mg / mL, 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, 0.03 mg / mL, 0.05 mg / mL, 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at least about 0.001 mg / mL, 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, or about 20 mg / mL. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at least about 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, each of the one or more peptides is present in the composition in an amount of about 0.001 mg / mL, 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or 5 mg / mL.
[0179] In some embodiments, the one or more peptides are present in the vesicle composition in a total amount of about 0.005% to about 0.2%. In some embodiments, the one or more peptides are present in the vesicle composition in a total amount of about 0.005% to about 0.01%, about 0.005% to about 0.05%, about 0.005% to about 0.1%, about 0.005% to about 0.15%, about 0.005% to about 0.2%, about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, is present in the vesicle composition in a total amount of about 0.01% to about 0.2%, about 0.02% to about 0.03%, about 0.02% to about 0.05%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, the one or more peptides are present in the vesicle composition in a total amount of about 0.01%, about 0.02%, about 0.021%, about 0.022%, about 0.023%, about 0.024%, about 0.025%, about 0.026%, about 0.028%, about 0.03%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the one or more peptides are present in the vesicle composition in a total amount of at least about 0.005%, 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, the one or more peptides are present in the vesicle composition in a total amount of up to about 0.01%, 0.05%, about 0.1%, about 0.15%, or about 0.2%.
[0180] In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001% to about 0.2%. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001% to about 0.002%, about 0.001% to about 0.005%, about 0.001% to about 0.01%, about 0.001% to about 0.05%, about 0.001% to about 0.1%, about 0.001% to about 0.15%, about 0.001% to about 0.2%, about 0.002% to about 0.005%, about 0.002% to about 0.01%, about 0.002% to about 0.05%, about 0.002% to about 0.1%, about 0.002% to about 0.15%, about 0.002% to about 0.2%, The vesicle composition is present in an amount of about 0.005% to about 0.01%, about 0.005% to about 0.05%, about 0.005% to about 0.1%, about 0.005% to about 0.15%, about 0.005% to about 0.2%, about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001%, 0.002%, 0.005%, 0.01%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at least about 0.001%, 0.002%, 0.005%, 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of up to about 0.002%, 0.005%, 0.05%, about 0.1%, about 0.15%, or about 0.2%.
[0181] vesicle-forming lipids In some embodiments, the vesicle composition comprises one or more vesicle-forming lipids. The vesicle-forming lipids act to encapsulate a portion of the oil-in-water emulsion. In some embodiments, this allows the oil-in-water emulsion to remain stable for a period of time.
[0182] The vesicle-forming lipid can be any lipid suitable for such purpose.In some embodiments, the vesicle-forming lipid comprises phospholipid, glycolipid, lecithin, ceramide, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof.In some embodiments, the vesicle-forming lipid comprises a combination of lipids.
[0183] In some embodiments, the vesicle-forming lipid comprises a phospholipid. In some embodiments, the phospholipid is naturally occurring, semi-synthetic, or synthetically prepared, or a mixture thereof. In one embodiment, the phospholipid is one or more esters of glycerol with one or two (equal or different) residues of fatty acid and phosphoric acid, where the phosphoric acid residue is in turn bound to a hydrophilic group, such as, for example, choline (phosphatidylcholine (PC)), serine (phosphatidylserine (PS)), glycerol (phosphatidylglycerol (PG)), ethanolamine (phosphatidylethanolamine (PE)), or inositol (phosphatidylinositol). Phospholipid esters with only one fatty acid residue are commonly referred to in the art as the "lyso" form of phospholipid, or "lysophospholipid". Usually, the fatty acid residues present in phospholipids are long chain aliphatic acids, typically containing 12-24 carbon atoms, or 14-22 carbon atoms, and the aliphatic chain may contain one or more unsaturations, or may be fully saturated. Examples of suitable fatty acids contained in phospholipids are, for example, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, and linolenic acid. Saturated fatty acids such as myristic acid, palmitic acid, stearic acid, and arachidic acid may be used.
[0184] In some embodiments, the phospholipid comprises one or more natural phospholipids. In some embodiments, the phospholipid comprises one or more semi-synthetic phospholipids. In some embodiments, the semi-synthetic phospholipid is a partially or fully hydrogenated derivative of naturally occurring lecithin. In some embodiments, the phospholipid comprises a fatty acid diester of phosphatidylcholine, ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, or sphingomyelin. In some embodiments, the phospholipid comprises hydrogenated phosphatidylcholine (e.g., Sunlipon 90H). In some embodiments, the phospholipid may be, for example, dilauroyl-phosphatidylcholine (DLPC), dimyristoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidylcholine (DPPC), diarachidoyl-phosphatidylcholine (DAPC), distearoyl-phosphatidylcholine (DSPC), dioleoyl-phosphatidylcholine (DOPC), 1,2 distearoyl-sn-glycero-3-ethylphosphocholine (ethyl-DSPC), dipentadecanoyl-phosphatidylcholine (DPDPC), 1-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC), 1-palmitoyl-2-myristoyl-phosphatidylcholine (PMPC), 1-palmitoyl-2-stearoyl-phosphatidylcholine (P SPC), 1-stearoyl-2-palmitoyl-phosphatidylcholine (SPPC), 1-palmitoyl-2-oleylphosphatidylcholine (POPC), 1-oleyl-2-palmitoyl-phosphatidylcholine (OPPC), dilauroylphosphatidylglycerol (DLPG) and its alkali metal salts, diarachidoylphosphatidylglycerol (DAPG) and its alkali metal salts, dimyristoylphosphatidylglycerol (DMPG) and its alkali metal salts, dipalmitoylphosphatidylglycerol (DPPG) and its alkali metal salts, distearoylphosphatidylglycerol (DSPG) and its alkali metal salts, dioleoyl-phosphatidylglycerol (DOPG) and its alkali metal salts,Dimyristoyl phosphatidic acid (DMPA) and its alkali metal salts, dipalmitoyl phosphatidic acid (DPPA) and its alkali metal salts, distearoyl phosphatidic acid (DSPA), diarachidoyl phosphatidic acid (DAPA) and its alkali metal salts, dimyristoyl phosphatidylethanolamine (DMPE), dipalmitoyl phosphatidylethanolamine (DPPE), distearoyl phosphatidylethanolamine (DSPE), dioleoyl phosphatidylethanolamine (DOPE), diarachidoyl phosphatidylethanolamine (DAPE), dilinoleyl phosphatidylethanolamine (DLPE), dimyristoyl phosphatidylserine (D MPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoyl phosphatidylserine (DSPS), dioleoyl phosphatidylserine (DOPS), dipalmitoyl sphingomyelin (DPSP), as well as distearoyl sphingomyelin (DSSP), dilauroyl-phosphatidylinositol (DLPI), diarachidoyl phosphatidylinositol (DAPI), dimyristoyl phosphatidylinositol (DMPI), dipalmitoyl phosphatidylinositol (DPPI), distearoyl phosphatidylinositol (DSPI), and dioleoyl-phosphatidylinositol (DOPI).
[0185] In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5% to about 2%, about 0.5% to about 5%, about 0.5% to about 8%, about 0.5% to about 10%, about 0.5% to about 12%, about 0.5% to about 15%, about 0.5% to about 20%, about 0.5% to about 25%, about 2% to about 5%, about 2% to about 8%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 5% to about 8%, about 5% to about 10%, about 5% to about 10%, about 5% to about 20%, about 2% to about 25%, about 5% to about 8 ...0%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 20%, about 2% to about 2 In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, about 25%, about 8% to about 10%, about 8% to about 12%, about 8% to about 15%, about 8% to about 20%, about 8% to about 25%, about 10% to about 12%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 12% to about 15%, about 12% to about 20%, about 12% to about 25%, about 15% to about 20%, about 15% to about 25%, or about 20% to about 25% (w / w). In some embodiments, the vesicle-forming lipid is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, the vesicle-forming lipids are present in an amount of at least about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, or about 20% (w / w) of the composition. In some embodiments, the vesicle-forming lipids are present in an amount of up to 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25% (w / w) of the composition.
[0186] In some embodiments, the vesicle-forming lipid is present in an amount of about 5% to about 15% (w / w) of the composition. In some embodiments, the vesicle-forming lipid is present in an amount of about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 11%, about 5% to about 12%, about 5% to about 13%, about 5% to about 14%, about 5% to about 15%, about 8% to about 9%, about 8% to about 10%, about 8% to about 11%, about 8% to about 12%, about 8% to about 13%, about 8% to about 14%, about 8% to about 15%, about 9% to about 10%, about 9% to about 11%, about 9% to about 12%, about 9% to about 13%, about 9% to about 14%, about 9% to about 15%, about 9% to about 10%, about 9% to about 11%, about 9% to about 12%, about 9% to about 15%, about 9% to about 16%, about 9% to about 17%, about 9% to about 18%, about 9% to about 19%, about 10% to about 20%, about 10% to about 21%, about 10% to about 22%, about 10% to about 23%, about 10% to about 24%, about 10% to about 25%, about 10% to about 26%, about 10% to about 27%, about 10% to about 28%, about 10% to about 29%, about 10% to about 30%, about 10% to about 31%, about 10% to about 32%, about 10% to about 33%, about 10% to about 34%, about 10 In some embodiments, the vesicle-forming lipid is present in an amount of about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% (w / w) of the composition. In some embodiments, the vesicle-forming lipids are present in an amount of at least about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, or about 14% (w / w) of the composition. In some embodiments, the vesicle-forming lipids are present in an amount of up to 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% (w / w) of the composition.
[0187] In some embodiments, the composition comprises a short-chain polyol. In some embodiments, the short-chain polyol acts to enhance the stability of the resulting lipid vesicles. In some embodiments, the short-chain polyol is a C2-C4 polyol containing two or three alcohol groups. In some embodiments, the short-chain polyol is propylene glycol. In some embodiments, the composition comprises propylene glycol. In some embodiments, the composition comprises butanediol. In some embodiments, the butanediol is 1,3-butanediol. In some embodiments, the butanediol is 2,3-butanediol. In some embodiments, the composition comprises propylene glycol, butanediol (e.g., 2,3 butanediol), or both.
[0188] In some embodiments, propylene glycol is present in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, propylene glycol is present in an amount of about 0.5% to about 2%, about 0.5% to about 5%, about 0.5% to about 8%, about 0.5% to about 10%, about 0.5% to about 12%, about 0.5% to about 15%, about 0.5% to about 20%, about 0.5% to about 25%, about 2% to about 5%, about 2% to about 8%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 5% to about 8%, about 5% to about 10%, about It is present in an amount of about 5% to about 12%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 8% to about 10%, about 8% to about 12%, about 8% to about 15%, about 8% to about 20%, about 8% to about 25%, about 10% to about 12%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 12% to about 15%, about 12% to about 20%, about 12% to about 25%, about 15% to about 20%, about 15% to about 25%, or about 20% to about 25%. In some embodiments, propylene glycol is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 10.5%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, propylene glycol is present in an amount of at least about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, or about 20%. In some embodiments, propylene glycol is present in an amount of up to 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, propylene glycol is present in an amount of about 1% to about 10%. In some embodiments, propylene glycol is present in an amount of about 1% to about 2%, about 1% to about 4%, about 1% to about 6%, about 1% to about 8%, about 1% to about 10%, about 2% to about 4%, about 2% to about 6%, about 2% to about 8%, about 2% to about 10%, about 4% to about 6%, about 4% to about 8%, about 4% to about 10%, about 6% to about 8%, about 6% to about 10%, or about 8% to about 10%. In some embodiments, propylene glycol is present in an amount of about 1%, about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, propylene glycol is present in an amount of at least about 1%, about 2%, about 4%, about 6%, or about 8%.In some embodiments, propylene glycol is present in an amount of up to 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, propylene glycol is present in about the same amount as the vesicle-forming lipid. In some embodiments, the ratio of propylene glycol to vesicle-forming lipid in the composition is about 2:1 to 1:2 (w / w).
[0189] In some embodiments, butanediol (e.g., 2,3-butanediol) is present in an amount of about 0.5% to about 25% (w / w) of the composition. In some embodiments, butanediol is present in an amount of about 0.5% to about 2%, about 0.5% to about 5%, about 0.5% to about 8%, about 0.5% to about 10%, about 0.5% to about 12%, about 0.5% to about 15%, about 0.5% to about 20%, about 0.5% to about 25%, about 2% to about 5%, about 2% to about 8%, about 2% to about 10%, about 2% to about 12%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 5% to about 8%, about 5% to about 10%, about 5% In some embodiments, butanediol is present in an amount of about 0.5%, about 2%, about 5%, about 8%, about 10%, about 10.5%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, butanediol is present in an amount of at least about 0.5%, about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, or about 20%. In some embodiments, butanediol is present in an amount of up to about 2%, about 5%, about 8%, about 10%, about 12%, about 15%, about 20%, or about 25%. In some embodiments, butanediol is present in an amount of about 1% to about 10%. In some embodiments, butanediol is present in an amount of about 1% to about 2%, about 1% to about 4%, about 1% to about 6%, about 1% to about 8%, about 1% to about 10%, about 2% to about 4%, about 2% to about 6%, about 2% to about 8%, about 2% to about 10%, about 4% to about 6%, about 4% to about 8%, about 4% to about 10%, about 6% to about 8%, about 6% to about 10%, or about 8% to about 10%. In some embodiments, butanediol is present in an amount of about 1%, about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, butanediol is present in an amount of at least about 1%, about 2%, about 4%, about 6%, or about 8%.In some embodiments, butanediol is present in an amount of up to about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, butanediol is present in about the same amount as the vesicle-forming lipid. In some embodiments, the ratio of butanediol to vesicle-forming lipid in the composition is about 2:1 to 1:2 (w / w).
[0190] In some embodiments, the lipid vesicles and / or the oil phase of the lipid vesicle portion of the composition comprises a sterol. In some embodiments, the sterol is a naturally occurring sterol. In some embodiments, the sterol is a synthetic sterol. In some embodiments, the sterol is cholesterol. In some embodiments, the cholesterol may be plant-derived cholesterol. In some embodiments, the cholesterol may be synthetic cholesterol. In some embodiments, the plant-derived cholesterol may be cholest-5-en-3-ol (e.g., PhytoChol®, SyntheChol®, Avanti#700100), or any other plant-derived cholesterol, or any combination thereof. In some embodiments, the sterol may be a phytosterol or a derivative thereof. In some embodiments, the phytosterol or a derivative thereof may be phytosterol MM, Advasterol™ 90 IP or 95 IP F, NET sterol-ISO, canola sterol, sitosterol 700095, lanosterol-95, brassicasterol, or any combination thereof.
[0191] In some embodiments, the sterol is present in an amount of about 0.1% to about 5% (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 0.1% to about 5%. In some embodiments, the sterol is present in an amount of about 0.1% to about 0.2%, about 0.1% to about 0.5%, about 0.1% to about 0.8%, about 0.1% to about 1%, about 0.1% to about 2%, about 0.1% to about 3%, about 0.1% to about 4%, about 0.1% to about 5%, about 0.2% to about 0.5%, about 0.2% to about 0.8%, about 0.2% to about 1%, about 0.2% to about 2%, about 0.2% to about 3%, about 0.2% to about 4%, about 0.2% to about 5%, about 0.5% to about 0.8% , about 0.5% to about 1%, about 0.5% to about 2%, about 0.5% to about 3%, about 0.5% to about 4%, about 0.5% to about 5%, about 0.8% to about 1%, about 0.8% to about 2%, about 0.8% to about 3%, about 0.8% to about 4%, about 0.8% to about 5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5%. In some embodiments, the sterol is present in an amount of about 0.1%, about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the sterol is present in an amount of at least about 0.1%, about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, or about 4%. In some embodiments, the sterol is present in an amount of up to about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the sterol is present in an amount of about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1.5% to about 2%, about 1.5% to about 2.5%, about 1.5% to about 3%, about 1.5% to about 4%, about 1.5% to about 5%, about 2% to about 2.5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2.5% to about 3%, about 2.5% to about 4%, about 2.5% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5% (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 4%, or about 5% (w / w) of the composition.In some embodiments, the sterol is present in an amount of at least about 1%, about 1.5%, about 2%, about 2.5%, about 3%, or about 4% (w / w) of the composition, in some embodiments, the sterol is present in an amount of up to 1.5%, about 2%, about 2.5%, about 3%, about 4%, or about 5% (w / w) of the composition.
[0192] Oil Phase The lipid vesicle compositions provided herein include oil-in-water emulsions. The oil component is selected so that the material is liquid at the operating temperature (e.g., room temperature) and is immiscible with water.
[0193] Any suitable oil can be used as oil phase.In some embodiments, oil comprises naturally occurring oil.In some embodiments, naturally occurring oil is derived from one or more plants or plant parts (e.g., seeds or nuts).In some embodiments, oil is naturally occurring oil such as olive oil, vegetable oil, sunflower oil, or other similar plant-derived oil.
[0194] In some embodiments, the oil phase is selected from the group consisting of vegetable oils, mono-, di-, and triglycerides, silicone fluids, mineral oils, and combinations thereof. In some embodiments, the oil phase comprises an emollient. In some embodiments, the emollient comprises caprylic and / or capric triglycerides (e.g., Labrafac CC). In some embodiments, the emollient comprises a natural oil-soluble emollient, such as an oil-soluble plant extract, essential oil, vegetable oil, vegetable butter, or any combination thereof. In some embodiments, the natural oil-soluble emollient comprises oil derived from sunflower. In some embodiments, the natural oil-soluble emollient comprises oil derived from avocado.
[0195] In some embodiments, the oil comprises a silicone oil or derivative, such as dimethicone. In some embodiments, the silicone oil comprises a siloxane polymer. In some embodiments, the siloxane polymer comprises C1-C3 substituents. In some embodiments, the siloxane is polydimethylsiloxane (PDMS). In some embodiments, the silicone oil is polymethylsilsesquioxane (e.g., Botanisil™ SP-360). In some embodiments, the oil is a mixture that includes a silicone oil (e.g., dimethicone) as a smaller component. In some embodiments, the silicone oil is incorporated to improve the feel of the resulting composition or as a moisturizer. In some embodiments, the oil comprises an amount of silicone oil up to about 5%, up to about 4%, up to about 3%, up to about 2%, or up to about 1%. In some embodiments, the silicone oil is present in an amount of about 0.1% to about 2% (w / w) of the composition. In some embodiments, the silicone oil is present in an amount of about 0.1% to about 0.5%, 0.1% to about 0.7%, 0.1% to about 1%, 0.1% to about 1.5%, 0.15% to about 2%, 0.5% to about 0.7%, 0.5% to about 1%, 0.5% to about 1.5%, 0.5% to about 2%, 0.7% to about 1%, 0.7% to about 1.5%, 0.7% to about 2%, 1% to about 1.5%, or 1% to about 2% (w / w). In some embodiments, the silicone oil is present in an amount of about 0.1%, 0.5%, 0.6%, 0.7%, 1%, 1.5%, or 2% of the composition.
[0196] In some implementations, the oil is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the oil is present in an amount of about 1% to about 5%, about 1% to about 10%, about 1% to about 15%, about 1% to about 20%, about 1% to about 25%, about 1% to about 30%, about 1% to about 35%, about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 10% to about 15%, about 10% to about ... The oil is present in an amount of about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 15% to about 35%, about 20% to about, 25%, about 20% to about 30%, about 20% to about 35%, about 25% to about 30%, about 25% to about 35%, or about 30% to about 35%. In some embodiments, the oil is present in an amount of about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%. In some embodiments, the oil is present in an amount of at least about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the oil is present in an amount of up to about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%. In some embodiments, the oil is present in an amount of about 5% to about 15%. In some embodiments, the oil is present in an amount of about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 11%, about 5% to about 12%, about 5% to about 13%, about 5% to about 14%, about 5% to about 15%, about 8% to about 9%, about 8% to about 10%, about 8% to about 11%, about 8% to about 12%, about 8% to about 13%, about 8% to about 14%, about 8% to about 15%, about 9% to about 10%, about 9% to about 11%, about 9% to about 12%, about 9% to about 1 In some embodiments, the oil is present in an amount of about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.In some embodiments, the oil is present in an amount of at least about 5%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, or about 14%. In some embodiments, the oil is present in an amount of up to about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.
[0197] In some embodiments, the oil comprises one or more triglycerides. In some embodiments, the triglycerides are medium chain triglycerides. In some embodiments, the medium chain triglycerides comprise fatty acid esters having a chain length of C6-C12.
[0198] In some embodiments, the triglyceride is present in an amount of about 1% to about 35% (w / w) of the composition. In some embodiments, the triglyceride is present in an amount of about 1% to about 5%, about 1% to about 10%, about 1% to about 15%, about 1% to about 20%, about 1% to about 25%, about 1% to about 30%, about 1% to about 35%, about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 10% to about 15%, about 1 In some embodiments, the triglyceride is present in an amount of about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35 ... In some embodiments, triglycerides are present in an amount of at least about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, triglycerides are present in an amount of up to about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, or about 35%.
[0199] In some embodiments, the lipid vesicles and / or the oil phase of the lipid vesicle portion of the composition comprises a sterol. In some embodiments, the sterol is cholesterol. In some embodiments, the cholesterol may be plant-derived cholesterol. In some embodiments, the plant-derived cholesterol may be PhytoChol®, SyntheChol®, or any other plant-derived cholesterol (e.g., Avanti#700100), or any combination thereof. In some embodiments, the sterol may be a phytosterol or a derivative thereof. In some embodiments, the phytosterol or a derivative thereof may be phytosterol MM, Advasterol™ 90 IP or 95 IP F, NET sterol-ISO, canola sterol, sitosterol 700095, lanosterol-95, brassicasterol, or any combination thereof.
[0200] In some embodiments, the sterol is present in an amount of about 0.1% to about 5% (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 0.1% to about 5%. In some embodiments, the sterol is present in an amount of about 0.1% to about 0.2%, about 0.1% to about 0.5%, about 0.1% to about 0.8%, about 0.1% to about 1%, about 0.1% to about 2%, about 0.1% to about 3%, about 0.1% to about 4%, about 0.1% to about 5%, about 0.2% to about 0.5%, about 0.2% to about 0.8%, about 0.2% to about 1%, about 0.2% to about 2%, about 0.2% to about 3%, about 0.2% to about 4%, about 0.2% to about 5%, about 0.5% to about 0.8% , about 0.5% to about 1%, about 0.5% to about 2%, about 0.5% to about 3%, about 0.5% to about 4%, about 0.5% to about 5%, about 0.8% to about 1%, about 0.8% to about 2%, about 0.8% to about 3%, about 0.8% to about 4%, about 0.8% to about 5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5%. In some embodiments, the sterol is present in an amount of about 0.1%, about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the sterol is present in an amount of at least about 0.1%, about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, or about 4%. In some embodiments, the sterol is present in an amount of up to about 0.2%, about 0.5%, about 0.8%, about 1%, about 2%, about 3%, about 4%, or about 5%. In some embodiments, the sterol is present in an amount of about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1.5% to about 2%, about 1.5% to about 2.5%, about 1.5% to about 3%, about 1.5% to about 4%, about 1.5% to about 5%, about 2% to about 2.5%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2.5% to about 3%, about 2.5% to about 4%, about 2.5% to about 5%, about 3% to about 4%, about 3% to about 5%, or about 4% to about 5% (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 4%, or about 5% (w / w) of the composition.In some embodiments, the sterol is present in an amount of at least about 1%, about 1.5%, about 2%, about 2.5%, about 3%, or about 4% (w / w) of the composition, in some embodiments, the sterol is present in an amount of up to about 1.5%, about 2%, about 2.5%, about 3%, about 4%, or about 5% (w / w) of the composition.
[0201] In some embodiments, the lipid vesicle composition comprises one or more penetration enhancers.In some embodiments, the penetration enhancer acts to increase the amount of anionic polymeric material permeation through one or more layers of skin when applied to the skin of an individual.In some embodiments, the penetration enhancer acts to increase the amount of one or more peptides permeation through one or more layers of skin when applied to the skin of an individual.
[0202] In some embodiments, a composition comprising one or more penetration enhancers, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising the one or more other penetration enhancers is applied to one or more layers of the skin of a similar or same skin sample or individual. In some embodiments, a composition comprising one or more penetration enhancers, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by more than 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising the one or more other penetration enhancers is applied to one or more layers of the skin of a similar or same skin sample or individual. In some embodiments, a composition comprising one or more penetration enhancers, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising the one or more other penetration enhancers is applied to one or more layers of the skin of a similar or same skin sample or individual.
[0203] In some embodiments, a composition comprising one or more nonionic surfactants having an HLB value of about 10 or less, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising one or more other nonionic surfactants having an HLB value of about 10 or less is applied to one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more nonionic surfactants having an HLB value of about 10 or less, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by more than 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising one or more other nonionic surfactants having an HLB value of about 10 or less is applied to one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more nonionic surfactants having an HLB value of about 10 or less, when applied to a skin sample or to the skin of an individual, increases penetration through one or more layers of the skin by about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 150%, or 200% compared to when the same or a similar composition not comprising one or more other nonionic surfactants having an HLB value of about 10 is applied to one or more layers of the skin of a similar or same skin sample or individual.
[0204] In some embodiments, the penetration enhancer is included in an oil-in-water emulsion of the composition, hi some embodiments, the penetration enhancer is included in the lipid bilayer of the composition.
[0205] There are various types of penetration enhancers that can be used. In some embodiments, the penetration enhancer comprises an ionic surfactant, a non-ionic surfactant, or a combination thereof. In some embodiments, the ionic surfactant, the non-ionic surfactant, or a combination thereof is not a penetration enhancer.
[0206] In some embodiments, the penetration enhancer comprises a nonionic surfactant or a combination of nonionic surfactants. In some embodiments, the penetration enhancer is a single nonionic surfactant. In some embodiments, the penetration enhancer is a combination of at least two, three, or four or more nonionic surfactants. In some embodiments, the penetration enhancer is a combination of two nonionic surfactants. In some embodiments, the penetration enhancer is a combination of three nonionic surfactants.
[0207] In some embodiments, the nonionic surfactant or combination of nonionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters, glycerol stearate, and combinations thereof.
[0208] In some embodiments, the combination of nonionic surfactants is a combination of polyethylene glycol ethers and sorbitan esters of aliphatic alcohols. In some embodiments, the combination of nonionic surfactants is a combination of polyethylene glycol ethers and sorbitan esters of aliphatic alcohols. In some embodiments, the combination of nonionic surfactants is a combination of polyethylene glycol ethers and polyethylene glycol fatty acid esters of aliphatic alcohols. In some embodiments, the combination of nonionic surfactants is a combination of polyethylene glycol ethers, sorbitan esters, and polysorbates of aliphatic alcohols. In some embodiments, the combination of nonionic surfactants is a combination of polyethylene glycol ethers, sorbitan esters, and polyethylene glycol fatty acid esters of aliphatic alcohols. In some embodiments, the combination of nonionic surfactants is a combination of polyethylene glycol ethers, polysorbates ... glycerol stearate of aliphatic alcohols.
[0209] In some embodiments, the combination of nonionic surfactants comprises a polyethylene glycol fatty acid ester and a sorbitan ester. In some embodiments, the combination of nonionic surfactants comprises a polyethylene glycol fatty acid ester and a polysorbate. In some embodiments, the combination of nonionic surfactants is a combination of a polyethylene glycol fatty acid ester, a polysorbate, and a sorbitan ester.
[0210] In some embodiments, the nonionic surfactant comprises a polyethylene glycol (PEG) ether of an aliphatic alcohol. In some embodiments, the PEG ether of an aliphatic alcohol has from about 2 to about 8 PEG groups and C 12 -C 22 The polyethylene glycol ether of the fatty alcohol comprises a fatty alcohol. In some embodiments, the polyethylene glycol ether of the fatty alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the polyethylene glycol ether of the fatty alcohol comprises 2-(2-octadecaoxyethoxy)ethanol. In some embodiments, the PEG ether of the fatty alcohol is super refined Brij® O2 or a derivative thereof. In some embodiments, a nonionic surfactant is added to the aqueous phase of the composition.
[0211] In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5% to about 2.5%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.5% to about 2.5%, about 1.2% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the PEG ether of an aliphatic alcohol is present in an amount of up to 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0212] In some embodiments, the nonionic surfactant comprises a sorbitan ester. In some embodiments, the sorbitan ester is a fatty acid ester. In some embodiments, the sorbitan ester is a C 12 -C 22A fatty acid ester. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate. In some embodiments, the sorbitan ester comprises sorbitan monopalmitate. In some embodiments, the sorbitan ester comprises sorbitan monostearate. In some embodiments, the sorbitan ester comprises sorbitan monooleate. In some embodiments, the sorbitan ester comprises sorbitan trioleate. In some embodiments, the sorbitan ester comprises sorbitan sesquioleate. In some embodiments, the sorbitan ester comprises sorbitan isostearate.
[0213] In some embodiments, the sorbitan ester is present in an amount of about 0.5% to about 2.5% (w / w) of the composition. In some embodiments, the sorbitan ester is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.5% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the sorbitan esters are present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the sorbitan esters are present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the sorbitan esters are present in an amount of up to 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0214] In some embodiments, the non-ionic surfactant comprises a polysorbate. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the polysorbate is polysorbate 20.
[0215] In some embodiments, the polysorbate is present in an amount of about 0.5% to about 2.5% (w / w) of the composition. In some embodiments, the polysorbate is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.5% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the polysorbate is present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the polysorbate is present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the polysorbate is present in an amount of up to about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0216] In some embodiments, the nonionic surfactant comprises a polyethylene glycol (PEG) fatty acid ester. In some embodiments, the PEG fatty acid ester comprises a C8-C hydroxyl group attached to each terminal hydroxyl group to form a fatty acid ester. 22The PEG chain is about 2-8 subunits containing fatty acids. In some embodiments, the PEG fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glyceride, or any combination thereof. In some embodiments, the PEG fatty acid ester is PEG-4 dilaurate.
[0217] In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5% to about 2.5% (w / w) of the composition. In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 1.2%, about 0.5% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 2.5%, about 0.8% to about 1%, about 0.8% to about 1.2%, about 0.8% to about 1.5%, about 0.8% to about 2%, about 0.8% to about 2.5%, about 1% to about 1.2%, about 1% to about 1.5%, about 1% to about 2%, about 1% to about 2.5%, about 1.2% to about 1.5%, about 1.2% to about 2%, about 1.2% to about 2.5%, about 1.5% to about 2%, about 1.5% to about 2.5%, or about 2% to about 2.5%. In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%. In some embodiments, the PEG fatty acid ester is present in an amount of at least about 0.5%, about 0.8%, about 1%, about 1.2%, about 1.5%, or about 2%. In some embodiments, the PEG fatty acid ester is present in an amount of up to 0.8%, about 1%, about 1.2%, about 1.5%, about 2%, or about 2.5%.
[0218] In some embodiments, the nonionic surfactant has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the composition comprises a plurality of nonionic surfactants, each having an HLB of about 10 or less. In some embodiments, the nonionic surfactants having an HLB of 10 or less are selected from Table 1, or any combination thereof.
[0219] In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is from about 0.5% to about 1%, from about 0.5% to about 1.5%, from about 0.5% to about 2%, from about 0.5% to about 3%, from about 0.5% to about 4%, from about 0.5% to about 5%, from about 0.5% to about 6%, from about 0.5% to about 7%, from about 0.5% to about 8%, from about 0.5% to about 10%, from about 1% to about 1.5%, from about 1% to about 2%, from about 1% to about 3%, from about 1% to about 4%, from about 1% to about 5%, from about 1% to about 6%, from about 1% to about 7%, from about 1% to about 8%, from about 1% to about 10%, from about 1.5% to about 2%, from about 1.5% to about 3%, from about 1.5% to about 4%, from about 1.5% to about 5%, from about 1.5% to about 6%, from about 1. .5% to about 7%, about 1.5% to about 8%, about 1.5% to about 10%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2% to about 6%, about 2% to about 7%, about 2% to about 8%, about 2% to about 10%, about 3% to about 4%, about 3% to about 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 10%, The nonionic surfactant or combination of nonionic surfactants is present in an amount of about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 10%, about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 10%, about 6% to about 7%, about 6% to about 8%, about 6% to about 10%, about 7% to about 8%, about 7% to about 10%, or about 8% to about 10%. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.5%, about 0.6%, about 0.7%, about 1%, 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8, or about 10%. In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.6% (e.g., 0.54% to about 0.66%). In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of about 0.7% (e.g., 0.63% to about 0.77%). In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount of at least about 0.5%, about 0.7%, about 1%, 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about, or about 8%.In some embodiments, the nonionic surfactant or combination of nonionic surfactants is present in an amount up to 0.7%, about 1%, about 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 10%.
[0220] In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion, the lipid bilayer, or both. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion. In some embodiments, the composition comprises a non-ionic surfactant in the lipid bilayer. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion and the lipid bilayer, where the composition comprises two or more different non-ionic surfactants.
[0221] In some embodiments, the penetration enhancer comprises a salicylate or a nicotinate. In some embodiments, the ester is a C1-C6 alkyl ester or a benzyl ester. In some embodiments, the penetration enhancer may be a vasodilator. In some embodiments, the penetration enhancer comprises methyl salicylate or benzyl nicotinate. In some embodiments, the penetration enhancer is a nicotinate present in an amount up to about 0.1%, 0.5%, 1%, 2%, or 3% (w / w) of the composition. In some embodiments, the nicotinate is present in an amount of about 0.1% to about 3%, about 0.1% to about 2%, about 0.1% to about 1%. In some embodiments, the benzyl nicotinate is present in an amount of about 0.5%.
[0222] In some embodiments, the penetration enhancer comprises a fatty acylated amino acid. In some embodiments, the fatty acylated amino acid is lysine. In some embodiments, the lysine is monoacylated with a fatty acid. In some embodiments, the penetration enhancer is monolauryl lysine. In some embodiments, the lysine is diacylated. In some embodiments, the penetration enhancer is dipalmitoyl lysine. In some embodiments, the fatty acylated amino acid is present in an amount of up to about 1%, up to about 2%, up to about 3%, up to about 4%, or up to about 5% (w / w) of the composition. In some embodiments, the fatty acylated amino acid is present in an amount of about 0.1% to about 5%, about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.5% to about 5%, about 0.5% to about 4%, about 0.5% to about 3%, about 0.5% to about 2%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, or about 1.5% to about 2.5%.
[0223] Cationic Surfactants In some embodiments, the composition further comprises a cationic surfactant. In some embodiments, the cationic surfactant is used to stabilize the water-in-oil emulsion (e.g., at the submicron emulsion stage before lipid vesicle formation). In some embodiments, the cationic surfactant is a monocationic surfactant. In some embodiments, the monocationic surfactant is a net monocationic (e.g., a phosphate that contains two side chains, each of which has a single cationic functionality, and is partially neutralized by the phosphate anion).
[0224] In some embodiments, the monocationic surfactant is a fatty amide-derived propylene glycol diammonium phosphate ester. In some embodiments, the monocationic surfactant is linoleamidopropyl PG-dimonium chloride diphosphate (e.g., Arlasilk™ PTM, Arlasilk™ EFA).
[0225] In some embodiments, the propylene glycol diammonium phosphate ester derived from a fatty amide is present in an amount of about 1% to about 20% (w / w) of the composition. In some embodiments, the propylene glycol diammonium phosphate ester derived from a fatty amide is present in an amount of about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1% to about 6%, about 1% to about 7%, about 1% to about 8%, about 1% to about 9%, about 1% to about 10%, about 1% to about 11%, about 1% to about 12%, about 1% to about 13%, about 1% to about 14%, about 1% to about 15%, about 1% to about 16%, about 1% to about 17%, about 1% to about 18%, about 1% to about 19%, about 1% to about 20%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%. , about 2% to about 6%, about 2% to about 7%, about 2% to about 8%, about 2% to about 9%, about 2% to about 10%, about 2% to about 11%, about 2% to about 12%, about 2% to about 13%, about 2% to about 14%, about 2% to about 15%, about 2% to about 16%, about 2% to about 17%, about 2% to about 18%, about 2% to about 19%, about 2% to about 20%, about 3% to about 4%, about 3% to about 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 9%, about 3% to about 10%, about 3% to about 11%, about 3% to about 12%, about 3% to about 13%, about 3% to about 14%, about 3% to about 15 %, about 3% to about 16%, about 3% to about 17%, about 3% to about 18%, about 3% to about 19%, about 3% to about 20%, about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 9%, about 4% to about 10%, about 4% to about 11%, about 4% to about 12%, about 4% to about 13%, about 4% to about 14%, about 4% to about 15%, about 4% to about 16%, about 4% to about 17%, about 4% to about 18%, about 4% to about 19%, about 4% to about 20%, about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 11%, about 5% to about 12%, about 5% to about 13%, about 5% to about 14%, about 5% to about 15%, about 5% to about 16%, about 5% to about 17%, about 5% to about 18%, about 5% to about 19%, about 5% to about 20%, about 6% to about 7%, about 6% to about 8%, about 6% to about 9%, about 6% to about 10%, about 6% to about 11%, about 6% to about 12%, about 6% to about 13%, about 6% to about 14%, about 6% to about 15%, about 6% to about 16%, about 6% to about 17%, about 6% to about 18%, about 6% to about 19%, about 6% to about 20%, about 7% to about 8%, about 7% to about 9%, about 7% to about 10%,About 7% to about 11%, about 7% to about 12%, about 7% to about 13%, about 7% to about 14%, about 7% to about 15%, about 7% to about 16%, about 7% to about 17%, about 7% to about 18%, about 7% to about 19%, about 7% to about 20%, about 8% to about 9%, about 8% to about 10%, about 8% to about 11%, about 8% to about 12%, about 8% to about 13%, about 8% to about 14%, about 8% to about 15%, about 8% to about 16%, about 8% to about 17%, about 8% to about 18%, about 8% to about 19%, about 8% to about 20%, about 9% to about 10%, about 9% to about 11% , about 9% to about 12%, about 9% to about 13%, about 9% to about 14%, about 9% to about 15%, about 9% to about 16%, about 9% to about 17%, about 9% to about 18%, about 9% to about 19%, about 9% to about 20%, about 10% to about 11%, about 10% to about 12%, about 10% to about 13%, about 10% to about 14%, about 10% to about 15%, about 10% to about 16%, about 10% to about 17%, about 10% to about 18%, about 10% to about 19%, about 10% to about 20%, about 11% to about 12%, about 11% to about 13%, about 11% to about 14%, about 1 1% to about 15%, about 11% to about 16%, about 11% to about 17%, about 11% to about 18%, about 11% to about 19%, about 11% to about 20%, about 12% to about 13%, about 12% to about 14%, about 12% to about 15%, about 12% to about 16%, about 12% to about 17%, about 12% to about 18%, about 12% to about 19%, about 12% to about 20%, about 13% to about 14%, about 13% to about 15%, about 13% to about 16%, about 13% to about 17%, about 13% to about 18%, about 13% to about 19%, about 13% to about 20%, about 14% to about The compound is present in an amount of about 15%, about 14% to about 16%, about 14% to about 17%, about 14% to about 18%, about 14% to about 19%, about 14% to about 20%, about 15% to about 16%, about 15% to about 17%, about 15% to about 18%, about 15% to about 19%, about 15% to about 20%, about 16% to about 17%, about 16% to about 18%, about 16% to about 19%, about 16% to about 20%, about 17% to about 18%, about 17% to about 19%, about 17% to about 20%, about 18% to about 19%, about 18% to about 20%, or about 19% to about 20%. In some embodiments, propylene glycol diammonium phosphate ester derived from a fatty amide comprises about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100or about 20% (w / w). In some embodiments, the propylene glycol diammonium phosphate ester derived from a fatty amide is present in an amount of at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%. In some embodiments, the propylene glycol diammonium phosphate ester derived from a fatty amide is present in an amount of up to about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%.
[0226] Additional Ingredients In some embodiments, the vesicle composition comprises additional components that, in some embodiments, improve one or more properties of the vesicle without dramatically altering the delivery of the anionic polymeric material, the peptide, or a combination thereof.
[0227] In some embodiments, the vesicle composition comprises one or more viscosity enhancing agents. In some embodiments, the viscosity enhancing agent increases the viscosity of the composition for improved stability of the vesicle composition and / or user feel. In some embodiments, the viscosity enhancing agent further acts as a surfactant. In some embodiments, the viscosity enhancing agent comprises one or more of a fatty alcohol, a wax, a fatty acid ester of glycerol, or any combination thereof. In some embodiments, the fatty alcohol is a C8-C 20In some embodiments, the fatty alcohol is cetyl alcohol (e.g., Crodacol C95). In some embodiments, the wax is a natural or synthetic wax. In some embodiments, the wax is beeswax. In some embodiments, the wax is synthetic beeswax. In some embodiments, the synthetic beeswax is Syncrowax™ BB4. In some embodiments, the synthetic beeswax is a non-animal derived beeswax. In some embodiments, the non-animal derived beeswax is Syncrowax™ SB1. In some embodiments, the fatty acid ester of glycerol is a monoester. In some embodiments, the monoester is a C8-C 24 An ester of a fatty acid. In some embodiments, the fatty acid ester of glycerol is glycerol monostearate.
[0228] In some embodiments, the viscosity enhancing agent is present in an amount of about 0.5% to about 10% (w / w) of the composition. In some embodiments, the viscosity enhancing agent is present in an amount of about 0.5% to about 5%, about 0.5% to about 5%, about 0.5% to about 4%, about 0.5% to about 3%, or about 0.5% to about 2% (w / w) of the composition. In some embodiments, the viscosity enhancing agent comprises a fatty alcohol in an amount of up to about 2%, a wax in an amount of up to about 2%, and a fatty acid ester of glycerol in an amount of up to about 5%. In some embodiments, the fatty alcohol is present in an amount of about 0.1 to about 1.5%. In some embodiments, the fatty alcohol is present in an amount of about 0.4% (e.g., 0.36% to about 0.44%). In some embodiments, the wax is present in an amount of about 0.1% to about 1%. In some embodiments, the wax is present in an amount of about 0.2% (e.g., about 0.18% to about 0.22%). In some embodiments, the wax is present in an amount of about 0.3% (e.g., about 0.27% to about 0.33%). In some embodiments, the fatty ester of glycerol is present in an amount of about 0.5% to about 2%. In some embodiments, the fatty ester of glycerol is present in an amount of about 0.8% (e.g., 0.72% to about 0.88%). In some embodiments, the fatty ester of glycerol is present in an amount of about 0.9%.
[0229] In some embodiments, the vesicle composition further comprises one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, or any combination thereof. In some embodiments, the vesicle composition further comprises a thickening agent. In some embodiments, the vesicle composition further comprises a preservative. In some embodiments, the vesicle composition further comprises a moisturizer. In some embodiments, the vesicle composition further comprises an emollient. In some embodiments, the vesicle composition further comprises a humectant. In some embodiments, the vesicle composition further comprises a fragrance (e.g., Mentha piperita). In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.01% to about 0.1%. In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.05%.
[0230] In some embodiments, the vesicle composition further comprises a humectant. In some embodiments, the composition comprises glycerol. In some embodiments, the glycerol is present in an amount of about 0.5% to about 25%, about 0.5% to about 20%, about 0.5% to about 15%, or about 0.5% to about 10% (w / w) of the composition. In some embodiments, the glycerol is present in an amount of about 1% to about 10%. In some embodiments, the glycerol is present in an amount of about 1% to about 2%, about 1% to about 4%, about 1% to about 6%, about 1% to about 8%, about 1% to about 10%, about 2% to about 4%, about 2% to about 6%, about 2% to about 8%, about 2% to about 10%, about 4% to about 6%, about 4% to about 8%, about 4% to about 10%, about 6% to about 8%, about 6% to about 10%, or about 8% to about 10%. In some embodiments, glycerol is present in an amount of about 1%, about 2%, about 4%, about 6%, about 8%, or about 10%. In some embodiments, glycerol is present in an amount of at least about 1%, about 2%, about 4%, about 6%, or about 8%. In some embodiments, glycerol is present in an amount of up to 2%, about 4%, about 6%, about 8%, or about 10%.
[0231] In some embodiments, the vesicle composition further comprises a preservative. In some embodiments, the preservative is a paraben ester. In some embodiments, the preservative is methylparaben or propylparaben or a combination thereof. In some embodiments, the preservative is a cosmetic preservative such as Euxyl® PE9010 or Spectrastat®. In some embodiments, the preservative comprises a phenoxyethanol / ethylhexylglycerin mixture. In some embodiments, the preservative comprises a combination of caprylhydroxamic acid, caprylyl glycol, and glycerin. In some embodiments, the preservative is present in an amount of up to about 1%, up to about 0.9%, up to about 0.8%, up to about 0.7%, up to about 0.6%, up to about 0.5%, up to about 0.4%, up to about 0.3%, up to about 0.2% (w / w) of the composition. In some embodiments, the preservative is present in an amount of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%.
[0232] In some embodiments, the composition further comprises a material for promoting a desired change in the skin, such as smoothing out wrinkles. In some embodiments, the composition comprises one or more carbohydrates or acceptable salts thereof. In some embodiments, the one or more carbohydrates are monosaccharides, disaccharides, or polysaccharides. In some embodiments, the carbohydrate or acceptable salts thereof comprises glucosamine phosphate. In some embodiments, the glucosamine phosphate comprises disodium acetyl phosphate glucosamine, such as acetyl N-acetyl-α-D-glucosamine 6-phosphate disodium salt (NovHyal™). In some embodiments, the carbohydrate comprises isomerized sugar (e.g., Hyanify™). In some embodiments, the one or more carbohydrates or acceptable salts thereof are in liquid form. In some embodiments, the one or more carbohydrates or acceptable salts thereof are in gel form. In some embodiments, the one or more carbohydrates or acceptable salts thereof are in solid form. In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in the composition in an amount of about 0.1% to about 1%.In some embodiments, the one or more carbohydrates or acceptable salts thereof are from about 0.1% to about 0.2%, from about 0.1% to about 0.3%, from about 0.1% to about 0.4%, from about 0.1% to about 0.5%, from about 0.1% to about 0.6%, from about 0.1% to about 0.7%, from about 0.1% to about 0.8%, from about 0.1% to about 0.9%, from about 0.1% to about 1%, or from about 0.2% to about 0.3%, about 0.2% to about 0.4%, about 0.2% to about 0.5%, about 0.2% to about 0.6%, about 0.2% to about 0.7%, about 0.2% to about 0.8%, about 0.2% to about 0.9%, about 0.2% to about 1%, about 0.3% to about 0.4%, about 0.3% to about 0.5%, about 0.3% to about 0.6%, about 0.3% to about 0.7%, about 0 0.3% to about 0.8%, about 0.3% to about 0.9%, about 0.3% to about 1%, about 0.4% to about 0.5%, about 0.4% to about 0.6%, about 0.4% to about 0.7%, about 0.4% to about 0.8%, about 0.4% to about 0.9%, about 0.4% to about 1%, about 0.5% to about 0.6%, about 0.5% to about 0.7%, about 0.5% to about 0.8%, about 0.5% In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in the composition in an amount of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.6%, about 0.8%, about 0.6%, about 0.9%, about 0.6%, about 0.7%, about 0.8%, about 0.7%, about 0.9%, about 0.7%, about 0.8%, about 0.9%, or about 0.9% to about 1%. In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in an amount of at least about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, or about 0.9%. In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in an amount of up to about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about %, 0.9%, or about 1%. In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in an amount of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, %, 0.9%, and 1%.In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in an amount of at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, %, 0.9%, and 1%. In some embodiments, the one or more carbohydrates or acceptable salts thereof are present in an amount of up to about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, %, 0.9%, and 1%.
[0233] In some embodiments, the composition comprises a polymer of amino acids. In some embodiments, the polymer of amino acids comprises high and low MW polymers of amino acids. In some embodiments, the polymer of amino acids comprises polyglutamic acid. In some embodiments, the polyglutamic acid comprises low MW polyglutamic acid (e.g., Hyfactor™ PGA LM) and / or high MW polyglutamic acid (e.g., Hyfactor™ PGA HM). In some embodiments, the polymer of amino acids is present in an amount of about 0.01% to about 0.2%. In some embodiments, the amino acid polymer is present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.01% to about 0.15%, about 0.01% to about 0.2%, about 0.05% to about 0.1%, about 0.05% to about 0.15%, about 0.05% to about 0.2%, about 0.1% to about 0.15%, about 0.1% to about 0.2%, or about 0.15% to about 0.2%. In some embodiments, the amino acid polymer is present in an amount of about 0.01%, about 0.05%, about 0.1%, about 0.15%, or about 0.2%. In some embodiments, the amino acid polymer is present in an amount of at least about 0.01%, about 0.05%, about 0.1%, or about 0.15%. In some embodiments, the polymer of amino acids is present in an amount up to about 0.05%, about 0.1%, about 0.15%, or about 0.2%.
[0234] In some embodiments, the composition further comprises collagen. In some embodiments, the collagen is human collagen. ...
Claims
1. (a) lipid vesicles, each of which comprises a lipid bilayer comprising a vesicle-forming lipid; (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants; A lipid vesicle composition comprising: the lipid bilayer, the oil-in-water emulsion, or a combination thereof, comprises one or more peptides; The one or more peptides have the amino acid sequence: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8 Including, Where: Xaa1 is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Gly, Lys, Pro, Tyr, or Val; Xaa2 is absent or selected from Ala, Arg, Cys, Gly, lie, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Cys, Gly, lie, Lys, Pro, Tyr, or Val; Xaa3 is absent or selected from Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, or Val; Xaa4 is absent or selected from Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Val; Xaa5 is absent or selected from Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Val; Xaa6 is absent or selected from Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Val, and derivatives of Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Val; Xaa7 is selected from Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Val; The lipid vesicle composition, wherein Xaa8 is selected from Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Val, and derivatives of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.
2. (a) lipid vesicles, each of which comprises a lipid bilayer comprising a vesicle-forming lipid; (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants; A lipid vesicle composition comprising: the lipid bilayer, the oil-in-water emulsion, or a combination thereof, comprises one or more peptides; A lipid vesicle composition, wherein the one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identity to any one of SEQ ID NOs: 1-51.
3. (a) lipid vesicles, each of which comprises a lipid bilayer comprising a vesicle-forming lipid; (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants; A lipid vesicle composition comprising: the lipid bilayer, the oil-in-water emulsion, or a combination thereof, comprises one or more peptides and anionic polymeric materials; The one or more peptides have the amino acid sequence: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8 Including, Where: Xaa1 is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Gly, Lys, Pro, Tyr, or Val; Xaa2 is absent or selected from Ala, Arg, Cys, Gly, lie, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Cys, Gly, lie, Lys, Pro, Tyr, or Val; Xaa3 is absent or selected from Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Phe, Pro, Tyr, or Val; Xaa4 is absent or selected from Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Val, and derivatives of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Val; Xaa5 is absent or selected from Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Gln, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Val; Xaa6 is absent or selected from Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Val, and derivatives of Ala, Arg, Asp, Gln, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Val; Xaa7 is selected from Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Val, and derivatives of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Val; The lipid vesicle composition, wherein Xaa8 is selected from Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Val, and derivatives of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.
4. (a) lipid vesicles, each of which comprises a lipid bilayer comprising a vesicle-forming lipid; (b) an oil-in-water emulsion encapsulated in said lipid vesicles and stabilized by one or more surfactants; A lipid vesicle composition comprising: the lipid bilayer, the oil-in-water emulsion, or a combination thereof, comprises one or more peptides and anionic polymeric materials; A lipid vesicle composition, wherein the one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identity to any one of SEQ ID NOs: 1-51.
5. 5. The lipid vesicle composition of claim 1, wherein the one or more peptides are encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof.
6. The lipid vesicle composition of any one of claims 1 to 5, wherein the one or more peptides are unmodified.
7. 7. The lipid vesicle composition of claim 1, wherein the one or more peptides are present at a concentration of about 0.001 mg / mL to about 10 mg / mL.
8. The lipid vesicle composition of any one of claims 1 to 7, wherein the one or more peptides comprise a tetrapeptide, a pentapeptide, a hexapeptide, or a combination thereof.
9. The lipid vesicle composition of claim 1 or 3, wherein the one or more peptides comprise an amino acid sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-51.
10. The lipid vesicle composition of any one of claims 1 to 9, wherein the one or more peptides comprise an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1 to 51.
11. The lipid vesicle composition according to any one of claims 1 to 10, wherein the one or more peptides have an amino acid sequence identical to any one of the amino acid sequences set forth in SEQ ID NOs: 1 to 51.
12. The lipid vesicle composition of any one of claims 1 to 11, wherein the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 31, 36, or 37.
13. The lipid vesicle composition according to any one of claims 1 to 12, wherein the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:
31.
14. The lipid vesicle composition according to any one of claims 1 to 13, wherein the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:
36.
15. The lipid vesicle composition of any one of claims 1 to 14, wherein the one or more peptides have an amino acid sequence identical to the amino acid sequence of SEQ ID NO:
37.
16. 3. The lipid vesicle composition of claim 1 or 2, wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof further comprises an anionic polymeric material.
17. 17. The lipid vesicle composition of any one of claims 1 to 16, wherein an anionic polymeric material is encapsulated in the lipid bilayer, the oil-in-water emulsion, or a combination thereof.
18. The lipid vesicle composition of any one of claims 1 to 16, wherein the anionic polymeric material comprises an anionic polysaccharide.
19. 17. The lipid vesicle composition of claims 1-16, wherein the anionic polymer is present in an amount from about 0.05 mg / mL to about 10 mg / mL of the lipid vesicle composition.
20. The lipid vesicle composition of any one of claims 1 to 16, wherein the anionic polysaccharide comprises hyaluronic acid or a salt thereof.
21. 21. The lipid vesicle composition of any one of claims 16 to 20, wherein the anionic polymeric material has a molecular weight of from about 5 kDa to about 500 kDa.
22. 22. The lipid vesicle composition of any one of claims 16 to 21, wherein the anionic polymeric material comprises a first anionic polymeric material and a second anionic polymeric material, each anionic polymeric material having a different molecular weight.
23. 23. The lipid vesicle composition of claim 22, wherein the first anionic polymeric material and the second anionic polymeric material are the same material.
24. 24. The lipid vesicle composition of claim 22 or 23, wherein the first anionic polymeric material has a molecular weight of up to about 75 kDa and the second anionic polymeric material has a molecular weight greater than about 75 kDa.
25. 25. The lipid vesicle composition of any one of claims 22 to 24, wherein the first anionic polymeric material has a molecular weight of about 5 kDa to about 50 kDa and the second anionic polymeric material has a molecular weight of about 100 kDa to about 500 kDa.
26. 26. The lipid vesicle composition of any one of claims 22 to 25, wherein the vesicle-forming lipids comprise phospholipids, glycolipids, lecithin, ceramide, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebrosides, or any combination thereof.
27. 27. The lipid vesicle composition of any one of claims 1 to 26, wherein the vesicle-forming lipids comprise phospholipids.
28. 28. The lipid vesicle composition of any one of claims 1 to 27, comprising vesicle-forming lipids in an amount of from about 0.5% to about 25% (w / w) of the lipid vesicle composition.
29. 29. The lipid vesicle composition of any one of claims 1 to 28, wherein the oil-in-water emulsion comprises a triglyceride in the oil component.
30. 30. The lipid vesicle composition of claim 29, wherein the triglyceride comprises a medium chain triglyceride.
31. 31. The lipid vesicle composition of claim 29 or 30, wherein the triglyceride is present in an amount of about 1% to about 35% (w / w) of the lipid vesicle composition.
32. The lipid vesicle composition of any one of claims 1 to 31, wherein the lipid vesicle composition comprises a sterol.
33. 33. The lipid vesicle composition of claim 32, wherein the sterol is present in an amount of about 1% to about 5% (w / w) of the lipid vesicle composition.
34. 34. The lipid vesicle composition of any one of claims 1 to 33, wherein the lipid vesicle composition comprises propylene glycol.
35. 35. The lipid vesicle composition of claim 34, wherein said propylene glycol is present in an amount of about 1% to about 25% (w / w) of said lipid vesicle composition.
36. 36. The lipid vesicle composition of any one of claims 1 to 35, comprising one or more viscosity enhancing agents.
37. 37. The lipid vesicle composition of any one of claims 1 to 36, wherein the one or more viscosity enhancing agents are present in an amount of about 0.5% to about 10% (w / w) of the lipid vesicle composition.
38. 38. The lipid vesicle composition of any one of claims 1 to 37, further comprising one or more penetration enhancers.
39. 40. The lipid vesicle composition of claim 38, wherein the one or more penetration enhancers comprise a non-ionic surfactant or a combination of non-ionic surfactants.
40. 40. The lipid vesicle composition of claim 39, wherein the non-ionic surfactant or the combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, sorbitan esters and polyethylene glycol fatty acid esters, and combinations thereof.
41. The polyethylene glycol ether of the aliphatic alcohol is 8 -C 22 41. The lipid vesicle composition of claim 40, comprising an aliphatic alcohol and a polyethylene glycol group having from about 2 to about 8 ethylene glycol subunits.
42. 42. The lipid vesicle composition of claim 40 or 41, wherein the polyethylene glycol ether of an aliphatic alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecaoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof.
43. 43. The lipid vesicle composition of any one of claims 40 to 42, wherein the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combination thereof.
44. 44. The lipid vesicle composition of any one of claims 40 to 43, wherein the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glycerides, or any combination thereof.
45. 45. The lipid vesicle composition of any one of claims 40-44, wherein the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof.
46. 46. The lipid vesicle composition of any one of claims 39 to 45, wherein the non-ionic surfactant or the combination of non-ionic surfactants has a hydrophobic-lipophilic balance (HLB) of about 10 or less.
47. 46. The lipid vesicle composition of any one of claims 39 to 45, wherein the non-ionic surfactant or the combination of non-ionic surfactants is present in an amount of about 0.5% to about 10% (w / w) of the lipid vesicle composition.
48. 48. The lipid vesicle composition of any one of claims 39 to 47, wherein at least one non-ionic surfactant is present in the oil-in-water emulsion.
49. 49. The lipid vesicle composition of any one of claims 39 to 48, wherein at least one non-ionic surfactant is present in the lipid bilayer.
50. 50. The lipid vesicle composition of any one of claims 39-49, wherein the one or more penetration enhancers comprise a combination of a sorbitan ester, a polysorbate, and a polyethylene glycol fatty acid ester.
51. 50. The lipid vesicle composition of any one of claims 38-49, wherein the one or more penetration enhancers comprise a combination of polyethylene glycol ethers of aliphatic alcohols, sorbitan esters, and polysorbates.
52. 50. The lipid vesicle composition of any one of claims 38-49, wherein the one or more penetration enhancers comprise monolauroyl lysine or dipalmitoyl lysine, or a combination thereof.
53. 53. The lipid vesicle composition of any one of claims 1 to 52, wherein the lipid vesicle composition comprises a cationic surfactant.
54. 54. The lipid vesicle composition of claim 53, wherein the cationic surfactant is a monocationic surfactant.
55. 55. The lipid vesicle composition of claim 53 or 54, wherein the cationic surfactant comprises a propylene glycol diammonium phosphate ester derived from a fatty amide.
56. 56. The lipid vesicle composition of any one of claims 53 to 55, wherein the cationic surfactant is present in an amount of about 1% to about 20% (w / w) of the lipid vesicle composition.
57. 56. The lipid vesicle composition of any one of claims 53 to 55, wherein the cationic surfactant is present in an amount of about 1% to about 10% (w / w) of the lipid vesicle composition.
58. 54. The lipid vesicle composition of claim 53, wherein the cationic penetration enhancer comprises a dicationic penetration enhancer.
59. 59. The lipid vesicle composition of claim 58, wherein the dicationic penetration enhancer is a gemini cationic surfactant.
60. 60. The lipid vesicle composition of claim 58 or 59, wherein the cationic penetration enhancer comprises a cationic polymer.
61. 61. The lipid vesicle composition of any one of claims 58-60, wherein the cationic penetration enhancer is present in an amount of from about 0.01% to about 1% (w / w) of the lipid vesicle composition.
62. 62. The lipid vesicle composition of any one of claims 38 to 61, wherein the penetration enhancer comprises a salicylate or a nicotinate.
63. Ester is C 1 -C 6 63. The lipid vesicle composition of claim 62, which is an alkyl ester or a benzyl ester.
64. 64. The lipid vesicle composition of claim 62 or 63, wherein the penetration enhancer comprises methyl salicylate or benzyl nicotinate.
65. 65. The lipid vesicle composition of any one of claims 1 to 64, further comprising one or more additional agents.
66. 66. The lipid vesicle composition of claim 65, wherein the additional agents comprise one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial agent, a biological extract, or any combination thereof.
67. 67. The lipid vesicle composition of any one of claims 1 to 66, wherein the lipid vesicle composition is formulated for topical application to the skin of a subject.
68. 68. The lipid vesicle composition of any one of claims 1 to 67, wherein the lipid vesicle composition is formulated to deliver an anionic polymer to a specific layer of the skin of a subject.
69. 69. The lipid vesicle composition of any one of claims 1 to 68, wherein the lipid vesicle composition is formulated to deliver one or more peptides to a specific layer of the skin of a subject.
70. 70. The lipid vesicle composition of any one of claims 1 to 69, wherein the lipid vesicle composition is formulated as a cream, lotion, suspension, or emulsion.
71. a) preparing an oil-in-water emulsion comprising one or more peptides by mixing an oil component of said oil-in-water emulsion with an aqueous component of said oil-in-water emulsion, wherein said oil component and / or said aqueous component of said oil-in-water emulsion comprises one or more surfactants; b) solubilizing the vesicle-forming lipids in an acceptable solvent other than water; c) adding said oil-in-water emulsion to the solubilized vesicle-forming lipids; d) mixing said oil-in-water emulsion with said solubilized vesicle-forming lipids under mixing conditions effective to form lipid vesicles comprising a lipid bilayer comprising vesicle-forming lipids, and the oil-in-water emulsion encapsulated in said lipid vesicles; 71. A method for preparing a lipid vesicle composition according to any one of claims 1 to 70, comprising:
72. 72. The method of claim 71, wherein (a) further comprises an anionic polymeric material.
73. 73. A method for achieving one or more cosmetic benefits by delivering a cosmetic agent below the skin surface of a subject, comprising the step of applying to said skin surface a lipid vesicle composition described in any one of claims 1 to 72.
74. 74. The method of claim 73, wherein the cosmetic agent is an anionic polymeric material.
75. 75. The method of claim 73 or 74, wherein the cosmetic agent is delivered to the dermis of the subject.
76. 74. The method of claim 73, wherein the cosmetic agent is one or more peptides.
77. 77. The method of claim 76, wherein the one or more cosmetic benefits include prevention of or temporary improvement in the appearance of one or more skin wrinkles.
78. 78. The method of claim 77, wherein the one or more skin wrinkles comprise moderate to severe glabellar lines associated with activity of the corrugator supercilii and / or procerus muscles, moderate to severe lateral canthal lines (crow's feet lines) associated with activity of the orbicularis oculi muscle, or moderate to severe forehead lines associated with activity of the frontalis muscle.
79. A composition comprising a peptide comprising the amino acid sequence of SEQ ID NO:
37.
80. 80. The composition of claim 79, further comprising one or more additional pharmaceutical agents.
81. 81. The composition of claim 80, wherein the one or more additional agents comprise one or more of a thickening agent, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial agent, a biological extract, or any combination thereof.
82. 82. The composition of claim 80 or 81, wherein the one or more additional agents comprises an anionic polymeric material.
83. 83. The composition of any one of claims 79 to 82, wherein the composition is formulated to deliver one or more peptides to a specific layer of the skin of a subject.
84. The composition of any one of claims 79 to 83, wherein the composition is formulated for topical application to the skin of a subject.
85. The composition of any one of claims 79 to 84, wherein the composition is formulated as a cream, lotion, suspension, or emulsion.
